UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF FLORIDA FORT LAUDERDALE DIVISION

In re

COMPREHENSIVE CLINICAL DEVELOPMENT, INC., et al.,

CASE NO. 13-17273-BK-JKO, Chapter 7 (JOINTLY ADMINISTERED)

Debtors.

NOTICE OF FILING REDACTED DEPOSITION TRANSCRIPT

Margarita Morales-Perez, Stephen M. Krupa, David Eichler, John Docherty, and Joseph Riley ("**Movants**"), by and through their undersigned counsel, hereby gives notice of filing a copy of the redacted deposition transcript of Marc Barmat, Trustee, taken on December 16, 2015 in support of their *Joint Sur-Reply to Replies to Response and Opposition to Motions to Approve Settlements and Bar Orders* (Doc. No. 1056).

I HEREBY CERTIFY that I am admitted to the Bar of the United States District Court for the Southern District of Florida and I am in compliance with the additional qualifications to practice in this Court as set forth in Local Rule 2090-1(A).

Dated: February 5, 2016.

BROAD AND CASSEL

Attorneys for Plaintiffs 390 North Orange Avenue, Suite 1400 Orlando, Florida 32801 Telephone: (407) 839-4200 Facsimile: (407) 425-8377

By: <u>/s/ Nicolette C. Vilmos</u> Nicolette C. Vilmos, Esq. Florida Bar No. 469051 <u>nvilmos@broadandcassel.com</u>

and

David A. Crichlow Karen B. Dine Rebecca Kinburn Katten Muchin Rosenman LLP 575 Madison Avenue New York, NY 10024 Telephone: 212-940-8941 Facsimile: 212-940-8776 david.crichlow@kattenlaw.com karen.dine@kattenlaw.com rebecca.kinburn@kattenlaw.com (Admitted Pro Hoc Vice)

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that a true and correct copy of the foregoing was served electronically upon all parties that have registered for CM/ECF service, including David C. Cimo, Esq. at <u>dcimo@gjb-law.com</u> and Marilee A. Mark, Esq. at <u>mmark@gjb-law.com</u>, Genovese Joblive & Battista, P.A., Special Litigation Counsel for the Trustee this 5th day of February, 2016.

By: /s/ Nicolette C. Vilmos

Nicolette C. Vilmos, Esq. Florida Bar No. 469051 nvilmos@broadandcassel.com



In the Matter of:

Comphensive Clinical Development

VS.

Steven Krupa

MARC BARMAT

December 16, 2015



www.OrangeLegal.com 800-275-7991 Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

ORANG	ELEGAL	Orange Legal
25		
24		
23		
22		
21		
20		
19		
18		
17		
16	REPORTED BY:	TONI MUSACCHIA, NOTARY PUBLIC, STATE OF FLORIDA
15		Boca Raton, Florida 33431
14	PLACE:	2255 Glades Road Suite 337 West
13	TAKEN BY:	COUNSEL FOR D&Os
12	TIME:	10:28 A.M 3:22 P.M.
11	DATE:	DECEMBER 16, 2015
10		(Noticed as Marc P. Barmat)
9	DEPOSITION OF:	
8	Debtoi	rs, /
7	DEVELOPMENT, INC	
6	COMPREHENSIVE CI	LINICAL
5	In re:	-
4		Chapter 7 (Jointly Administered)
3	(CASE NO: 13-17273-JKO
2		SOUTHERN DISTRICT OF FLORIDA FORT LAUDERDALE DIVISION
1	τ	JNITED STATES BANKRUPTCY COURT

800-275-7991

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 5 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 APPEARANCES: 2 NICOLETTE C. VILMOS, PL Nvilmos@broadandcassel.com 3 OF: BROAD AND CASSEL 390 North Orange Avenue, Suite 1400 Orlando, Florida 32801 4 Counsel for the Joseph Riley, John Docherty, 5 David Eichler and Stephen M. Krupa 6 ELAN A. GERSHONI, ESQUIRE 7 Egershoni@osslaw.com OF: O'QUINN STUMPHAUZER & SLOMAN 8 One Southeast Third Avenue, Suite 1820 9 Miami, Florida 33131 10 Counsel for John J. McGovern DAVID A. CRICHLOW, ESQUIRE 11 David.crichlow@kattenlaw.com KATTEN, MUCHIN, ROSENMAN, LLP OF: 12 575 Madison Avenue 13 New York, New York 10022 Counsel for Director Defendants 14 IVAN J. REICH, ESQUIRE 15 Ivan.reich@gray-robinson.com GRAY ROBINSON, P.A. 16 OF: 401 E. Las Olas Blvd. Suite 1000 Fort Lauderdale, Florida 33301-4210 17 Counsel for Margarita Morales-Perez 18 19 DAVID C. CIMO, ESQUIRE Dcimo@qjb-law.com 2.0 and MARILEE A. MARK, ESQUIRE Mmark@gjb-law.com 21 GENOVESE, JOBLOVE & BATTISTA, P.A. OF: 22 100 Southeast Second Street, 44th Floor Miami, Florida 33131 23 Counsel for Trustee, Marc Barmat 24 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 6 of 159

3

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 INDEX 2 TESTIMONY OF MARC BARMAT 3 Direct Examination by Ms. Vilmos5 4 Cross Examination by Mr. Reich		
3 Direct Examination by Ms. Vilmos5 4 Cross Examination by Mr. Reich56 5 CERTIFICATE OF OATH	1	INDEX
4 Cross Examination by Mr. Reich	2	TESTIMONY OF MARC BARMAT
5 CERTIFICATE OF OATH	3	Direct Examination by Ms. Vilmos5
6 CERTIFICATE OF REPORTER	4	Cross Examination by Mr. Reich56
<pre>7 ERRATA SHEET</pre>	5	CERTIFICATE OF OATH138
<pre>8 NOTIFICATION LETTER</pre>	6	CERTIFICATE OF REPORTER139
9 ****** 10 E X H I B I T S 11 EXHIBIT No. 1	7	ERRATA SHEET140
10 E X H I B I T S 11 EXHIBIT NO. 1	8	NOTIFICATION LETTER141
<pre>11 EXHIBIT No. 1</pre>	9	* * * * *
<pre>(Motion of Chapter 7 Trustee to approve the Grant Thornton settlement) 13 EXHIBIT No. 2</pre>	10	EXHIBITS
<pre>13 EXHIBIT No. 2</pre>		(Motion of Chapter 7 Trustee to approve the Grant
<pre>(Motion to approve the McGladrey settlement) 14 EXHIBIT No. 3</pre>	12	Thornton settlement)
<pre>EXHIBIT No. 3</pre>		
<pre>EXHIBIT No. 4</pre>	15	(Sworn testimony and declaration with regard to
EXHIBIT No. 5	17	(Declaration with regard to Grant Thornton dated
<pre>case against the officer and the director defendants) 20 EXHIBIT No. 67 21 (Claims register and it has a date on it of August 29, 2013 regarding case number 17273) 22 EXHIBIT No. 77 23 (Claims register with regard to case number 17282) 24 EXHIBIT No. 87 (Adversary complaint to avoid and recover avoidable</pre>	18	
<pre>EXHIBIT No. 67 (Claims register and it has a date on it of August 29, 2013 regarding case number 17273) EXHIBIT No. 77 (Claims register with regard to case number 17282) 24 EXHIBIT No. 87 (Adversary complaint to avoid and recover avoidable</pre>	19	1 1 1
August 29, 2013 regarding case number 17273)22EXHIBIT No. 7	20	EXHIBIT No. 6
 EXHIBIT No. 7	21	
 23 (Claims register with regard to case number 17282) 24 EXHIBIT No. 8	22	
(Adversary complaint to avoid and recover avoidable	23	
		(Adversary complaint to avoid and recover avoidable



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 7 of 159

4

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

EXHIBITS (Cont'd) 1 2 (Defendant Grant Thornton, LLP's answer and affirmative defenses to Plaintiff's adversary 3 complaints in the Grant Thornton adversary proceeding) 4 5 (Plaintiff's initial disclosures in the Grant 6 Thornton adversary) 7 (Defendant Grant Thornton's motion for summary judgment in the Grant Thornton adversary) 8 9 (Grant Thornton's initial disclosures) 10 EXHIBIT No. 13.....7 (Plaintiff's disclosure of expert testimony) 11 12 (Grant Thornton's disclosure of expert witness) 13 (Plaintiff's response in opposition to Defendant 14 Grant Thornton's motion for summary judgment and cross-motion for partial summary judgment with 15 incorporated memo of law) 16 (Grant Thornton's reply in support of its motion for 17 summary judgment) 18 (Grant Thornton's response in opposition to 19 Plaintiff's cross-motion for summary judgment) 20 EXHIBIT No. 18.....7 (Plaintiff's reply memorandum) 21 22 (Correspondence dated January 12, 2012) 23 EXHIBIT No. 20.....7 (Correspondence dated January 30, 2012) 24 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 8 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	EXHIBITS (Cont'd)
2	EXHIBIT No. 217 (February 28, 2011 letter)
3 4	EXHIBIT No. 227 (Officer and director adversary complaint)
5	EXHIBIT No. 237 (Printout of docket on the CCD case)
6 7	EXHIBIT No. 247 (Printout of docket on the CCD NW case)
8	EXHIBIT No. 257 (Docket from the adversary proceeding)
9 10	EXHIBIT No. 267 (Barmat v McGovern)
11	EXHIBIT No. 277 (Barmat v Grant Thornton)
12 13	EXHIBIT No. 287 (Barmat v McGovern)
14	EXHIBIT No. 297 (Schedules and amendments for CCD NW)
15 16	EXHIBIT No. 307 (Schedules and amendments for CCD)
17	EXHIBIT No. 317 (Claims registers)
18 19	EXHIBIT No. 327 (Claims registers)
20	EXHIBIT No. 337 (First amended adversary complaint)
21	EXHIBIT No. 347
22	(McGladrey adversary complaint)
23	EXHIBIT No. 357 (McGladreay adversary proceeding)
24 25	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 9 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	EXHIBITS (Cont'd)
2	EXHIBIT No. 36103 (December 2010 letter)
3	
4	
5	(Exhibits were retained by Atty Vilmos)
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	* * * * *
22	STIPULATIONS
23	It is hereby stipulated and agreed by and between
24	counsel present for the respective parties, and the deponent, that the reading and signing of the
25	deposition are hereby RESERVED.
ORANG	GELEGAL Orange Legal 800-275-7991

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 10 of 159

7

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

PROCEEDINGS 1 2 * * * * 3 THE COURT REPORTER: Do you swear or affirm 4 that the testimony you are about to give will be the truth, the whole truth, and nothing but the 5 6 truth? 7 THE WITNESS: I do. MARC BARMAT, 8 9 having been first duly sworn, was examined and testified as follows: 10 11 MS. VILMOS: I am going to have you 12 pre-mark these exhibits. 13 (Exhibits Numbers 1 through 35 pre-marked for identification.) 14 DIRECT EXAMINATION 15 BY MS. VILMOS: 16 17 Ο. Good morning. 18 Good morning. Α. 19 Can you please state your name for the 0. 20 record. Marc Barmat. 21 Α. 22 Where are you currently employed? 0. 23 Α. Furr & Cohen. 24 Q. How long have you been a Chapter 7 Trustee? Just over four years. From the time I was 25 Α.

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 11 of 159

8

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	appointed, I believe. I think November probably
2	would have been November, December four years ago,
3	I think, is when I got my first cases.
4	Q. How long have you been a practicing
5	attorney?
6	A. I graduated law school in 1994. So since
7	1994.
8	Q. I'm going to hand you what we've marked as
9	Exhibit Number 1. And for identification purposes
10	this is the motion of Chapter 7 Trustee to approve
11	the Grant Thornton settlement.
12	Have you seen that document before?
13	A. Yes.
14	Q. Is it an accurate representation of the
15	settlement terms between the Trustee and Grant
16	Thornton?
17	A. Yes, the actual settlement is attached.
18	Q. Exhibit Number 2 is the motion to approve
19	the McGladrey settlement with the settlement also
20	attached.
21	Have you seen that motion and settlement?
22	A. Yes.
23	Q. Is that settlement does that settlement
24	reflect the terms between the Trustee and McGladrey?
25	A. Yes.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 12 of 159

9

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Q. Has anything between the with the Grant
2	Thornton and McGladrey settlement, any terms have
3	changed since the execution of that settlement?
4	A. No.
5	Q. Exhibit Number 3 is the sworn testimony and
6	declaration with regard to McGladrey.
7	Have you seen that document before?
8	A. Yes.
9	Q. Is that your signature on the last page of
10	that document?
11	A. Yes.
12	Q. Are the statements that you made in this
13	declaration accurate?
14	A. Yes.
15	Q. Is there anything that you would change?
16	A. No.
17	MS. MARK: For purposes of the record, I
18	just wanted to point out that we reserve the
19	right to supplement to the extent that the
20	Trustee deems it necessary or appropriate prior
21	to the evidentiary hearing and that we would
22	comply per the Court's instruction.
23	MR. CIMO: Also on one of the declarations
24	we did an
25	MS. MARK: An amended that was Grant
URAN	GELEGAL Orange Legal

800-275-7991

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 13 of 159

10

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

	ORANO	GELEGAL Orange Legal
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?17MS. MARK: Yes.18MR. CIMO: Off the record.19(Whereupon, an off-the-record discussion20was held.)21BY MS. VILMOS:22Q. I handed you what we marked as Exhibit23Number 4, which is the declaration with regard to	25	Have you seen this document before?
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?17MS. MARK: Yes.18MR. CIMO: Off the record.19(Whereupon, an off-the-record discussion20was held.)21BY MS. VILMOS:22Q. I handed you what we marked as Exhibit	24	Grant Thornton dated December 7, 2015.
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?17MS. MARK: Yes.18MR. CIMO: Off the record.19(Whereupon, an off-the-record discussion20was held.)21BY MS. VILMOS:	23	Number 4, which is the declaration with regard to
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?17MS. MARK: Yes.18MR. CIMO: Off the record.19(Whereupon, an off-the-record discussion20was held.)	22	Q. I handed you what we marked as Exhibit
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?17MS. MARK: Yes.18MR. CIMO: Off the record.19(Whereupon, an off-the-record discussion	21	BY MS. VILMOS:
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?17MS. MARK: Yes.18MR. CIMO: Off the record.	20	was held.)
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?17MS. MARK: Yes.	19	(Whereupon, an off-the-record discussion
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.16MR. REICH: That's the correct one?	18	MR. CIMO: Off the record.
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent14after that to everybody and that is the correct15one.	17	MS. MARK: Yes.
It was our paralegal had uploaded a prior version that would but there was nothing substantively different. There were some typos and then we took the exact language from the setoff provision and put it in there. MR. CIMO: For the record MR. MARK: I just want to make sure, for example, that the Grant Thornton one MR. REICH: Does the exhibits that you sent over prior to the deposition contain the amended proper one? MS. MARK: A subsequent e-mail was sent after that to everybody and that is the correct	16	MR. REICH: That's the correct one?
2It was our paralegal had uploaded a prior3version that would but there was nothing4substantively different. There were some typos5and then we took the exact language from the6setoff provision and put it in there.7MR. CIMO: For the record8MS. MARK: I just want to make sure, for9example, that the Grant Thornton one10MR. REICH: Does the exhibits that you sent11over prior to the deposition contain the amended12proper one?13MS. MARK: A subsequent e-mail was sent	15	one.
It was our paralegal had uploaded a prior version that would but there was nothing substantively different. There were some typos and then we took the exact language from the setoff provision and put it in there. MR. CIMO: For the record MS. MARK: I just want to make sure, for example, that the Grant Thornton one MR. REICH: Does the exhibits that you sent over prior to the deposition contain the amended proper one?	14	after that to everybody and that is the correct
It was our paralegal had uploaded a prior version that would but there was nothing substantively different. There were some typos and then we took the exact language from the setoff provision and put it in there. MR. CIMO: For the record MS. MARK: I just want to make sure, for example, that the Grant Thornton one MR. REICH: Does the exhibits that you sent over prior to the deposition contain the amended	13	MS. MARK: A subsequent e-mail was sent
It was our paralegal had uploaded a prior version that would but there was nothing substantively different. There were some typos and then we took the exact language from the setoff provision and put it in there. MR. CIMO: For the record MS. MARK: I just want to make sure, for example, that the Grant Thornton one MR. REICH: Does the exhibits that you sent	12	proper one?
It was our paralegal had uploaded a prior version that would but there was nothing substantively different. There were some typos and then we took the exact language from the setoff provision and put it in there. MR. CIMO: For the record MS. MARK: I just want to make sure, for example, that the Grant Thornton one	11	over prior to the deposition contain the amended
It was our paralegal had uploaded a prior version that would but there was nothing substantively different. There were some typos and then we took the exact language from the setoff provision and put it in there. MR. CIMO: For the record MS. MARK: I just want to make sure, for	10	MR. REICH: Does the exhibits that you sent
It was our paralegal had uploaded a prior version that would but there was nothing substantively different. There were some typos and then we took the exact language from the setoff provision and put it in there. MR. CIMO: For the record	9	example, that the Grant Thornton one
2 It was our paralegal had uploaded a prior 3 version that would but there was nothing 4 substantively different. There were some typos 5 and then we took the exact language from the 6 setoff provision and put it in there.	8	MS. MARK: I just want to make sure, for
2 It was our paralegal had uploaded a prior 3 version that would but there was nothing 4 substantively different. There were some typos 5 and then we took the exact language from the	7	MR. CIMO: For the record
2 It was our paralegal had uploaded a prior 3 version that would but there was nothing 4 substantively different. There were some typos	6	setoff provision and put it in there.
2 It was our paralegal had uploaded a prior 3 version that would but there was nothing	5	and then we took the exact language from the
2 It was our paralegal had uploaded a prior	4	substantively different. There were some typos
	3	version that would but there was nothing
1 Thornton. And we sent you an e-mail with that.	2	It was our paralegal had uploaded a prior
	1	Thornton. And we sent you an e-mail with that.

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 14 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 Α. Yes. 2 0. Is that your signature on page nine? 3 Α. Yes. 4 0. Are the statements that you attest to here true and accurate? 5 6 Α. Yes. Is there anything that you would change? 7 0. No, subject to what Ms. Mark stated earlier 8 Α. about the previous declaration. 9 10 0. I'm handing you Exhibit Number 5, which is 11 the first amended adversary complaint in the 12 adversary case against the officer and the director 13 defendants. It is dated -- a filing date of 14 September 14, 2015. 15 Have you seen this document before? 16 Α. Yes. 17 Is that the adversarial lawsuit against the 0. officer and director defendants that you filed on 18 19 behalf of the estate? 20 Α. Yes. Exhibit Number 6 is the claims register and 21 0. 22 it has a date on it of August 29, 2013 regarding case 23 number 17273. 24 Have you seen that document before? Α. Yes. 25

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 15 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Q. Was that one of the exhibits that you
2	provided in addition to your declarations with regard
3	to the settlement motion?
4	A. It's an exhibit from the Court's website
5	and I believe it was included on our exhibit
6	registry, yes.
7	Q. Do you know for what purpose you provided
8	that with regard to the exhibit register for the 9019
9	motions?
10	A. Potential use of the hearing; to show the
11	administrative insolvency of the estate and whatever
12	other reasons we might need it for. If it has to go
13	litigation further.
14	Q. Exhibit Number 7, claims register with
14 15	Q. Exhibit Number 7, claims register with regard to case number 17282. That was listed on your
15	regard to case number 17282. That was listed on your
15 16 17	regard to case number 17282. That was listed on your exhibit register with regard to these motions as
15 16 17	regard to case number 17282. That was listed on your exhibit register with regard to these motions as well. Do you know for what purpose you plan on
 15 16 17 18 19 	regard to case number 17282. That was listed on your exhibit register with regard to these motions as well. Do you know for what purpose you plan on utilizing that exhibit?
 15 16 17 18 19 	<pre>regard to case number 17282. That was listed on your exhibit register with regard to these motions as well. Do you know for what purpose you plan on utilizing that exhibit? A. Potentially the same reasons as the other</pre>
 15 16 17 18 19 20 	<pre>regard to case number 17282. That was listed on your exhibit register with regard to these motions as well. Do you know for what purpose you plan on utilizing that exhibit? A. Potentially the same reasons as the other exhibit registry.</pre>
 15 16 17 18 19 20 21 	<pre>regard to case number 17282. That was listed on your exhibit register with regard to these motions as well. Do you know for what purpose you plan on utilizing that exhibit? A. Potentially the same reasons as the other exhibit registry. MR. REICH: The second case that's the</pre>
 15 16 17 18 19 20 21 22 	<pre>regard to case number 17282. That was listed on your exhibit register with regard to these motions as well. Do you know for what purpose you plan on utilizing that exhibit? A. Potentially the same reasons as the other exhibit registry. MR. REICH: The second case that's the Northwest case?</pre>
 15 16 17 18 19 20 21 22 23 24 	<pre>regard to case number 17282. That was listed on your exhibit register with regard to these motions as well. Do you know for what purpose you plan on utilizing that exhibit? A. Potentially the same reasons as the other exhibit registry. MR. REICH: The second case that's the Northwest case? A. Yes.</pre>

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 16 of 159

13

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. Adversary complaint to avoid and recover
2	avoidable transfers and for other relief. Marc
3	Barmat versus Grant Thornton. Case 15-01233, docket
4	entry one.
5	Q. I'll hand you Exhibit Number 9. If you can
6	identify that document?
7	A. Defendant Grant Thornton, LLP's answer and
8	affirmative defenses to Plaintiff's adversary
9	complaints in the Grant Thornton adversary
10	proceeding. 15-1233, docket entry five.
11	Q. Same for Exhibit Number 10.
12	A. Plaintiff's initial disclosures in the
13	Grant Thornton adversary. 15-1233, docket entry six.
14	Q. Exhibit Number 11.
15	A. Defendant Grant Thornton's motion for
16	summary judgment in the Grant Thornton adversary.
17	Same case, docket entry seven.
18	Q. Exhibit Number 12.
19	A. Same adversary proceeding. Docket entry
20	eight. Grant Thornton's initial disclosures.
21	Q. Exhibit Number 13?
22	A. Same adversary complaint. Plaintiff's
23	disclosure of expert testimony. Docket entry 10.
24	Q. Exhibit Number 14.
25	A. Same adversary proceeding. Grant



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 17 of 159

14

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Thornton's disclosure of expert witness. 1 Docket 2 entry 11. Exhibit Number 15. 3 0. Same adversary proceeding. Plaintiff's 4 Α. response in opposition to Defendant Grant Thornton's 5 motion for summary judgment and cross-motion for 6 partial summary judgment with incorporated memo of 7 law. Docket entry 14. 8 Exhibit Number 16. 9 Q. 10 Α. Same adversary proceeding. Grant 11 Thornton's reply in support of its motion for summary 12 judgment. Docket entry 34. 13 Q. Exhibit Number 17. 14 Α. Same adversary proceeding. Grant Thornton's response in opposition to Plaintiff's 15 cross-motion for summary judgment. Docket entry 35. 16 17 Exhibit Number 18. 0. Same adversary proceeding. Plaintiff's 18 Α. reply memorandum of law in further support of his 19 20 cross-motion for partial summary judgment. Docket 21 entry 38. Exhibit Number 19. 22 0. 23 Correspondence dated January 12, 2012. Α. 24 Filed -- docket entry 7-1 on Grant Thornton's letterhead to Mr. McGovern. 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 18 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Q. Exhibit Number 20.
2	A. Correspondence dated January 30, 2012 on
3	Grant Thornton letterhead directed to Ms.
4	Morales-Perez. Docket entry 7-2.
5	Q. Exhibit Number 21.
6	A. Grant Thornton letterhead on February 28,
7	2011 letter to Mr. McGovern. Docket entry 7-3.
8	MS. VILMOS: It appears that I marked
9	Exhibit Number 22 is also the officer and
10	director adversary complaint. I marked it twice
11	so we can just move along from that.
12	BY MS. VILMOS:
13	Q. Exhibit Number 23.
14	A. Appears be the printout of the docket on
15	the CCD case, 13-17273.
16	Q. Exhibit Number 24.
17	A. Printout of docket on CCD Northwest,
18	13-17282.
19	Q. Exhibit Number 25.
20	A. Docket from the adversary proceeding,
21	15-01411.
22	MR. REICH: Which case is that?
23	THE WITNESS: Barmat v McGladrey.
24	BY MS. VILMOS:
25	Q. Exhibit Number 26.



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 19 of 159

16

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. This is from Barmat v McGovern. Case
2	number or adversary proceeding number 15-01232.
3	Q. Exhibit Number 27.
4	A. Docket from Barmat v Grant Thornton.
5	Adversary proceeding number 15-01233.
6	Q. Exhibit Number 28.
7	A. Docket from Barmat v McGovern. Adversary
8	proceeding 15-01232.
9	Q. I'm going to
10	MR. REICH: Is Exhibit Numbers 26 and 28
11	the same document?
12	MS. VILMOS: I think that they are but
13	they're formatted different. There was two of
14	them in the FTP site so I printed both of them
15	out.
16	THE WITNESS: That appears to be the case.
17	They both go through ECF number 117. They're
18	both in the same case.
19	MS. VILMOS: They're just formatted
20	differently.
21	THE WITNESS: Yes.
22	MR. REICH: So Exhibit Numbers 26 and 28
23	are the same and Exhibit Numbers 22 and 5 are the
24	same, correct?
25	THE WITNESS: If you're asking me a
ORANG	ELEGAL Orange Legal

800-275-7991

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 20 of 159

17

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

question, I'll check. 1 2 MR. REICH: I'm asking Nicolette that. 3 MS. VILMOS: That is correct. 4 BY MS. VILMOS: Exhibit Number 29 I'm keeping in the 5 0. If you can identify that, please. 6 bucket. Case number 13-17282. Looks like ECF 1. 7 Α. Т think it's the schedules and all the amendments to 8 9 the schedules in general for CCD Northwest. 10 MR. REICH: When you say "schedules," 11 schedules --12 THE WITNESS: Petition -- I mean, I can go 13 through it. ECF one is the petition, ECF 25 looks like the schedules and statement of 14 financial affairs. ECF 33 looks like it's 15 16 probably amended schedules and SOFA. Do you want 17 me to go through each of these? SOFA is an 18 acronym for statement of financial affairs. 19 Do you want me to go through them? ECF 34 20 is global notes and statements of limitations, methodology and disclaimers regarding debtors' 21 22 schedules of assets and liabilities and statement 23 of financial affairs. Then it goes to ECF 36, 24 list of creditors holding 20 largest unsecured claims - second amended. That looks like it. 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 21 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Did you give is there a 27? Never mind,
2	I got it. The paper is coming out.
3	MS. MARK: Off the record for one second.
4	(Whereupon, an off-the-record discussion
5	was held.)
6	THE WITNESS: Here is 29. And the same
7	thing for 30.
8	BY MS. VILMOS:
9	Q. If you can identify that?
10	A. Number 30 is from case number 13-17273,
11	docket entry one, which is the CCD petition. And
12	then it goes to docket entry 100, which is the
13	amended petition. Docket entry 101, global notes and
14	statements of limitations, methodology and
15	disclaimers regarding debtors' schedules of assets
16	and liabilities on statement of financial affairs.
17	Continuing on to ECF 163, which is the first page
18	is the summary of schedules amended. It goes through
19	to include amended schedules all the amended
20	schedules. I shouldn't say "all." I believe all of
21	the amended schedules. Then it goes to ECF number
22	2010 list of creditors holding 20 largest unsecured
23	claims - second amended. That appears to be it.
24	Q. I believe 31 and 32 are duplicates probably
25	for the same reasons. These are the claim registers.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 22 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	31 is for 17273 and 32 is for 17282. I believe we
2	identified those already.
3	If you can identify
4	MR. REICH: You said 31 is which case?
5	THE WITNESS: CCD. 32 is CCW Northwest.
6	MR. REICH: Claims register?
7	THE WITNESS: Correct.
8	MR. REICH: Is that another duplicate?
9	MS. VILMOS: I think that she's right.
10	MS. MARK: We had two separate ones. We
11	had a GT exhibit register and a McGladrey exhibit
12	register. Some of the documents relate to both.
13	For example, the claim registers relate to both.
14	So it was listed for both main case, the
15	McGladrey one and then it was listed on the GT
16	one.
17	BY MS. VILMOS:
18	Q. If you can identify Exhibit Number 33
19	please.
20	A. Exhibit Number 33 is the first amended
21	adversary complaint to avoid and recover avoidable
22	transfers for damages and for other relief and demand
23	for a jury trial in the McGladrey adversary
24	proceeding, 15-1411, ECF number five.
25	Q. Exhibit Number 34?

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 23 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. McGladrey adversary complaint to avoid or
2	recover avoidable transfers and damages for other
3	relief and demand for jury trial, ECF number one. 33
4	is the first amended and 34 is the original.
5	Q. And Exhibit Number 35, please.
6	A. McGladrey adversary proceeding.
7	Defendants' motion to dismiss the first amended
8	complaint, ECF 15.
9	Q. Thank you. So I'm going ask this question
10	as it relates to both settlements in the Grant
11	Thornton and the McGladrey case that you have.
12	Do you are the settlements in your
13	opinion fair and equitable as it relates to the
14	officer and director defendants that we represent?
15	A. Yes. I mean, you're not part of the
16	settlement except to the extent the bar order and I
17	think the bar order is appropriate for the reasons
18	set forth in my declaration and papers that were
19	filed.
20	Q. Can you explain why you believe that it
21	would be fair and equitable to the directors and
22	officers or how is it fair and equitable?
23	A. It's a pretty broad question. I can go
24	into each lawsuit I suppose if you want?
25	Q. That would be great.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 24 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. So the Grant Thornton lawsuit was for
2	recovery of avoidable transfers of approximately
3	\$259,000. The proposed settlement is \$175,000. Even
4	if it were a slam dunk I think 175 for 259 is
5	certainly a settlement that falls well above the
6	lowest range of reasonableness.
7	In that particular case it's not your
8	standard run of the mill avoidable transfer. There
9	were various defenses that were asserted by Grant
10	Thornton and a motion for summary judgment. They
11	asserted a mediation defense that we failed to seek
12	mediation before the lawsuit. But even more
13	important than that, the claims that we have against
14	Grant Thornton are very complex. They're not a
15	standard fraudulent transfer. In order to prevail
16	against Grant Thornton they're going to assert that
17	there were reasonable equivalent value. In order to
18	determine whether or not there was reasonable
19	equivalent values, we have to get into all the
20	intricacies of GAAP and GAAS and that will require a
21	lot of time, effort and expense. And, once again,
22	the maximum amount we were potentially going recover
23	is 259, we're getting 175.
24	The bar order I think is appropriate
25	because again if you want me to pull out the

25 because, again -- if you want me to pull out the

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 25 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	declaration I can go point by point. But generally
2	we meet the Justice Oaks standards and we meet the
3	Mumford standards set forth in the 11 Circuit
4	opinion. The cases are interrelated. I don't think
5	that the claims that the D&Os allege to have against
6	Grant Thornton actually exist for several reasons.
7	First I think it's premature, not ripe in
8	order for the D&Os to have a claim against Grant
9	Thornton. It's not ripe because I will have to I
10	will have to prevail against the D&Os first in order
11	for their potential claim against Grant Thornton
12	Grant Thornton to ripen.
13	Above that, the claim for contribution and
14	indemnity against Grant Thornton I don't think exists
15	understood Florida law and under the pleading in this
16	case. In order for there to be a claim for
17	contribution under Florida Statutes actually, I
18	take that back because Grant Thornton is not for
19	breach of fiduciary duty. In order for the D&Os to
20	have a claim for indemnity in this particular case
21	against Grant Thornton they would have to show that
22	they were that Grant Thornton was wholly
23	responsible 100 percent responsible. By
24	definition if I prevail against the D&Os and Judge
25	Olson would have determined that there is some fault
1	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 26 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 on behalf of the D&Os. The allegations against the D&Os and Grant 2 3 Thornton arise out of the same facts essentially. 4 We're alleging that the D&Os provided materially inaccurate information to the auditors, Grant 5 Thornton and McGladrey. And based upon those 6 allegations it's seems to me that it's impossible 7 that there could be a circumstance where if I prevail 8 against the D&Os that they can assert that Grant 9 10 Thornton would be 100 percent responsible and therefore kick in the indemnity clause. 11 12 So based upon those facts in general as 13 well as anything that I may have missed because I'm not looking directly at my declaration when I have 14 all information at my fingertips. I think the 15 settlement with Grant Thornton is incredibly fair and 16 reasonable. It falls well within the Justice Oaks 17 standards and the Mumford standards. 18 All the same arguments apply with regard to 19 20 the McGladrey settlement with some additional. The lawsuit against McGladrey is for the professional 21

22 negligence counts. In addition to the avoidable 23 transfer of approximately \$666,000. The thing that 24 distinguishes the McGladrey case from the others is 25 that McGladrey is asserting the pari delicto defense,



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 27 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	which is a complete defense.
2	In my opinion I think we would prevail but
3	I don't make the decisions, the judge makes the
4	decisions. To me it would be a gamble to turn away
5	\$175,000 settlement. Now mind you, I would love to
6	have more \$175,000 in both cases. I hired very
7	skilled and competent counsel and they reported to me
8	we discussed everything. And we believe that, again,
9	175 meets all the appropriate Justice Oaks standards
10	and the Mumford standards.
11	We run the risk if were to go to trial of
12	getting zero. And that's not a risk that I wanted to
13	take on. This estate administratively insolvent. I
14	need the \$350,000 for both settlements to fund the
15	biggest asset that remains in this estate which is
16	the cause of action against the officers and
17	directors. And in order to do that that's going be
18	expensive and I need the money to pursue that.
19	So when we look at the standards; Mumford,
20	Justice Oaks, the facts as alleged in both complaints
21	as well as against the D&Os I think it's fair and
22	equitable. Of course I don't expect the D&Os to like
23	it but it doesn't mean that I'm not meeting my
24	fiduciary duties for both of these settlements that
25	you're objecting to.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 28 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 What did you allege was the wrong doing Ο. 2 with regard to Grant Thornton, what did they do 3 wrong? 4 Α. I mean, are you asking me do I -- did I memorize the complaint? 5 You can just tell me -- I mean, you 6 No. 0. filed the lawsuit. What was the alleged misconduct 7 or omission? 8 9 Α. Grant Thornton was provided materially 10 inadequate information by the officers and directors and Grant Thornton did not recognize that; did not do 11 12 their duties in accordance with GAAP and GAAS and as 13 a result they were paid \$259,000 and we don't believe 14 they provided reasonable and equivalent value in exchange for that and therefore we believe it's 15 avoidable. 16 I will defer to the complaint in case I'm 17 missing something. And if I said anything that's 18 19 inconsistent with that, again, I'll defer to the 20 complaint. My competent counsel prepared the complaint with consultation with me. This isn't a 21 22 memory test but I think I somewhat fairly described 23 it. 24 Q. Same question from for McGladrey, what did you allege that they did wrong? 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 29 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. Again, the same basic allegations but it
2	included counts for professional negligence,
3	accounting malpractice, as well as avoidance of
4	fraudulent avoidance of transfers. I think there
5	were a couple of other counts in that complaint as
6	well, which I have to if you put complaint in
7	front of me I'll defer to that.
8	Q. Does the settlement or the bar order
9	benefit the directors and officers?
10	A. I don't know that that's a standard that it
11	needs to benefit the officers and directors. I think
12	it's consistent with the law, which is the 11th
13	Circuit law.
14	Q. But is there a benefit?
15	MR. CIMO: Objection to form.
16	THE WITNESS: That's my fiduciary duty
17	is not to benefit the officers and directors.
18	BY MS. VILMOS:
19	Q. Is it fair and equitable to them
20	specifically?
21	MR. CIMO: Objection to form.
22	THE WITNESS: It's not fair and
23	inequitable. I think one of the important
24	things, again, that's described in detail in the
25	papers is that the bar order does not prohibit

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 30 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	the officers and directors for alleging anything
2	that they can under applicable non-bankruptcy law
3	for a setoff. And, again, the exact language of
4	the bar order is in my declaration. I can read
5	it verbatim if you would like. But essentially
6	they are not without recourse so to speak.
7	BY MS. VILMOS:
8	Q. Would the directors' and officers'
9	contribution indemnity claims give them a greater
10	benefit than a setoff claim?
11	MS. MARK: Objection to form.
12	MR. CIMO: Objection to form.
13	THE WITNESS: I don't believe that they
14	have a contribution or indemnity claim.
15	BY MS. VILMOS:
16	Q. Assuming that they do?
17	MR. CIMO: Same objection.
18	THE WITNESS: In order for me to assume
19	that, I would have to ignore the law. So
20	maybe ask me the question again.
21	BY MS. VILMOS:
22	Q. Ignore what a law?
23	A. Florida Statutes, Florida case law.
24	Q. Regarding?
25	A. Contribution and indemnity claims.
	I. concretedation and indennity craimb.

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 31 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Q. But let's assume that the Court finds that
2	they have contribution and indemnity claims, would
3	their contribution and indemnity claims be a greater
4	benefit than setoff or does setoff provide the
5	officers and directors a greater claim than
6	contribution and indemnification?
7	MR. CIMO: Objection to the form.
8	THE WITNESS: I'll answer it this way. I
9	assume what you're trying to say is that you
10	think that their contribution and indemnity claim
11	is worth more than 175. The bar order was
12	drafted in such a way that it's consistent with
13	11th Circuit law; Mumford specifically and all
14	the cases that have followed Mumford as well as
15	the other cases in this district that are
16	referenced in the opposition to the reply in
17	response to your opposition papers. So
18	MR. REICH: I will object and move to
19	strike the answer as being nonresponsive on the
20	grounds that while you are an attorney and it's
21	nice you want to issue a legal opinion here, Mr.
22	Barmat, you're being asked factual questions and
23	you should be answering factual answers. Your
24	contact is as Trustee and not as a lawyer.
25	MR. CIMO: I object to the statement that's

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 32 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 made counsel from the Gray Robinson firm and move
2 to strike his comment as being inappropriate and
3 harassing my witness. Continue.
4 BY MS. VILMOS:
5 Q. Let's talk about Mumford. So you indicate
6 that the settlement follows Mumford, correct?
7 A. Correct.
8 Q. The settlement, both of them?
9 A. Yes.
10 Q. And in your declaration you indicate that
11 the D&Os alleged right to assert indemnification and
12 contribution are exactly the same type of claims that
13 may be barred under Mumford; isn't that correct?
14 A. Mumford dealt with those claims as well,
15 yes, indemnity and contribution.
16 Q. In Mumford were the indemnification and
17 contribution claims asserted?
18 THE WITNESS: Do you have anything to say,
19 Mr. Reich, about the question? I don't want to
20 give a legal opinion. If you want me to give a
21 legal opinion?
22 MR. CIMO: You don't need to ask Mr. Reich.
23 Just answer the question.
24 MR. REICH: Just answer the questions that
25 are asked.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 33 of 159

30

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	MR. CIMO: That's what he's been doing.
2	You can answer the question. I object to
3	the form.
4	THE WITNESS: Can you repeat the question?
5	MS. VILMOS: Yes.
6	BY MS. VILMOS:
7	Q. In Mumford were the objecting parties
8	indemnification and contribution claims, were they
9	asserted at the time that the settlement was
10	approved?
11	A. Are you you're asking me factually in
12	the Mumford case?
13	Q. Factually.
14	A. If you can provide me a case of the Mumford
15	opinion I'll gladly review it. I read the Mumford
16	opinion several times in the past. Do I remember
17	every single thing about Mumford as I sit here right
18	now? I don't. I know upon reading Mumford and
19	comparing that to the facts in this particular case,
20	I felt they were directly on point and I'll leave it
21	at that.
22	Q. And do you recall in Mumford what the
23	was there a setoff issue in Mumford that was
24	addressed?
25	A. Are you talking about the dollar for dollar
ORANO	GELEGAL Orange Legal

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 34 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 issue? 2 0. Yes. 3 Α. I recall that. Do you recall factually what the settlement 4 0. 5 terms were with regard to the dollar for dollar setoff? 6 7 MR. CIMO: Object to the form. THE WITNESS: I am not sure I understand 8 9 your question. Are you asking me how much did 10 they settle for in Mumford? 11 BY MS. VILMOS: 12 0. No, not the exact amount. But what was the 13 rationale to provide the dollar for dollar setoff in Mumford? 14 Again, I'll defer to the opinion. 15 Α. 16 0. Were the -- do you recall whether the 17 settling parties had the ability to pay what the contribution and indemnification claims would be in 18 19 Mumford? I think there was an insurance policy in 20 Α. Mumford if T remember. 21 22 Do you recall what the limitations were in 0. Mumford -- the insurance limitations? 23 I'll pull this out of my elbow. I think it 24 Α. was like \$400,000. Am I right, do I have good 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 35 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 memory? 2 You do have good memory. 0. 3 Do you recall if there was an issue if or if the Court took into consideration the fact that 4 there was only a \$400,000 policy in that case and 5 that the contribution and indemnification claims 6 would be more than \$400,000? 7 You appear to have Mumford in front of 8 Α. 9 you so --10 0. I actually don't. I have the declaration 11 in front of me. 12 That could be correct. But, again, if you Α. 13 allow me to look at the Mumford opinion, I'll confirm 14 what you're saying. 15 0. I mean would that be distinguishable in this case? 16 17 MR. CIMO: Objection to the form. 18 BY MS. VILMOS: 19 We don't -- you admit in your declaration 0. 20 that Grant Thornton and McGladrey have the financial wherewithal to pay if you were to prevail the full 21 22 amount that you're seeking; isn't that correct? 23 I think I admit that it's likely. I have Α. not looked at either of their books and records but 24 that is probably true that they would have the 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 36 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

financial ability. 1 2 0. What is the approximate dollar amount in 3 which you're suing the directors and officers for? Millions. 4 Α. How many millions? 5 0. I'll take the insurance policy benefits. 6 Α. Okay. Is that -- are you only seeking the 7 0. policy or are you seeking more than the policy? 8 We served --9 Α. 10 MR. CIMO: Objection to the form. THE WITNESS: We served offer of 11 12 judgments/proposal for settlement I believe 13 yesterday in the amount \$4.25 million. So we'll take \$4.25 million. 14 MR. REICH: Objection. Move to strike. 15 The question was, what are you suing for and not 16 17 what you'll take. MR. CIMO: I object to motion the motion to 18 19 strike. 20 MR. REICH: You can object all you want. MR. CIMO: You can object to the form if 21 22 you don't like the answer. The judge decides to 23 strike it, not you. 24 BY MS. VILMOS: 25 If you want to take a moment, the complaint Q.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 37 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	is one of the exhibits. I don't know if you want to
2	look to see
3	MR. CIMO: Let's take a moment, sure. Fish
4	through this stack of two feet of documents.
5	THE WITNESS: We're talking about the D&O
6	complaint you want me to look at?
7	MS. VILMOS: Yes. I think it's Exhibit
8	Number 5.
9	THE WITNESS: Is the answer going to be
10	there is no exact number in the complaint before
11	I start looking? I think that's the answer,
12	there is no exact number in the complaint. If
13	you tell me it's different then I'll spend the
14	time going through it. I don't think that I need
15	to have an exact answer right now. We're
16	still
17	BY MS. VILMOS:
18	Q. There isn't an exact number. But I guess
19	what I'm trying to ask is that you're asking for I
20	believe what you asked for is a range of damages in
21	there and I don't want to that's why I'm asking
22	you to look because I don't want to the way that I
23	read the complaint you can tell me if I'm wrong
24	I'll do it this way, I'm not trying to trick you
25	is that I believe that you're asking for whatever

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 38 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	damages that the company had as a result of the
2	allegations against the D&Os, which would include the
3	amounts filed in the claims registers?
4	A. That sounds accurate but I'll defer to my
5	skilled counsel if that's incorrect.
6	Q. Do you know how much the claims are as we
7	sit here today?
8	A. I believe I put that in my declaration. If
9	not, you provided me with the you marked as an
10	exhibit the claims register it look like
11	Exhibit Number 6 is the CCD claims register, which
12	has \$92 million in secured; 12 plus million of
13	priority; 33,000, administrative. CCD Northwest
14	MR. REICH: Did you say 33,000 or 33
15	million?
16	THE WITNESS: Sorry, nine million. It
17	doesn't put commas in there.
18	Again, I'll defer to the claims register.
19	It looks like 9.2 million of secured; 1.2
20	priority; 33,000 in administrative.
21	BY MS. VILMOS:
22	Q. Which is Exhibit Number 6?
23	A. Correct, I was looking at Exhibit Number 6.
24	Exhibit Number 7, which is CCD Northwest or
25	NW claims register shows 27 looks like 27 million
	CELECAL Orange Legal



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 39 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	and change of total claims of which is comprised of
2	8.7 secured, 16 million 16.2 priority and 26,000
3	administrative.
4	Q. So you would agree that's more than the
5	policy limits?
6	A. I would agree with you on that, correct.
7	Q. So if you prevail you would anticipate that
8	the D&Os would have to come out of pocket to pay your
9	judgment that you're seeking?
10	A. Yes, and perhaps the insurance company.
11	Q. And would you also agree with me then that
12	to the extent that the D&Os would have contribution
13	and indemnity claims that those would cover
14	potentially more than a setoff of your two
15	settlements with Grant Thornton and McGladrey?
16	A. Once again you're asking me to assume
17	something which I think is inaccurate based upon the
18	law. But those numbers are greater if it's a math
19	question, yes.
20	Q. In the settlements with Grant Thornton and
21	McGladrey who requested the bar order?
22	A. The defendants requested the bar order.
23	Q. So it was not something that you offered as
24	part of the settlement?
25	A. I think that's correct. I was involved in

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 40 of 159

1	an overseeing respect. I have counsel who were doing
2	the actual negotiating. But I certainly believe it
3	was something they requested.
4	Q. In your four years approximately as Trustee
5	how many settlements have you entered into where you
6	requested a bar order?
7	A. This is the first case where it would have
8	been appropriate. Did you say where I requested a
9	bar order?
10	Q. Correct.
11	A. Well, I haven't requested a bar order.
12	Q. Let me ask it this way then
13	A. This is the first case I've been involved
14	in that's involved a bar order where I'm the Trustee.
15	Q. As an attorney have you ever been involved
16	in a settlement either with that had a bar order
17	in it?
18	A. If I say yes the follow up question would be
19	what case perhaps. I don't recall. I know I never
20	personally as an attorney litigated a bar order
21	issue. Whether I have been involved in a case that
22	had a settlement in which a bar order was included,
23	it's possible but I don't have a specific
24	recollection.
25	Q. Did Grant Thornton or McGladrey explain to

Orange Legal 800-275-7991

ORANGE LEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 41 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

you why they were requesting a bar order? 1 2 Α. Grant Thornton and McGladrey did not speak 3 directly to me, they would have spoken with my 4 counsel. What claims are enjoined by the bar orders 5 0. that are in the settlements? 6 I'll --7 Α. Objection to form. 8 MR. CIMO: 9 THE WITNESS: I'll defer to the language in 10 the bar orders. But I believe they would enjoin 11 the claims of your clients if that's what you're 12 asking? 13 BY MS. VILMOS: 14 0. Are there -- are you aware of any other third-party claims that have been threatened or that 15 16 exist against Grant Thornton and McGladrey? MR. CIMO: I'll instruct the witness not to 17 18 answer to the extent it requires attorney/client privilege information about -- such potential 19 20 activities. If you don't have any information 21 from that, you can answer. 22 THE WITNESS: The only information I would 23 have received would have been from my counsel. 24 BY MS. VILMOS: 25 Q. Not getting into conversations with your



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 42 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	counsel, just in general, based on your opinion in
2	entering into the settlement agreement, who would
3	have claims against Grant Thornton and McGladrey?
4	MR. CIMO: I'll object to the question.
5	I'm objecting to the form at this time. I will
6	instruct you not to answer it if this speculative
7	questions continues. You can still answer.
8	THE WITNESS: As I sit here right now I
9	don't know the answer.
10	BY MS. VILMOS:
11	Q. Can you think of anyone that would have
12	claims against Grant Thornton and McGladrey that
13	wouldn't belong to the estate?
14	MR. CIMO: Objection to the form.
15	THE WITNESS: That's relevant to this
16	settlement?
17	MS. VILMOS: Yes.
18	THE WITNESS: Nothing comes to my head as I
19	sit here.
20	BY MS. VILMOS:
21	Q. In negotiating the settlement, did you
22	specifically consider whether or not the directors
23	and officers would have contribution indemnification
24	claims against Grant Thornton and McGladrey?
25	A. Once again I'll defer to counsel but we

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 43 of 159

40

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	talked about the terms of the settlement, it's
2	applicability to Justice Oaks and Mumford.
3	Q. That really wasn't my question. My
4	question was did you specifically take into
5	consideration the officers and directors' claims
6	against McGladrey and Grant Thornton when you were
7	negotiating the settlement?
8	MR. CIMO: Objection to the form.
9	THE WITNESS: I think that's all part of
10	the settlement; any potential indemnity and
11	contribution claims, which as I testified to
12	before, I don't think exist.
13	BY MS. VILMOS:
14	Q. Okay. But was it specifically discussed
15	that there was a concern that the directors and
16	officers had claims and therefore the bar order was
17	necessary?
18	A. Are you asking me to disclose to you the
19	conversations I had with my counsel?
20	Q. No, I'm not. You entered into a settlement
21	that's been filed with the Court that you're asking
22	for approval and as part of that you have to meet the
23	Justice Oaks and the Mumford standards and you're
24	asking you're telling the Court that it's a
25	necessary part of the settlement and that Grant

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 44 of 159

41

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Thornton and McGladrey would not enter into the
2	settlement without it, correct?
3	A. That's correct.
4	Q. I am trying to under why.
5	A. Why they wouldn't enter it enter it?
6	Q. Yes.
7	A. Well, I assume you have to consult with
8	them. It takes two to have a settlement. And they
9	would not do the settlement without the bar order.
10	Q. They didn't articulate to you why?
11	A. Once again, I didn't personally speak with
12	them. The negotiating and conversations would have
13	been with my with my counsel and their counsel.
14	Q. You don't
15	A. I mean, they don't want to pay the estate
16	money and then potentially have to pay additional
17	money. They went to pay money and be done.
18	Q. Be done with what?
19	A. With having to pay money with as it relates
20	to CCD I suppose.
21	Q. But shouldn't you as the Trustee requesting
22	the settlement and indicating that it's fair and
23	equitable and necessary have an understanding as to
24	why the bar order is necessary?
25	MR. CIMO: Objection to the form.



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 45 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

-	
1	THE WITNESS: I think it's obvious and I
2	think I testified to it. But if you're asking me
3	to jump into the minds of Grant Thornton and
4	McGladrey, I don't know that that's appropriate.
5	Anybody, in general, would want a bar order so
6	the terms of the bar order get applied and they
7	don't have to engage in additional litigation or
8	payments.
9	BY MS. VILMOS:
10	Q. But sitting here today you don't know of
11	any particular litigation or payments in which Grant
12	Thornton and McGladrey would be faced with?
13	MR. CIMO: Objection to the form.
14	THE WITNESS: Other than the D&Os?
15	MS. VILMOS: Correct.
16	THE WITNESS: You asked me that before and
17	I as I'm sitting here I don't have any
18	additional parties to
19	BY MS. VILMOS:
20	Q. Is it then safe to assume that the bar
21	order was requested specifically to bar the D&Os from
22	their indemnification and contribution claims?
23	MR. CIMO: Objection to the form.
24	THE WITNESS: Once again, if I understand
25	your question correctly, you're asking me to

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 46 of 159

43

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	speculate as to what Grant Thornton and
2	McGladrey's rationale would be; is that what
3	you're asking me?
4	BY MS. VILMOS:
5	Q. You're part of this settlement. I presume
6	that you would have an understanding.
7	A. I can I tell you why I wanted to settle. I
8	can't tell you why they would want to settle other
9	than presuming or speculating.
10	Q. Okay, let's speculate.
11	MR. CIMO: Objection to the form.
12	THE WITNESS: They wanted to pay money to
13	get this over with and not have to pay any more
14	money in the future.
15	BY MS. VILMOS:
16	Q. And you do not believe that the officers
17	and directors have valid contribution and
18	indemnification claims, correct?
19	A. For the reasons set forth in the papers
20	that were filed in this case by my counsel, yes.
21	Q. If the D&Os don't have contribution and
22	indemnification claims would the bar order be
23	necessary?
24	A. Necessary for who?
25	Q. For Grant Thornton and McGladrey.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 47 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. I think you're asking me again to speculate
2	what they would feel is appropriate or necessary and
3	I can't do that. I can tell you from my perspective.
4	It was necessary because that's how I got the
5	settlements, plural.
6	Q. So I would need to ask them?
7	A. You need to ask them what's in their mind
8	as to why they entered into a settlement?
9	Q. Yes.
10	MR. CIMO: Objection to the form.
11	THE WITNESS: Other than what's contained
12	within the papers. I mean, they filed responses
13	to your objection to the settlement. So if you
14	wanted more information other than what's in
15	their papers filed by their counsel, then I guess
16	you have to do whatever you have to do.
17	BY MS. VILMOS:
18	Q. Do you know how much has been paid to
19	professionals in this case to date?
20	A. In the Chapter 7 case?
21	Q. Yes.
22	A. I have a copy of the Form 2 that I can
23	provide you which incidentally will be inconsistent
24	with my declaration in one respect, which is Furr &
25	Cohen from the previously approved fee application.



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 48 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	We got paid Furr & Cohen got paid some attorney
2	fees. \$93,153.20 and that's in accordance with ECF
3	number 1010, which were the remaining fees due under
4	that order. So that would change the declaration to
5	the extent that there would be \$93,000 less of a
6	liability I'm sorry, less of cash yes, less a
7	of cash and less of a liability.
8	Q. Would entering into the settlements and
9	receiving the payments pay any of the Chapter 11 or 7
10	admins?
11	A. It would go into the bucket. It will go
12	into the bank account and it will be used consistent
13	with the priorities set forth in the bankruptcy code
14	and consistent with any needs that I have and they
15	get court approved.
16	Q. Okay. So right now are there more in
17	expenses that need to be paid outstanding expenses
18	than assets?
19	A. The estate will remain administratively
20	insolvent is that the question even upon
21	receiving the \$350,000 if that gets approved if
22	the settlements gets approved; is that your question?
23	Q. Yes.
24	A. Definitely administratively insolvent if
25	we're talking about Chapter 11 admins, which is part



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 49 of 159

46

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

of administrative insolvency, so, yes. 1 2 How is the estate benefitting from the 0. 3 settlements? 4 Α. It's providing the estate money that will be used to go after the D&Os to pay necessary 5 expenses. If we're going have to litigate this all 6 7 the way that will be expensive and I need that money to do that. 8 9 MS. VALMOS: Let's take a recess. 10 (Whereupon, a brief recess was taken from 11 11:26 a.m. to 11:55 a.m.) 12 BY MS. VILMOS: 13 Ο. The two settlements with Grant Thornton and 14 McGladrey, in each one of them \$61,250 comes off the top of the settlements to go to counsel; isn't that 15 16 correct? 17 Α. It's consistent with the Court approved arrangement in which they were employed, yes. 18 19 So what is the total sum after the 0. 20 approximate \$120,000 getting paid to counsel that will go into the estate if these settlements are 21 22 approved? 23 Α. It would be 350,000 minus 61,000 and change 24 minus the other 61,000 and change. 25 And if that amount came into the estate Q.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 50 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	today what let me go back and ask you this: When
2	you looked at the claim registers earlier, I don't
3	recall if you told me what the amount of the
4	unsecured claims are; can you check on that?
5	A. What numbers are they?
6	MR. REICH: Exhibit Numbers 6 and 7.
7	MR. CIMO: Off the record.
8	(Whereupon, an off-the-record discussion
9	was held.)
10	THE WITNESS: Referring to claims register
11	ECF number six from CCD, secured claims are 9.2
12	million; priority, 1.2 million; and
13	administrative 33,000.
14	MR. REICH: The question was unsecured.
15	BY MS. VILMOS:
16	Q. Unsecured?
17	A. I can't give you a number. I can only
18	break it down as the claims register breaks it down.
19	Q. Okay.
20	A. So
21	MR. REICH: Let me ask you a question:
22	Compared to that, what's the total amount of
23	claims?
24	THE WITNESS: The total amount of claims
25	including secured priority and administrative as
ORANO	GELEGAL Orange Legal

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 51 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	set forth in the claims register 23.4 million.
2	MR. REICH: And the number on the
3	Northwest?
4	THE WITNESS: Exhibit Number 7 claims
5	register from CCD Northwest shows a total amount
6	of claims of 27.7 million.
7	MR. REICH: Just to short circuit real
8	quick.
9	MS. VILMOS: Go ahead.
10	MR. REICH: And if you subtract the secured
11	priority and admin claims that are listed on
12	there that will leave you with the unsecured
13	numbers in each of those cases?
14	THE WITNESS: I do not believe that's
15	correct. I believe that's incorrect. I believe
16	that if you added secured priority administrative
17	it would equal the total claims but
18	MR. REICH: It's your testimony there is no
19	unsecured
20	THE WITNESS: No, that's not my testimony.
21	Actually, I think you might be correct. But if
22	you give me a calculator I will confirm that.
23	MR. REICH: You don't have to give me an
24	exact number, just confirm that's how you
25	understand it.
1	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 52 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	THE WITNESS: Under the the claims
2	register where it has the 27.7 million.
3	MR. CIMO: You want to add it up?
4	THE WITNESS: I think you might be correct,
5	Ivan, because when I added in CCW Northwest, the
6	secured priority administrative assuming that
7	I added them correct it came out to 25 million
8	and change. And so that would leave me to
9	believe that it's roughly 2 million 2 plus
10	million of unsecured I think.
11	BY MS. VILMOS:
12	Q. So you agree with me that getting the
13	approximate \$230,000 into the estate if these
14	settlements were to be approved would not be enough
15	to pay any of the unsecured, priority secured or
16	admins?
17	A. I would disagree when it comes to admins.
18	But I don't know the answer because it's premature to
19	know that right now.
20	Q. You had testified earlier that if the bar
21	order is entered that the D&Os would still maintain
22	recourse; is that correct?
23	A. The language of the bar order allows for
24	the D&Os to make arguments that are allowable under
25	available nonbankruptcy law for setoffs. There's



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 53 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	more thorough detailed language that I can read
2	verbatim if you would like me to but that's
3	essentially what it says.
4	Q. And is it your opinion that approximately
5	the \$230,000 that we would be entitled to in setoff
6	is fair and equitable when faced with \$60 million
7	worth of claims?
8	MR. CIMO: Objection to the form.
9	THE WITNESS: Aside from whether I accept
10	or don't accept the premise of the question, I
11	think the settlements are fair and equitable. So
12	you can put whatever caveats there are. If it's
13	consistent with what's happening in this case
14	when it comes to total amounts of claims
15	including admins, et cetra, the answer is, yes,
16	it is fair and equitable in my business judgment
17	and professional opinion.
18	BY MS. VILMOS:
19	Q. What about specifically with regard to the
20	directors and officers?
21	MR. CIMO: Same objection.
22	THE WITNESS: I don't believe that the
23	standard of approval of the settlements are
24	whether it's fair or whether well, I can't
25	tell you whether the officers and directors are

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 54 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	going to like it. I assume they're not going to
2	like it but it doesn't mean that this doesn't
3	meet the standards that are appropriate that
4	have been put forth in the 11 Circuit opinion and
5	all the cases that have followed it, as well as
6	all the other cases that have taken place in the
7	Southern District that are referenced in our
8	paper. I believe both these settlements fall
9	well above the lowest range of reasonableness as
10	set forth in Justice Oaks, Mumford and all the
11	other applicable case law.
12	BY MS. VILMOS:
13	Q. As it specifically relates to the bar
14	orders that you're seeking in this case, what is the
15	unusual circumstance that would authorize a bar order
16	to be entered in these two settlements?
17	MR. CIMO: Objection to the form.
18	THE WITNESS: The settlements wouldn't
19	exist as they do but for the bar order because
20	they were a required element. I mean, I'll
21	defer if you want me to look at my declarations?
22	MS. VILMOS: Sure.
23	THE WITNESS: Repeat the question, please.
24	BY MS. VILMOS:
25	Q. What is the unusual circumstance that
	<u> </u>
ODANIC	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 55 of 159

52

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	authorizes a bar order in these two settlements?
2	MR. CIMO: Objection to the form.
3	THE WITNESS: Unusual circumstance? I
4	don't specifically remember that that's one of
5	the factors. If I'm wrong, I'll defer to my
6	declaration. But an unusual circumstance?
7	BY MS. VILMOS:
8	Q. Extraordinary circumstance.
9	MR. CIMO: Same objection.
10	THE WITNESS: I'm re-reading the Justice
11	Oaks and Mumford elements factors and as I set
12	forth in the declaration and I think as I
13	testified to and your question again is what is
14	the extraordinary circumstance?
15	BY MS. VILMOS:
16	Q. Let me rephrase it. Is there an unusual or
17	extraordinary circumstance that warrants a bar order
18	in these two settlements?
19	A. I wouldn't
20	MR. CIMO: Objection to the form.
21	THE WITNESS: I wouldn't have a settlement
22	without the bar order. I think that's the
23	circumstance that's requiring the bar order.
24	BY MS. VILMOS:
25	Q. But other than that factor there's no other
ORANO	GELEGAL Orange Legal

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 56 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 reason? 2 Α. There's --3 MR. CIMO: Same objection. The reason that it's in there 4 THE WITNESS: is because it's -- it was requested and there 5 wouldn't be a settlement without them. The 6 reason why it's appropriate are set forth in my 7 declaration in all the papers and I think that I 8 testified as to why they're consistent with the 9 10 applicable case law. 11 BY MS. VILMOS: 12 But you agree with me that just because the 0. 13 settling party request it that doesn't mean that it's 14 warranted in every case? MR. CIMO: Objection to form. 15 16 THE WITNESS: I imagine there's 17 hypothetically some cases where it wouldn't be appropriate. 18 In this case I think it's 19 appropriate. 20 BY MS. VILMOS: And you would also agree with me that 21 Ο. 22 there -- that the settlement and bar orders do not 23 benefit the directors and officers in any way? 24 MR. CIMO: Objection to the form. THE WITNESS: I don't know if there's not 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 57 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	any way. I imagine in the pending adversaries
2	that we're seeking to settle; McGladrey and Grant
3	Thornton, I suppose, can make some counterclaims
4	or cross-claims not cross-claims,
5	counterclaims or they can implead or whatever the
6	appropriate method would be, they can bring the
7	D&Os into those cases I suppose somehow and this
8	would stop that. I'm just thinking of what
9	benefits there could be and this resolves that.
10	BY MS. VILMOS:
11	Q. If they did bring in the directors and
12	officers we would have a right to cross-claim against
13	them, wouldn't we?
14	MR. CIMO: Objection to the form.
15	THE WITNESS: That's up to you guys.
16	BY MS. VILMOS:
17	Q. But that right would exist?
18	MR. CIMO: Same objection.
19	THE WITNESS: You're talking about
20	indemnity and contribution?
21	MS. VILMOS: Yes.
22	THE WITNESS: I would stand on my testimony
23	before as to the appropriateness of that.
24	BY MS. VILMOS:
25	Q. I'm using your hypothetical. If the



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 58 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 lawsuits continued then perhaps Grant Thornton and 2 McGladrey would have the right to bring us into their 3 adversaries? 4 Α. In theory I suppose that's an option. And in theory under your scenario then we 5 0. would have the right to defend and bring our own 6 claims against them? 7 MR. CIMO: Objection to the form. 8 9 If they're permissible under THE WITNESS: 10 law. 11 BY MS. VILMOS: 12 So other than, I guess, taking away any 0. 13 rights that they may have to bring us into their 14 lawsuit, is there -- what benefit do you see that the settlements provide those directors and officers? 15 16 MR. CIMO: Same objection. It's providing a benefit to 17 THE WITNESS: If -- I'll leave it to the officers 18 my estate. and directors to decide whether they think 19 20 there's any benefits to it. BY MS. VILMOS: 21 22 I'm asking specifically for your opinion. 0. 23 Α. Other than what I testified to, I can't 24 think of anything else as I sit here right now. 25 Thank you. I have no further MS. VILMOS:



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 59 of 159

56

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 questions. 2 (Whereupon, a luncheon recess was taken 3 from 12:07 p.m. to 1:29 p.m.) CROSS EXAMINATION 4 5 BY MR. REICH: 6 0. Good afternoon, Mr. Barmat, how are you? 7 Α. Great, how are you? 8 We know each other. We practiced in cases 0. together before, correct? 9 10 Α. I know who you are, Ivan. 11 0. We had cases before? 12 I think we had one maybe. Α. 13 Q. Now, in your role as a Chapter 7 Trustee, 14 you are the Chapter 7 Trustee of two legal entities in this case called CCD and CCD NW -- abbreviated 15 16 names? 17 Α. Correct. 18 Stands for Comprehensive Clinical 0. 19 Development and the Northwest version, correct? 20 Α. Yes. So when I talk about CCD, I'll be saying 21 0. CCD. And when I just say Northwest or NW, I'll be 22 23 talking about Northwest. 24 Α. I understand. 25 Is it your understanding that CCD NW is Q.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 60 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	known is Charles River as you remember?
2	A. That sounds familiar, yes.
3	Q. And that CCD NW at one time was acquired by
4	CCD, correct?
5	A. CCD NW was acquired by CCD. I'm not saying
6	that that's incorrect but I can't confirm that.
7	Q. In the three complaints the operative
8	complaints for purposes of what we discussed; which
9	would be the D&O complaint, which is Exhibit Number 5
10	to this deposition; the Grant Thornton adversary
11	complaint, which is Exhibit Number 8 to this
12	deposition; the McGladrey complaint, which is
13	Exhibit Number 33 to this deposition. It references
14	to what's known as the Charles River acquisition; are
15	you familiar with what the Charles River acquisition
16	is?
17	A. Yes.
18	Q. In fact, it's also been referred to at
19	times as what's known as Project Ginger; are you
20	familiar with that term?
21	A. That's not ringing a bell. I'm not saying
22	you're wrong. I don't have everything in my
23	immediate memory.
24	Q. Now, this case was not originally a Chapter
25	7, correct?



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 61 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 Α. Correct. 2 0. It was converted? 3 Α. Correct. 4 0. So prior to this conversion of this case 5 there was a creditors' committee in this case, 6 correct? That's my understanding. 7 Α. And creditors committees engage in certain 8 0. discovery under Rule 2004; are you aware of that? 9 10 Α. I don't dispute it. 11 Well, as part -- when the case was turned 0. 12 over to you, following conversion, did you acquire 13 the discovery materials of the creditors committee? 14 Α. I don't specifically recall. 15 0. Are you aware there were in the range of about 20 depositions under 2004 taken during the 16 course of these examinations? 17 I couldn't have given you that number but I 18 Α. 19 won't dispute it. 20 Were you aware that was a substantial Q. number of depositions taken? 21 22 Generally aware. The case went on for a Α. 23 period of time amount -- not that long a period of 24 time but there was a lot of stuff going on. Of course, I wasn't actively involved at that time but I 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 62 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	hadn't been appointed.
2	Q. I understand that. What I'm trying to find
3	out is as part of your normal duties as a Chapter 7
4	Trustee, particularly in the post conversion context,
5	you endeavor to obtain your hands on all discovery
6	materials of either the debtor or of the committee to
7	go forward as part of your ongoing investigation,
8	correct?
9	A. Only if I thought it was necessary or
10	appropriate for a particular reason. It's possible I
11	would assume if you want me to assume a lot of
12	it had to do with it probably the purchase of the
13	assets that was fait accompli by the time I was there
14	so it really wouldn't have been that or I wouldn't
15	have needed to know all the intricacies of that.
16	Q. So at the time of the Chapter 7 conversion
17	were all of the hard assets in other words non
18	we will call them non causes of action. When I say
19	"hard," I'm including tangibles like intellectual
20	properties and things like that non cause of
21	action type assets, had they already been sold?
22	A. There was an early phase and a late phase
23	which was substantially the business and they were
24	both sold during the Chapter 11.

Q. Preceding the conversion, before you took

ORANGELEGAL

25

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 63 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 over? 2 Before I took over. Α. 3 0. So when you took over the assets of the 4 estate were comprised of the potential causes of action; is that correct? 5 Whether there were some small 6 Α. Yes. assets -- I can't tell you unless you want me to 7 But certainly the substantial assets were look. 8 these three lawsuits and the incredibly difficult 9 10 task figuring out to what do with 14,000 boxes of clinical trial records. I don't know if you want me 11 12 to get into the specifics of that but if necessary I can get into that. I some had receivables -- I am 13 14 looking at my Form 2 that I collected from my quick glance and I had a lawsuit that was settled not too 15 16 long ago with UnitedHealthcare Services for \$85,000. Not only do you have the causes of action 17 Ο. that you actually asserted, UnitedHealthcare and 18 19 these three lawsuits, do you also have any other 20 potential causes of action that might exist out there 21 as well? 22 Any cause of action other than the Α. 23 bankruptcy estate would be mine as the Trustee. 24 0. As part of your job as the Trustee it's your job to investigate the validity of those causes 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 64 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	of action and potentially the estate, correct?
2	That's your normal job as the Trustee?
3	A. Of course. Myself individually or through
4	professionals that I hire to
5	Q. That was my next question. In many
6	instances you hire professionals to assist you in
7	that regard; is that correct?
8	A. True.
9	Q. I've known you for a while. You're
10	besides being a Chapter 7 Trustee, you're a
11	well-known bankruptcy lawyer in this community
12	that's your primary area of practice?
13	A. I'm a bankruptcy lawyer and I'm a
14	bankruptcy Trustee.
15	Q. Correct. And your firm also is primarily a
16	known as a bankruptcy firm?
17	A. That's fair. Although we do other things.
18	Q. Correct. It's my understanding the general
19	counsel to the Trustee in this case and I don't
20	mean the adversaries I'm talking about the general
21	counsel Trustee in the main case is the Furr & Cohen
22	firm, correct?
23	A. Correct.
24	Q. Mr. Wernick is, I guess, handling most of
25	that work?

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 65 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

-	
1	A. Mostly I would say, that's fair to say.
2	Q. And then for your particular litigations
3	you retained outside special counsel, which in the
4	case of these three cases is the Genovese, Joblove
5	firm including Mr. Cimo and Ms. Mark; is that
6	correct?
7	A. Yes. There were some adversaries that
8	at least the one, UnitedHealthcare that we that
9	Furr & Cohen internally handled.
10	Q. You did, okay. You hired the Genovese firm
11	because of their unique skills and talents with
12	respect to these types of case the more complex
13	A. Mr. Cimo
14	Q account malpractice, D&O cases.
15	Mr. Cimo's office has a reputation?
16	A. Mr. Cimo, Ms. Mark and the Genovese firm
17	have a very good reputation for handling D&O claims
18	and that was certainly one of the factors I used in
19	retaining them.
20	Q. Right. I mean and you also retained as
21	part of this bankruptcy process, you have other
22	professionals to assist you in your duties including
23	the retention of accountants, right?
24	A. Capilla.
25	Q. Mr. Soneet Capilla?



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 66 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. Soneet Capilla and his firm.
2	Q. Soneet Capilla & Mukamal?
3	A. Originally it wasn't Capilla & Mukamal but
4	it is now.
5	Q. Correct. In assessing the strengths and
6	weaknesses of the various cases you utilized the
7	service of both counsel special counsel and your
8	experts; is that correct?
9	A. Of course.
10	Q. Including evaluation of settlements as
11	well, correct?
12	A. Of course.
13	Q. And if in your role as Trustee you also
14	serve the role of the even though they're
15	nonoperating because they're now Chapter 7 you
16	serve the role of officers, directors, management of
17	the company you make all executive decisions with
18	respect to the affairs of these two corporate
19	entities; am I correct?
20	MR. CIMO: Objection to the form.
21	THE WITNESS: As you said in your question,
22	it's a Chapter it's nonoperating Chapter 7 so
23	I don't think that is applicable.
24	BY MR. REICH:
25	Q. It's still they're still corporations,



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 67 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	correct?
2	A. I am the bankruptcy Trustee of the
3	bankruptcy estate of those two corporations.
4	Q. You are the ultimate decision maker of
5	decisions made on these two corporations from the
6	motion you became appointed the Trustee, correct?
7	MR. CIMO: Objection to the form.
8	THE WITNESS: My roles are dictated by the
9	bankruptcy code and I'm a fiduciary of these
10	corporations. I'm not I don't want to just
11	blankly say yes to what you're saying because I
12	don't completely comprehend the scope of what
13	BY MR. REICH:
14	Q. I'm trying to find out for example, you
15	made your decision to hire the Genovese, Joblove
16	firm, correct?
17	A. As stated, yes.
18	Q. Do you have to run it by anybody else, the
19	board of directors or
20	A. I make the final decision.
21	Q. You make the final decision. Same thing
22	with the hiring of Mr. Capilla?
23	A. I make the final decision.
24	Q. Same thing with respect to bringing the
25	lawsuits, am I correct?



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 68 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

-			
1	Α.	I make the final decision.	
2	Q.	With respect to settlement of the lawsuits;	
3	same thin	ng, you make the final decision?	
4	Α.	Yes.	
5	Q.	And in your decision making process you	
6	retain pr	ofessionals to assist you in that regard,	
7	correct?		
8	Α.	Yes.	
9	Q.	And, in fact, has there been a is the	
10	0 Capilla firm also doing the tax work for the estate?		
11	A.	Yes.	
12	Q.	So you retained them to do the tax work?	
13	A.	Yes.	
14	Q.	And you recognize that operating companies	
15	also reta	in accounting firms to do tax work, correct?	
16	Α.	Is your question do operating companies	
17	retain ac	countants to do tax work?	
18	Q.	Yes.	
19	A.	I believe that's a fair general statement.	
20	Q.	It's a fair general statement that they	
21	also retain accounting firms to do audits; is that		
22	correct?		
23	A.	Yes.	
24	Q.	To help them supplement those areas where	
25	the compa	ny may be deficient; is that correct?	

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 69 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. I suppose there could be a multitude of	
2	reasons why any company would hire any accountant or	
3	auditor.	
4	Q. Sometimes they hire accounting firms to do	
5	due diligence on transactions; is that correct?	
6	A. I believe that's correct.	
7	Q. Sometimes they hire law firms to assist	
8	with due diligence; is that correct, on transactions?	
9	A. That seems logical to me.	
10	Q. Okay. Now with respect to these companies,	
11	CCD and CCD NW, do you know who the law firm was that	
12	was hired to do the due diligence with respect to the	
13	Charles River transaction?	
14	A. Not off the top of my head, no.	
15	Q. Would you if I told you that the that	
16	it was DLA Piper did the due diligence with respect	
17	to that transaction, would that refresh your	
18	recollection?	
19	A. Sounds familiar now that you mentioned DLA	
20	Piper.	
21	Q. DLA Piper was the due diligence counsel for	
22	CCD and the acquisition of what's now CCD NW, Charles	
23	River, correct?	
24	A. I don't know that to be incorrect. It	
25	sound correct.	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 70 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Q. Are you also aware that CCD retained Grant	
2	Thornton to conduct the due diligence on the exact	
3	same transaction; were you aware of that?	
4	A. That sounds correct.	
5	Q. In fact, I'll ask you to look at what's	
6	DE73 in the Grant Thornton adversary case, it's	
7	Exhibit Number 15 of yours, which would also make it	
8	in this	
9	A. Exhibit Number 21.	
10	Q. Exhibit Number 21 in this case, which is a	
11	February 28, 2011 letter.	
12	Can you tell me what that letter is?	
13	A. It's a Grant Thornton letter to	
14	Mr. McGovern regarding proposed acquisition of	
15	Charles River Clinical Services Northwest, Inc.,	
16	dated February 28, 2011.	
17	Q. And do you see the scope of work there?	
18	A. I believe that's what I just read you	
19	mean the I do see it, yes.	
20	Q. And there's Exhibit A to the scope of work,	
21	do you see that? It would say page 25 of 29 at the	
22	top.	
23	A. Proposed work plan?	
24	Q. Yes. All the way through page 27; do you	
25	see that?	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 71 of 159

68

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. Yes, I'm looking at it.	
2	Q. And what's the difference what's	
3	Comprehensive Neuroscience, Inc.?	
4	A. As I sit here I don't recall.	
5	Q. And Charles River Clinical Services	
6	Northwest, Inc., is what's now known as CCD NW?	
7	A. I believe that's true.	
8	Q. And is Comprehensive Neuroscience, Inc. now	
9	known as CCD?	
10	A. I think that's true but I'll defer to the	
11	pleadings. But I think that's true.	
12	Q. And says on page 24 of 29 of this	
13	document do you see the signature of Mr. John	
14	McGovern, chief executive officer dated March 3, 2011	
15	for Comprehensive Neuroscience, Inc.?	
16	A. I see page 24 of 29 and what you described,	
17	yes.	
18	Q. Does that refresh your recollection as to	
19	whether Comprehensive Neuroscience is the same	
20	company as what is now known as CCD?	
21	A. I think that's true.	
22	Q. Now, in the adversary complaint against	
23	what I call the D&Os, which is Exhibit Number 5	
24	I'm not going to get into the details of it but	
25	there is great number of allegations that the D&Os	

ORANGE LEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 72 of 159

69

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

breached their respective fiduciary duties with 1 2 respect to the Charles River transaction; you aware 3 of that? 4 Α. I think that's one of the allegations against them, correct. 5 And in the Grant Thornton complaint, 6 0. Exhibit Number 8 -- I'll ask you to pull out 7 Exhibit Number 8. 8 9 Α. I will. 10 0. Docket entry one in the Grant Thornton case 11 15-01233. 12 I'm looking at it. Α. 13 Q. Can you turn to paragraph nine, please. 14 Α. I'm looking at it. Now, this is a one count complaint under 15 0. 16 statutory avoidance counts; is that correct? 17 Α. Yes. 18 It's based upon a legal theory that Grant Ο. 19 Thornton did not provide the debtor with reasonably 20 equivalent value for its services, okay --21 MR. CIMO: Objection to the form. MR. REICH: I'm looking and it says lack 22 23 reasonably -- okay, it's fine. 24 BY MR. REICH: 25 For not -- based upon Grant Thornton's Q.

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 73 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	failure to among other things adequately or properly
2	audit the debtors financial statement for the year
3	ending 2011 based upon the acts and omissions of the
4	debtors former officer and directors and/or control
5	persons as alleged in that certain adversary
6	proceeding which I'll say is the D&O case
7	pending in the above caption to the administrative
8	bankruptcy case; you see that, sir, right?
9	A. Yes, I do.
10	Q. It says what Grant Thornton didn't do is
11	properly audit the financial statement for the year
12	ending 2011; do you see that?
13	A. I do.
14	Q. You do not sue can you tell me why you
15	do not sue Grant Thornton for negligence for
16	professional malpractice like you do in the McGladrey
17	complaint, which is Exhibit Number 33?
18	MR. CIMO: I am going to object to the form
19	and instruct the witness not to answer to the
20	extent it's inquiring on attorney/client
21	privilege information or work product of your
22	professionals.
23	BY MR. REICH:
24	Q. I'll you to the extent it doesn't. Was
25	there a reason why you only sued Grant Thornton on an



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 74 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	avoidance count when in McGladrey you sued them for
2	both an avoidance count and for professional
3	negligence?
4	MR. CIMO: Same instruction.
5	THE WITNESS: To answering that question
6	will require me to violate the privilege that was
7	just announced by Mr. Cimo.
8	BY MR. REICH:
9	Q. Is there a reason that you as the Trustee
10	did not sue Grant Thornton in this complaint for its
11	conduct with respect to the due diligence that it
12	conducted on CCD's behalf or at time which I guess
13	called Comprehensive Neuroscience with respect to
14	the Charles River transaction.
15	MR. CIMO: Same instruction.
16	THE WITNESS: Same response.
17	BY MR. REICH:
18	Q. I'll also ask you is there a reason you did
19	not sue DLA Piper with respect to their due diligence
20	with respect to the Charles River transaction?
21	MR. CIMO: Same instruction.
22	THE WITNESS: Same response.
23	BY MR. REICH:
24	Q. Now, what I gather from this is that you
25	made a conclusion based upon advice of counsel and



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 75 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	work product that you chose not to pursue them I
2	don't want to get into why, okay? But you will admit
3	that the complaint against Grant Thornton does not
4	include challenging the work that it performed in the
5	due diligence as reflected in the exhibit that we
6	were looking at Exhibit sorry, DE73 is
7	Exhibit Number 21; is that correct?
8	MR. CIMO: Objection to the form. You can
9	answer.
10	THE WITNESS: I believe \$259,333 that was
11	received, that is the subject of this complaint,
12	would include the work that was performed by
13	Grant Thornton, which I believe would include
14	what you were just talking about.
15	BY MR. REICH:
16	Q. So the 259,000 that's set forth in
17	paragraph eight and these various checks and wire
18	transfers would include the services performed with
19	respect to the due diligence that Exhibit Number 21
20	covers; is that correct?
21	A. I believe that to be true.
22	Q. But the complaint in paragraph nine is that
23	the lack of reasonably equivalent service value was
24	not provided as it relates to the audit, not with
25	respect to the due diligence; is that correct?



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 76 of 159

73

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	MR. CIMO: Objection to the form.
2	THE WITNESS: Paragraph nine says what
3	paragraph nine says.
4	BY MR. REICH:
5	Q. So paragraph nine says that Grant
6	Thornton the reason there is no lack of reasonable
7	equivalent value is it didn't adequately and properly
8	audit the debitor's financial statement for the year
9	ending 2011 based upon the acts and omissions of the
10	D&Os as set forth in the D&O case if I'm
11	paraphrase rather than repeating it again is it an
12	accurate paragraph?
13	A. I'm going to stick with the language in
14	paragraph nine.
15	Q. Now, let me ask you this question: In the
16	case against my client, the former CFO of the
17	company, and against the other officers I'm sorry,
18	the other officers, Mr. McGovern and the directors
19	Mr. Crinchlow and Ms. Vilmos' clients you stated
20	that they have not done they breach their
21	fiduciary duties or improperly handled their duties
22	to the company by virtue of having done the Charles
23	Recover Transaction; is that correct?
24	MR. CIMO: Objection to form.
25	THE WITNESS: That was one.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 77 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

BY MR. REICH: 1 2 0. Amongst other things that was one of them, 3 correct? 4 Α. Correct. And you did not sue Grant Thornton for 5 0. their work as related to providing the due diligence 6 on that transaction and you did not -- is that's 7 8 correct? 9 MR. CIMO: Objection to the form. 10 THE WITNESS: I don't believe that's 11 correct. 12 BY MR. REICH: 13 Q. You did sue them for the work they 14 performed as related to the due diligence? Grant Thornton? 15 Α. 16 0. Yes. 17 Α. I believe that's part of the \$259,000. 18 You're suing them for the return of their 0. 19 fees, okay? But are you actually -- but you're 20 stating in paragraph nine that the reason they are to return all those fees is because you didn't do a good 21 22 job on the audit. You don't say anything about not 23 doing a good job on the due diligence; is that 24 correct? MR. CIMO: Objection to the form. 25 **ORANGELEGAL**

C 8

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 78 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Mischaracterizes what the complaint says. You
2	need to read the paragraph and not try to
3	mischaracterize what it say.
4	THE WITNESS: It does say all or certain of
5	the services it provided to one or both, et
6	cetera. And then it says among other things, et
7	cetera. I think
8	BY MR. REICH:
9	Q. So it's your testimony here today here
10	today that that lawsuit covered the due diligence as
11	well? Their malfeasance with respect to the
12	conducting of due diligence was covered within the GT
13	lawsuit?
14	MR. CIMO: Objection to the form.
15	BY MR. REICH:
16	Q. Is that
17	A. Those are your words.
18	Q. That's my question and I'm looking for your
19	answer.
20	MR. CIMO: If that's the question, I object
21	to the form. You can answer.
22	THE WITNESS: The complaint is for recovery
23	of avoidable transfers up to \$259,000 259,333
24	as alleged in the complaint. Services that were
25	provided for in exchange for the 259,335,



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 79 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	we're seeking the avoidance of those payments.
2	BY MR. REICH:
3	Q. So it's your position that the McGladrey
4	sorry, strike that. That the GT lawsuit that you are
5	settling, subject to the pending settlement motion,
6	is intended to cover claims under this complaint that
7	were made relating to GT's failure to perform its
8	duties the due diligence as set forth in
9	Exhibit Number 21?
10	MR. CIMO: Objection to the form.
11	THE WITNESS: Exhibit 21.
12	BY MR. REICH:
13	Q. The retention due diligence retention
14	for Charles River?
15	A. It's not a complicated complaint so the
16	complaint stands for itself.
17	Q. I'm asking you a question. Is your is
18	the lawsuit I'll ask you two questions; one about
19	the lawsuit and one about the settlement, okay?
20	Is the lawsuit intended to cover the
21	malfeasance on Grant Thornton's part with respect to
22	failure to perform the services on Exhibit Number 21?
23	A. I think so, yeah. Well, it's for the
24	recovery of avoidable transfers. We did not get
25	reasonable equivalent value in exchange for the

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 80 of 159

77

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

services provided as set forth in the complaint. 1 2 0. Which services? 3 MR. CIMO: Objection to the form. 4 BY MR. REICH: I'll make it easier, go to Exhibit Numbers 5 0. 6 19 --7 MR. CIMO: You're not making it easy. BY MR. REICH: 8 Exhibit Numbers 19 and 20 are two retainer 9 Q. exhibits. 10 11 MR. CIMO: I'm trying to understand the 12 relevance of this to the 9019 factors. If you're 13 going to tie it in, that's great. I'm trying to 14 understand how this has anything to do with approval of the settlement. I'll let you keep 15 16 qoinq. MR. REICH: I'll explain it to Judge Olson. 17 18 MR. CIMO: You don't need to yet but get 19 him on the phone and see what he has to say about 20 this. MR. REICH: You have a complaint against my 21 client --22 23 MR. CIMO: You don't need to explain now. 24 MR. REICH: Fine. 25 MR. CIMO: At some point we will give him a

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 81 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	call and you can explain to him.
2	BY MR. REICH:
3	Q. Look at Exhibit Number 19, which is 7-1 or
4	DE71, which is also Exhibit Number 13 in your exhibit
5	register.
6	A. The answer is I think that all the service
7	provided that are referenced in 7.1, 7.2 and 7.3 are
8	covered within the allegations of our complaint.
9	Q. Including the tax services that would be
10	provided under Exhibit Number 20?
11	A. There's three separate retainer agreements
12	and I believe they're all included within the
13	allegations. And I know that they had affirmative
14	defenses with regard to the language contained in
15	these in these three retainer agreements.
16	Affirmative defenses as well as motion for summary
17	judgment that dealt with it.
18	Q. Exhibit Number 19 is the 2011 audit
19	retention; is that correct?
20	A. Exhibit which one?
21	Q. Exhibit Number 19.
22	MR. CIMO: Objection to the form. The
23	document speaks for itself.
24	MR. REICH: I am asking him what his
25	understanding

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 82 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	THE WITNESS: It's the January 12, 2012
2	letter and
3	MR. REICH: If Mr. Cimo would like you to
4	read what the scope of services are just
5	MR. CIMO: I think the document speaks for
6	itself. I mean, we can waste time
7	MR. REICH: I know we can.
8	THE WITNESS: There was three; there was
9	tax, there was an audit and there was
10	BY MR. REICH:
11	Q. Due diligence?
12	A. Due diligence.
13	Q. Is 19 the audit one, is 20 the tax one?
14	A. It look like yes, 19 is audit.
15	Q. 20 is tax and 21 is due diligence; am I
16	correct?
17	MR. CIMO: Let the record reflect the
18	witness is flipping through the pages of the
19	document to read it.
20	MR. REICH: Is that an objection?
21	MR. CIMO: No.
22	MR. REICH: Speaking objection is improper.
23	MR. CIMO: There is no video. He is going
24	through the pages so he can read it, which you
25	can do too. We'll stipulate that's what it is.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 83 of 159

80

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 THE WITNESS: There you go. 2 MR. CIMO: We stipulate that that's what it 3 says. BY MR. REICH: 4 5 You mentioned before -- so 19 through 21 0. are all included within the services of which you 6 complained in paragraph nine of the GT complaint? 7 Paragraph nine is not the entire complaint. 8 Α. 9 But, yes, in general. 10 Q. Where in there are you complaining about 11 the tax services that were provided? 12 MR. CIMO: Objection to the form. Asked 13 and answered. This is inappropriate. Paragraph 14 nine speaks for itself. He read to you the language that says it's not limited. 15 16 MR. REICH: After your speaking objection, are instructing him not to answer. 17 18 MR. CIMO: I am going to --19 MR. REICH: Fine. 20 MR. CIMO: I'm not doing it now but I'm 21 telling you this is starting to harass him 22 because he already answered your question. 23 BY MR. REICH: 24 Q. Where in the complaint does it say you're complaining for the tax services that were provided? 25

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 84 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	A. Paragraph 8 is \$259,355, that encompasses
2	the services that were provided by GT. Paragraph 9
3	says the lack of reasonably equivalent value as
4	provided by GTL in regard to all or certain of all or
5	certain of the service it provided to one or both
6	debtors for the GTL transfers based upon its failure
7	to among other things adequately or properly audit
8	the debtors financial, et cetera. There are caveats
9	in there. It says all or certain of the services.
10	It says among other things.
11	Q. Is the among other things inclusive of the
12	due diligence and the tax services?
13	A. Inclusive of all the services that were
14	provided in exchange \$259,335, which, I believe, is
15	inclusive of the three scopes of services referenced
16	in 19, 20 and 21.
17	Q. Okay. With respect to the Charles River
18	transaction, what was it that GT did wrong in
19	providing due diligence services as it relates to
20	what my client, the former CFO, and the officers
21	and Mr. McGovern and the other directors do?
22	MR. CIMO: I'll instruct the witness not to
23	answer because now you're taking a substantive
24	deposition of this witness. You can get the
25	judge to give you information on that.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 85 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	MR. REICH: The fact of the matter is this
2	is about
3	MR. CIMO: I don't care what you say it's
4	about.
5	MR. REICH: Are you going to instruct him
6	not to answer?
7	MR. CIMO: If the Court orders him to
8	answer, he will. Right now you're taking a
9	substantive deposition and I am objecting. If
10	the Judge disagrees
11	MR. REICH: What is it that
12	MR. CIMO: I am not arguing with you.
13	MR. REICH: You have to prove the
14	reasonableness of the settlement, okay.
15	MR. CIMO: We're going to.
16	MR. REICH: You are? You haven't yet but
17	that's besides the point.
18	MS. MARK: We will see about that.
19	MR. REICH: GT was supposed to provide due
20	diligent services, okay? You're claiming you
21	sued them for the recovery of the work they did
22	under those services, okay? You're settling for
23	them for the failure to properly do the due
24	diligence of the services. I'm trying to get to
25	your analysis of that and how it relates to my

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 86 of 159

83

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	clients my client.
2	MR. CIMO: That wasn't question you asked.
3	The question you asked was substantively a
4	question about liability. This goes to the very
5	underlying basis of the lawsuit.
6	MR. REICH: You can't
7	MR. CIMO: I'm instructing the witness not
8	to answer at this time. If the Court orders
9	MR. REICH: Mark that.
10	MR. CIMO: If the Court orders him to
11	answer it, we'll bring him back and he will
12	answer it.
13	You're now going into substantive areas
14	which are not within the scope of the borrower or
15	the 9019 motion.
16	BY MR. REICH:
17	Q. Let's ask the question. If my client had
18	relied upon Grant Thornton's services in conducting
19	the due diligence on the Charles River transaction
20	and my client was found liable in the case against
21	her for not doing her duties well as alleged against
22	her, would you not think that my client could rely
23	upon Grant Thornton's due diligence reports and
24	services to make a contribution or potential
25	indemnity claim against them?
1	

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 87 of 159

84

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Objection to the form. 1 MR. CIMO: You can 2 answer if you can. 3 THE WITNESS: I think after second or third 4 not in your question I got confused. So you may have to rephrase it. 5 MR. REICH: You want me to rephrase it, I 6 will rephrase it. 7 BY MR. REICH: 8 9 If Grant Thornton didn't do a good job in Ο. 10 its due diligence wouldn't my client be able to assert a contribution and indemnity claim against 11 12 them in the event it was found liable in a case based 13 on the allegations against her with respect to Charles River? 14 15 MR. CIMO: Objection to the form. You may 16 answer if you can. THE WITNESS: Under the terms of the bar 17 order there are certain provisions that provide 18 19 some protection that I believe are available for 20 your client. BY MR. REICH: 21 22 My question wasn't in terms of the 0. 23 borrower, my question was without the borrower. If 24 there was no borrower -- in fact, if you never even sued Grant Thornton or you never settled Grant 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 88 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Thornton, would my client be able to assert against 1 2 Grant Thornton contribution and indemnity claims --3 MR. CIMO: Objection to the form. 4 BY MR. REICH: -- if they were -- if she was found liable 5 Ο. for her malfeasance with respect to the Charles River 6 7 transaction? MR. CIMO: Objection. 8 BY MR. REICH: 9 10 Q. Is a case against us? 11 MR. CIMO: Objection to the form. You 12 answer if you can. 13 THE WITNESS: You can assert any claim that 14 you're interested in asserting. It will be up to the Judge to determine whether it's a valid 15 claim. 16 17 BY MR. REICH: 18 Did you or your counsel have an opportunity Ο. 19 to review the various deposition transcripts that were obtained from either the debtor or the committee 20 21 prior to the conversion? 22 I didn't personally review any of those Α. 23 deposition transcripts as far as I can remember and I 24 don't know specifically whether my counsel did or 25 didn't.



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 89 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 Same thing with the documents that Ο. Okav. 2 were produced in connection with the then Chapter 11 3 case? When the case was first converted to a 7 I 4 Α. looked at a lot of stuff. I in no way can remember 5 or testify as to what exactly I looked at. As far as 6 7 what my counsel looked at, I don't know exactly -specifically everything that they looked at. 8 9 In these two cases were claims bar dates Q. 10 set? 11 Corporate cases they're set automatically. Α. 12 It's not like in an individual case where you have to file a notice to get a claims bar deadline. 13 14 0. Do you know what claims bar dates in both 15 of these cases are? If I look at the claims register I can tell 16 Α. 17 you. That will be on exhibits -- I believe 18 Q. 19 Exhibit Number 6 and 7. 20 Α. For the CCD case the last date to file claims is 12/31/13. And on the CCD Northwest it 21 22 doesn't sav. There you qo, that's my answer. 23 0. Have these cases been administratively consolidated? 24 They were administrative consolidated 25 Α. **ORANGELEGAL**

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 90 of 159

87

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

during the course of the Chapter 11. 1 2 Have they ever been subsequently 0. 3 consolidated? 4 Α. No, I don't believe so. So both CCD and CCD NW have different 5 0. creditors; is that correct? 6 7 MR. CIMO: Objection to the form. THE WITNESS: That would require me to go 8 9 and cross reference them right now. 10 BY MR. REICH: 11 I'm not saying there's not crossover 0. 12 creditors but I'm saying they have their own 13 independent obligations and debts? 14 MR. CIMO: Objection to the form. You can 15 answer if you can. 16 THE WITNESS: There -- I mean, there are 17 two separate estates and there are two separate sets of claims that were filed. 18 19 BY MR. REICH: 20 0. With respect to the GT settlement did you do any allocation of the \$175,000 between CCD and CCD 21 22 NW? 23 No. CCD NW reported no distribution that Α. was filed in that case. If it has to be withdrawn at 24 some point for any more particular reason and 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 91 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	reopened then that can happen.
2	Q. So when the monies comes into this if
3	this settlement is approved, and the 175,000 per case
4	net of attorney's fees 61,000 in attorney's fees
5	comes into respective cases, it will only come into
6	CCD case; is that correct?
7	A. Yes.
8	Q. And so the creditors of CCD NW will not be
9	getting any monies as a result of these settlements;
10	is that correct?
11	MR. CIMO: Objection to the form.
12	THE WITNESS: That remains to be seen.
13	BY MR. REICH:
14	Q. Why does it remain to be seen? What can
15	happen to change that?
16	A. If for some reason it became appropriate to
17	reopen the CCD Northwest case then that would change
18	it.
19	Q. Do you have any potential to reallocate the
20	net proceeds of the settlement into CCD NW?
21	MR. CIMO: Objection to the form. I will
22	instruct you not to answer to the extent it
23	requires you to give your work product or your
24	thought process on how you're going to do
25	something in the future or advice of counsel.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 92 of 159

89

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

MARC	BARMAT
1	Other than you can answer.
2	THE WITNESS: I think to answer that would
3	require me to I'll follow my attorney's
4	instructions.
5	MR. CIMO: I am not instructing you not to
6	answer.
7	THE WITNESS: I am asserting the privilege.
8	BY MR. REICH:
9	Q. You're saying you can't answer without
10	invading due privilege; is that your answer?
11	MR. CIMO: Objection. I didn't just raise
12	due privilege.
13	BY MR. REICH:
14	Q. Other than attorney/client work product?
15	A. Ask the question again.
16	MR. CIMO: It would help if you rephrase.
17	THE WITNESS: My settlement this
18	settlement that's before the Court
19	MR. REICH: Both GT and McGladrey?
20	THE WITNESS: All the same answers would
21	apply to my analysis whether it was just the CCD
22	case or the CCD NW case.
23	BY MR. REICH:
24	Q. What is that analysis?
25	A. If the CCD NW case didn't exist and those

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 93 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	creditors didn't exist and those creditors didn't
2	exist, the same analysis would exist just based upon
3	the claims register for CCD.
4	Q. What I'm trying to ascertain is how much of
5	the 175 net in each case is going to CCD NW
6	creditors, that's what I'm trying to ascertain. Can
7	you answer that question without invading the
8	privilege?
9	MR. CIMO: I want to object to the form. I
10	think he's already answered that. I thought you
11	were going
12	MR. REICH: You're objecting to everything.
13	MR. CIMO: That's not true.
14	He did tell you he wasn't sure right now
15	and that he may reopen that estate at a later
16	date, that's my recollection.
17	BY MR. REICH:
18	Q. What would cause you to reopen that estate?
19	MR. CIMO: Object to the form of the
20	question. You can re-answer.
21	THE WITNESS: As I sit here, I can't tell
22	you.
23	BY MR. REICH:
24	Q. Reopening the estate means you're going to
25	get new assets, correct?



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 94 of 159

91

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Objection to the form. 1 MR. CIMO: 2 THE WITNESS: Not necessarily. 3 BY MR. REICH: 4 0. If you get a recovery against our clients you might reopen CCD NW? 5 MR. CIMO: Objection to the form. 6 THE WITNESS: Anything is possible. 7 BY MR. REICH: 8 9 Right now you have not received any money Q. 10 as a result of the D&O case and both cases are 11 administratively insolvent, correct? 12 I know for sure your client hasn't paid Α. 13 anything and the cases are administratively 14 insolvent, yes. 15 0. When you allocate the 175 per case -- per 16 settlement, is it your testimony that the entire 17 amount is going to be allocated into the CCD estate? 18 MR. CIMO: Objection to the form. 19 It's premature for me to THE WITNESS: 20 answer that. I don't have the answer right now. BY MR. REICH: 21 22 I'm trying to figure out when you're 0. 23 approving settlement for the benefit of the 24 creditors, CCD and CCD NW, which are two bankruptcy estates that have not been subsequently consolidated, 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 95 of 159

92

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

how are you going to ascertain how that money will 1 2 flow down to the creditors of those respective 3 estates? 4 MR. CIMO: Object to the form. THE WITNESS: I am not sure I need to have 5 that answer right now. As I understand it this 6 deposition is scheduled to determine whether 7 these settlements are appropriate under the 8 9 applicable standards. I think, in fact, the 10 notice says that. I am not here to testify what 11 distribution is ultimately -- the specifics of the distribution. So I can't tell you --12 13 BY MR. REICH: 14 0. You answered Ms. Vilmos' question before, 15 the monies would come in after the payments of the --16 the contingency payments to the Genovese firm are 17 going go to the payment of the administrative 18 expenses; is that correct? I can't tell you that exactly. But 19 Α. certainly they're not going to go to the general 20 unsecured which is what I think the question was. 21 22 And that is -- okay. 0. 23 It may go to experts against your client. Α. 24 0. Now secured creditors, whatever claims they have remaining, are they now unsecured as a result of 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 96 of 159

93

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	the sale of the assets?
2	MR. CIMO: Objection to the form. Only to
3	the extent that it requires you to divulge any
4	confidential or privilege information or
5	discussions with your general counsel about these
6	issues. Otherwise, you can answer.
7	THE WITNESS: I have not done claims I
8	haven't done claims objections. So there may be
9	proper and appropriate bases to object to the
10	claims that are pending right now.
11	BY MR. REICH:
12	Q. Have the secured creditors in these cases
13	been paid anything as of yet other than whatever they
14	were entitled to as a result of the asset sales that
15	occurred preconversion?
16	A. I didn't pay secured creditors
17	Q. I said in these cases and that's
18	A. In the Chapter 11.
19	Q. Well, I said preconversion sale.
20	A. Preconversion sale in the Chapter 11?
21	Q. Yes.
22	A. The assets were sold for less
23	Q. It's the same case it's just a converted
24	case.
25	A. In the Chapter 11, early in the late
ORANG	ELEGAL Orange Legal

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 97 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	phase assets were sold for roughly \$5 million, which
2	I believe all went to Oxford.
3	Q. So Oxford being a secured creditor,
4	correct?
5	A. Correct.
6	Q. With some carve outs, correct?
7	A. Some carve outs.
8	Q. Was Oxford paid in full on its claims?
9	A. No.
10	Q. And Oxford has not received any monies
11	other than what it received as a result of those two
12	sales; is that correct?
13	A. I'm holding some money in an earmarked
14	account with I think about \$23,000 in it that may or
15	may not end up going to Oxford.
16	Q. Will any monies be going to the priority
17	creditors?
18	A. I don't know.
19	Q. Right now you said you know for sure that
20	the general unsecured are not going to see any?
21	A. There currently exists there's 23,000 in
22	one account and that's the Oxford escrow account and
23	there's 31,000 approximately in the other account
24	the other estate account. Hopefully there will be
25	350,000 minus Genovese's contingency fee that will go

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 98 of 159

95

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	into that account and I can't tell you where that
2	money will go may go because it may go to experts.
3	You guys may call me tomorrow and say you're going to
4	accept the \$4.25 million settlement and then this
5	money will be used to pay other people.
6	Q. Okay.
7	MR. REICH: For the record, I'm going move
8	to strike all references to the settlement the he
9	made throughout the deposition and ask they be
10	redacted from the transcript. Will you
11	stipulate
12	MR. CIMO: I have no objection.
13	MR. REICH: It occurred throughout this
14	deposition.
15	MR. CIMO: Well, it wasn't we're happy
16	to do that.
17	MR. REICH: We'll have a transcript.
18	MR. CIMO: This should not be filed with
19	the Court without a redaction.
20	MR. REICH: Correct. Any references to
21	for the court reporter's purposes purpose, any
22	reference to any offers of judgment, including us
23	discussing it now and what we're doing about it
24	now should be redacted from the transcript.
25	MR. CIMO: Or the word settlement.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 99 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	MR. REICH: Settlement or offer of judgment
2	or anything
3	MS. VILMOS: No.
4	MR. REICH: Only the settlement not the
5	settlement with McGladrey, not the settlement
6	with GT go off the record for a second.
7	(Whereupon, an off-the-record discussion
8	was held.)
9	BY MR. REICH:
10	Q. When Mr. Cimo and Ms. Mark's firm was
11	retained by yourself, it was subject to approval by
12	the bankruptcy court, correct?
13	A. Yes.
14	Q. And the terms of that retention were
15	disclosed to the bankruptcy court, correct?
16	A. Yes.
17	Q. And they were approved as counsel, correct?
18	A. Yes.
19	Q. Were they approved by the individual basis?
20	In other words you had to go to the Court for each of
21	these litigations or just in general for all these
22	litigations collectively?
23	A. I think there was only one.
24	Q. One for all the litigations?
25	A. I think that's true, yes.

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 100 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 So the terms of -- so the Genovese firm is 0. 2 getting paid a contingency fee; is that correct? 3 Α. Yes. 4 0. What's the percentage amount for the 5 contingency fee? I think it's 35 but I'll defer to --6 Α. Which would be the same amount whether it's 7 Ο. 8 the GT case, the McGladrey case or the D&O case, correct? 9 10 Α. I believe that's true. 11 So when you said before to Ms. Vilmos that 0. 12 you needed the money to pay for counsel to litigate 13 against us --14 Α. That's not what I said. MR. CIMO: Objection to the form. 15 16 BY MR. REICH: 17 Q. What did you say? 18 Α. The cost and expenses associated with the continuing litigation. There's expert witnesses that 19 20 will have to be retained -- they cost money. 21 Q. Expert witnesses have been retained, 22 correct? 23 MR. CIMO: Objection to form. THE WITNESS: There will be additional --24 if you're talking about Mr. Capilla and his firm? 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 101 of 159

98

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 MR. REICH: Yes. 2 THE WITNESS: I need more than Mr. Capilla 3 and his firm in my view. BY MR. REICH: 4 Are you familiar with a transaction 5 0. 6 known -- referred to as the CMT spinoff; do you know what that is? 7 Not specifically. But, again -- I mean, 8 Α. there's a lot of stuff that I looked at and reviewed 9 10 and discussed. I don't remember every single thing. 11 You charge in the complaint against 0. Okay. 12 the D&Os they're somehow liable with respect to that 13 transaction. Do you know when that transaction 14 occurred? MR. CIMO: I'll object to this line of 15 16 questioning. Unless you can tell me how it relates to 9019 motion and the bar order. If you 17 18 can, I will happy to let you keep going. 19 MR. REICH: Well, I'll tie into the audits. 20 MR. CIMO: You did that with the prior 21 ones. 22 MR. REICH: I did it before with respect to 23 the due diligence. 24 MR. CIMO: If you ask him whether the services involved regarding CMT are somehow 25 **ORANGELEGAL**

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 102 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	involved in any of these lawsuits, his answer, I
2	think, is going to be yes. We can truncate this.
3	I am going object to the substantive
4	questions that go to the merits of the case. He
5	was not prepared for that to testify today. He
6	was prepared to the 9019 motion, your objections
7	and the bar order relief.
8	MR. REICH: Let me ask a question broadly
9	rather than drilling
10	MR. CIMO: Try it that way and then we'll
11	try to narrow it down.
12	MR. REICH: I'll try to do it that way.
13	BY MR. REICH:
14	Q. If conduct of the two accounting firms were
15	relied upon by the D&Os and upon that reliance the
16	D&Os acted in a certain way that leads to them being
17	liable to you under the D&O case, okay, without the
18	borrower would the D&Os have the ability to assert
19	claims any sort of claims against the accounting
20	firms?
21	MR. CIMO: Objection to the form. You can
22	answer if you can.
23	THE WITNESS: I think your client can
24	assert whatever claims they chose to. Whether
25	they're appropriate under Florida law or



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 103 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	applicable law will be for a judge to determine.
2	I also think that the facts as you set them forth
3	in your question is not consistent with the
4	allegations. For the most part since we're
5	talking generally, the D&Os are the one who
6	provide the information to the auditors who do
7	the auditing. Now, I understand that that's not
8	the full and complete summary of everything that
9	we're talking about but that certainly a part of
10	it.
1 1	DY MD DETCH.

11 BY MR. REICH:

12 You say that -- you opened it up -- that we 0. 13 provided the information to the auditors, in the case 14 of the due diligence, which is within the scope of what you sued GT for and the scope of the settlement 15 with GT, the due diligence was of an outside entity 16 17 so that the information flow would not be going from the D&Os to Grant Thornton but it will be going from 18 19 Grant Thornton and Piper back to the D&Os; am I 20 correct or am I wrong? MR. CIMO: Objection to the form. 21 22 BY MR. REICH: 23 0. Am I correct or wrong? 24 MR. CIMO: Same objection. If you can answer this question, be my guess. 25



Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

THE WITNESS: I don't think I can answer 1 2 that guestion. 3 BY MR. REICH: How do you understand due diligence works? 4 0. MR. CIMO: I'll object and I'll instruct 5 the witness not to answer because you're now 6 going back into the substance of the lawsuit. 7 Mark the question. If the Judge orders him 8 to answer it, we'll bring him back to answer it. 9 10 Again, we do not want questions that are designed 11 to get into the substance of the allegations 12 against your clients or against the parties we 13 settled with. 14 BY MR. REICH: Do you know which lawsuit was filed first; 15 0. 16 the D&O cases or accounting cases? MR. CIMO: The record speaks for itself. 17 BY MR. REICH: 18 19 Do you know? 0. 20 Α. I have to look. In fact, the Grant Thornton case makes 21 0. 22 specific reference in paragraph nine to the D&O case; 23 am I right? We went over that before; am I correct? 24 Α. If you want me to pull --25 Q. You --

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 105 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Paragraph nine. 1 Α. 2 0. We only talked about it maybe 20 minutes 3 ago. 4 Α. If you're telling me that the D&O case was filed first then if that's what the record 5 reflects --6 That's not my question. My question was: 7 0. Does the Grant Thornton case make specific reference 8 to the D&O case? 9 10 MR. CIMO: We will stipulate that it does. 11 THE WITNESS: Yes. 12 MR. REICH: You'll stipulate, Counsel. 13 BY MR. REICH: 14 0. Does the McGladrey case make specific reference throughout to certain malfeasances of the 15 D&Os that were not picked up by McGladrey in the 16 17 course of their audit? MR. CIMO: We will stipulate -- not what 18 We will stipulate that the McGladrey 19 you said. 20 complaint makes references to the D&O complaint and the allegations in there. It says what it 21 22 says. 23 MR. REICH: Off the record. 24 (Whereupon, an off-the-record discussion was held.) 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 106 of 159

103

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

MR. CIMO: We don't use the word 1 2 malfeasance by the way, you did. 3 BY MR. REICH: 4 0. I'll hand you what I will now mark as Exhibit Number 36. 5 (Exhibit Number 36 marked for 6 identification.) 7 BY MR. REICH: 8 This would be Exhibit Number 36 here, 9 Ο. 10 Exhibit Number 6 to your exhibit register in the 11 McGladrey case. It's a December 2010 letter. It's 12 also docket entry 15-1 in the McGladrey case. 13 Do you recognize this to be the McGladrey retention for the 2010 audit? 14 15 Α. That's what it appears to be, yes. 16 Do you see where the scope of services are 0. 17 on here and that would be -- under audit services; do 18 you see that section? 19 Α. I'm looking at. 20 Did you want me to read it? Have you looked at it? 21 Q. 22 Α. In the past, not in the --23 Is it your understanding that the audit 0. services that are set forth in this exhibit are to 24 cover for year 2000 auditing of the internal controls 25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 107 of 159

104

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 of the debtors? 2 MR. CIMO: Objection to the form. 3 THE WITNESS: Say that one more time. 4 BY MR. REICH: 5 The internal controls -- throughout the D&O Ο. complaint you talk about there's lack of certain 6 internal controls and in the McGladrey suit you sue 7 them for not picking up these controls; is that a 8 9 fair assessment of what the McGladrey suit says? 10 MR. CIMO: Objection to the form. I will 11 instruct the witness not to answer. That 12 completely mischaracterizes what the document 13 says. The document speaks for itself. If you 14 ask him a specific question about a specific paragraph, I'll allow him to answer. 15 16 And I have the McGladrey complaint here to show him. 17 18 MR. REICH: We have the McGladrey complaint which is exhibit --19 20 MR. CIMO: Exhibit Number 33. BY MR. REICH: 21 22 And this is the operative 0. 23 McGladrey complaint -- the first amended -- DE5 in 24 the McGladrey case? 25 MR. CIMO: We stipulate that as the

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 108 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

operative one that was pending at the time of 1 2 settlement. 3 MR. REICH: Okay. 4 BY MR. REICH: 5 Do you see in subpart B starting on page 4 0. 6 of paragraph 16 --7 What page? Α. Page 4. 8 0. 9 Α. Thank you. 10 0. Paragraph 16 through 24 there is a 11 discussion about the secured facility officer of 12 financial; do you see that, \$5 million credit 13 facility? 14 Α. Right. It went from \$5 million and then it went up to 7 plus million. 15 16 Q. What is it that you assert that McGladrey failed to pick up or do or somehow violated its 17 18 professional duties to the debtor with respect to the 19 Oxford credit facility? 20 Α. I will defer to this complaint in its 21 entirety. 22 What's your under understanding of what 0. 23 McGladrey failed to do? 24 MR. CIMO: Do you want to read the complaint before you answer? 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 109 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 THE WITNESS: Yes. 2 MR. CIMO: Why don't we take a break --3 BY MR. REICH: You can read the complaint and tell us what 4 0. it was with respect to the Oxford Credit Facility 5 that McGladrey failed to do? 6 7 Generally they violated -- they didn't Α. comply with GAAP and GAAS, which are complicated 8 9 I'm not an accountant, I'm not an auditor. things. 10 I understand that these are the allegations. In order to approve them we would need GAAP and GAAS, 11 12 experts -- standard of care experts. We're settling 13 right now for a fair and reasonable amount as to the 14 benefit of the estate. If I'm going to get into all of the intricacies of every single allegation in this 15 16 complaint it's going to take discovery, it will deplete the assets of the estate and that is not 17 appropriate for this estate in my business judgment. 18 So you can ask me specifics about what he said, she 19 20 said and what he did or didn't do and I'll probably 21 give you the same general answer. 22 0. But so -- if it's not appropriate to ask 23 those questions --24 Α. I didn't say it wasn't appropriate. 25 Q. If it was appropriate for you to spend



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 110 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	estate money to pursue these and find out the answers
2	as to was wrong with the Oxford Credit Facility then
3	my question is I ask you that same exact question
4	with respect to the D&Os?
5	MR. CIMO: Objection. We move to I'm
6	not going to move to strike. I'll instruct the
7	witness not the answer. It's not a question.
8	It's just harassing at this point.
9	BY MR. REICH:
10	Q. My question is it says that paragraph 22
11	from after March 2011 the company is not in
12	compliance with certain financial covenants, okay?
13	What were those financial covenants that warrant
14	them?
15	A. Are you familiar with in pari delicto?
16	That's a full defense.
17	Q. You
18	A. I run the risk of getting zero in this
19	case. I run the risk of spending lots and lots of
20	money that I don't have in the estate in order to get
21	to trial. There's no guarantee that I'm going to win
22	this lawsuit. I think I have a strong argument. I
23	think I have strong counsel. Every case I think
24	what you're arguing is that every single case should
25	just go to trial. That's not how the bankruptcy

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 111 of 159

108

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

system operates, it's not what the case law states 1 2 when it comes settlement under 9019. I don't have 3 to --4 MR. CIMO: Let him finish, please. Thank 5 you. THE WITNESS: I don't have to cross every 6 "T" and dot every "I" because in order to do so 7 depletes estate assets, which I don't have. 8 9 Everything that is presented to me at this time 10 based upon everything that's in front of me, 11 which I believe gives me enough information to 12 enter into the settlement for the benefit of this 13 estate. 14 BY MR. REICH: Was there something that supported the pari 15 0. 16 delicto defense that was latterly presented to you 17 with respect to the Oxford Credit Facility? Were 18 there certain facts that were presented to you that 19 made you consider that possibly the pari delicto 20 defense would be sustainable? 21 MR. CIMO: Object to the form. To the 22 extent you had conversations with counsel or work 23 product information in formulating any such 24 belief. Other than that you can answer. I did not speak with them 25 THE WITNESS:

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 112 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case.	 have benefit of seeing the pleadings or the motions and the opposition that were filed just as you have. And they certainly asserted that with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&OS didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	 have benefit of seeing the pleadings or the motions and the opposition that were filed just as you have. And they certainly asserted that with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set
 motions and the opposition that were filed just as you have. And they certainly asserted that with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&OS didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	 motions and the opposition that were filed just as you have. And they certainly asserted that with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&OS didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. MR. REICH: Substance of which case? 	 motions and the opposition that were filed just as you have. And they certainly asserted that with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set
 as you have. And they certainly asserted that with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	4as you have. And they certainly asserted that5with tenacity.6BY MR. REICH:7Q. What is your understanding of what they're8asserting that the D&Os didn't do properly with9respect to Oxford Credit10A. My understanding would either come from11conversations I had with counsel or what they set12forth in it's the docket that you and I can13retrieve equally.14Q. How is the debtor harmed by the McGladrey15failure to pick up in the audit the things that you16allege against them in this complaint with respect to17the Oxford Credit Facility?18MR. CIMO: I will object to the form. To19the extent it requires you to divulge work20product or information that you learned through21counsel. I am not going to instruct you not to22answer even though we're substantively getting23into the substance of the case.24MR. REICH: Substance of which case?	 as you have. And they certainly asserted that with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set
 with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	 with tenacity. BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. MR. REICH: Substance of which case? 	5 with tenacity. 6 BY MR. REICH: 7 Q. What is your understanding of what they're 8 asserting that the D&Os didn't do properly with 9 respect to Oxford Credit 10 A. My understanding would either come from 11 conversations I had with counsel or what they set
 BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	 BY MR. REICH: Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. MR. REICH: Substance of which case? 	 6 BY MR. REICH: 7 Q. What is your understanding of what they're 8 asserting that the D&Os didn't do properly with 9 respect to Oxford Credit 10 A. My understanding would either come from 11 conversations I had with counsel or what they set
 9 Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	 Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. MR. REICH: Substance of which case? 	 Q. What is your understanding of what they're asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set
 asserting that the D&Os didn't do properly with respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	8 asserting that the D&Os didn't do properly with 9 respect to Oxford Credit 10 A. My understanding would either come from 11 conversations I had with counsel or what they set 12 forth in it's the docket that you and I can 13 retrieve equally. 14 Q. How is the debtor harmed by the McGladrey 15 failure to pick up in the audit the things that you 16 allege against them in this complaint with respect to 17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	8 asserting that the D&Os didn't do properly with 9 respect to Oxford Credit 10 A. My understanding would either come from 11 conversations I had with counsel or what they set
 9 respect to Oxford Credit A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. 14 Q. How is the debtor harmed by the McGladrey 15 failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	 9 respect to Oxford Credit 10 A. My understanding would either come from 11 conversations I had with counsel or what they set 12 forth in it's the docket that you and I can 13 retrieve equally. 14 Q. How is the debtor harmed by the McGladrey 15 failure to pick up in the audit the things that you 16 allege against them in this complaint with respect to 17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case? 	9 respect to Oxford Credit 10 A. My understanding would either come from 11 conversations I had with counsel or what they set
 A. My understanding would either come from conversations I had with counsel or what they set forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	10A. My understanding would either come from11conversations I had with counsel or what they set12forth in it's the docket that you and I can13retrieve equally.14Q. How is the debtor harmed by the McGladrey15failure to pick up in the audit the things that you16allege against them in this complaint with respect to17the Oxford Credit Facility?18MR. CIMO: I will object to the form. To19the extent it requires you to divulge work20product or information that you learned through21counsel. I am not going to instruct you not to22answer even though we're substantively getting23into the substance of the case.24MR. REICH: Substance of which case?	10 A. My understanding would either come from 11 conversations I had with counsel or what they set
11 conversations I had with counsel or what they set 12 forth in it's the docket that you and I can 13 retrieve equally. 14 Q. How is the debtor harmed by the McGladrey 15 failure to pick up in the audit the things that you 16 allege against them in this complaint with respect to 17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case.	11 conversations I had with counsel or what they set 12 forth in it's the docket that you and I can 13 retrieve equally. 14 Q. How is the debtor harmed by the McGladrey 15 failure to pick up in the audit the things that you 16 allege against them in this complaint with respect to 17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	11 conversations I had with counsel or what they set
12forth in it's the docket that you and I can13retrieve equally.14Q. How is the debtor harmed by the McGladrey15failure to pick up in the audit the things that you16allege against them in this complaint with respect to17the Oxford Credit Facility?18MR. CIMO: I will object to the form. To19the extent it requires you to divulge work20product or information that you learned through21counsel. I am not going to instruct you not to22answer even though we're substantively getting23into the substance of the case.	 forth in it's the docket that you and I can retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. MR. REICH: Substance of which case? 	
 retrieve equally. Q. How is the debtor harmed by the McGladrey failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. 	13retrieve equally.14Q. How is the debtor harmed by the McGladrey15failure to pick up in the audit the things that you16allege against them in this complaint with respect to17the Oxford Credit Facility?18MR. CIMO: I will object to the form. To19the extent it requires you to divulge work20product or information that you learned through21counsel. I am not going to instruct you not to22answer even though we're substantively getting23into the substance of the case.24MR. REICH: Substance of which case?	
14Q. How is the debtor harmed by the McGladrey15failure to pick up in the audit the things that you16allege against them in this complaint with respect to17the Oxford Credit Facility?18MR. CIMO: I will object to the form. To19the extent it requires you to divulge work20product or information that you learned through21counsel. I am not going to instruct you not to22answer even though we're substantively getting23into the substance of the case.	14Q. How is the debtor harmed by the McGladrey15failure to pick up in the audit the things that you16allege against them in this complaint with respect to17the Oxford Credit Facility?18MR. CIMO: I will object to the form. To19the extent it requires you to divulge work20product or information that you learned through21counsel. I am not going to instruct you not to22answer even though we're substantively getting23into the substance of the case.24MR. REICH: Substance of which case?	12 forth in it's the docket that you and I can
15 failure to pick up in the audit the things that you allege against them in this complaint with respect to the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case.	15 failure to pick up in the audit the things that you allege against them in this complaint with respect to 17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	13 retrieve equally.
16 allege against them in this complaint with respect to 17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case.	16 allege against them in this complaint with respect to 17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	14 Q. How is the debtor harmed by the McGladrey
17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case.	17 the Oxford Credit Facility? 18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	15 failure to pick up in the audit the things that you
MR. CIMO: I will object to the form. To the extent it requires you to divulge work product or information that you learned through counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case.	18 MR. CIMO: I will object to the form. To 19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	16 allege against them in this complaint with respect t
19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case.	19 the extent it requires you to divulge work 20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	17 the Oxford Credit Facility?
20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case.	20 product or information that you learned through 21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case. 24 MR. REICH: Substance of which case?	18 MR. CIMO: I will object to the form. To
21 counsel. I am not going to instruct you not to 22 answer even though we're substantively getting 23 into the substance of the case.	 counsel. I am not going to instruct you not to answer even though we're substantively getting into the substance of the case. MR. REICH: Substance of which case? 	19 the extent it requires you to divulge work
22 answer even though we're substantively getting23 into the substance of the case.	 answer even though we're substantively getting into the substance of the case. MR. REICH: Substance of which case? 	20 product or information that you learned through
23 into the substance of the case.	 23 into the substance of the case. 24 MR. REICH: Substance of which case? 	21 counsel. I am not going to instruct you not to
	24 MR. REICH: Substance of which case?	22 answer even though we're substantively getting
24 MR. REICH: Substance of which case?		23 into the substance of the case.
	25 MR. CIMO: Any of the cases. I am not	24 MR. REICH: Substance of which case?
25 MR. CIMO: Any of the cases. I am not		25 MR. CIMO: Any of the cases. I am not

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 113 of 159

110

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

instructing him not to answer. 1 2 THE WITNESS: I'll defer to the filing in 3 this case deepening insolvency is certainly one 4 of the issues. BY MR. REICH: 5 So you're claiming that the opinion of the 6 0. Oxford Credit Facility led to a deepening insolvency 7 8 of the debt; is that your position? I think that's described in the complaint 9 Α. 10 and the papers that have been filed. 11 With respect to Part C starting on page 0. 12 six, Charles River acquisition, paragraphs 25 through 37 of the McGladrey complaint. I will ask the same 13 14 question about -- what was the harm in the Charles River acquisition as a result of McGladrey not 15 16 picking things up on its 2010 audit? Same objection. You can answer 17 MR. CIMO: 18 if you can. In addition to what's alleged here? I 19 Α. 20 mean, you can read it just like I can read it, Mr. Reich. 21 22 Let me ask you this: With respect to all 0. 23 three of the complaints; the D&O complaint, the 24 McGladrey complaint, and the GT complaint; do you personally have personal knowledge of anymore 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 114 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	specificity as to the bad conduct of either the D&Os
2	or the accounting firms other than as set forth in
3	these three respective complaints?
4	MR. CIMO: I will object to form and
5	instruct you not to answer to the extent that you
6	also knowledge that you gained from your
7	conversations with your lawyers.
8	THE WITNESS: Any additional information I
9	would have obtained would have been through
10	conversations with my attorneys.
11	BY MR. REICH:
12	Q. Is there anything that you would have been
13	able to testify to in a court of law on the ultimate
14	merits of any of those cases that are more specific
15	than what's set forth in those three complaints?
16	MR. CIMO: Objection to the form. Same
17	instruction.
18	MR. REICH: It wouldn't be the same
19	instruction because you're just telling him he
20	can't talk about his attorney/client.
21	BY MR. REICH:
22	Q. Other than attorney/client privilege, which
23	you can't talk about, is there any more detail that
24	you have that you can talk about in a court of law?
25	MR. CIMO: I'll object to the form. He

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 115 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 showed you a proof of claim register, he showed 2 you a Form 2. There is other stuff he knows, 3 which he has personal knowledge of, which doesn't 4 go to the underlying case and that's why I 5 objected to the form or wasn't around when 6 these transactions happened. 7 THE WITNESS: And you saw my declaration. 8 It's not just me regurgitating what's in the 9 complaint. 10 BY MR. REICH: 11 Q. So the harm to the estate on all these 12 transactions is 13 A. All of what transactions? 14 Q. All the transactions set forth in these 15 three complaints. 16 A. Okay. 17 Q. The conduct; either the acts or omissions 18 that are complained of in these three complaints. 19 The end of the day, the ultimate harm is the amount 10 of the debt that is burdened on these entities as 21 mR. CIMO: Objection to the form. 23 Mischaracterizes what each of the lawsuits 24 actually allege. 25
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay. Q. The conduct; either the acts or omissions that are complained of in these three complaints. The end of the day, the ultimate harm is the amount of the debt that is burdened on these entities as reflected in the claims registers in MR. CIMO: Objection to the form.
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay. Q. The conduct; either the acts or omissions that are complained of in these three complaints. The end of the day, the ultimate harm is the amount of the debt that is burdened on these entities as reflected in the claims registers in MR. CIMO: Objection to the form.
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay. Q. The conduct; either the acts or omissions that are complained of in these three complaints. The end of the day, the ultimate harm is the amount of the debt that is burdened on these entities as reflected in the claims registers in
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay. Q. The conduct; either the acts or omissions that are complained of in these three complaints. The end of the day, the ultimate harm is the amount of the debt that is burdened on these entities as
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay. Q. The conduct; either the acts or omissions that are complained of in these three complaints. The end of the day, the ultimate harm is the amount
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay. Q. The conduct; either the acts or omissions that are complained of in these three complaints.
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay. Q. The conduct; either the acts or omissions
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints. A. Okay.
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these three complaints.
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions? Q. All the transactions set forth in these
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is A. All of what transactions?
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these transactions is
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH: Q. So the harm to the estate on all these
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint. BY MR. REICH:
you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the complaint.
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration. It's not just me regurgitating what's in the
 you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened. THE WITNESS: And you saw my declaration.
you a Form 2. There is other stuff he knows, which he has personal knowledge of, which doesn't go to the underlying case and that's why I objected to the form or wasn't around when these transactions happened.
2 you a Form 2. There is other stuff he knows, 3 which he has personal knowledge of, which doesn't 4 go to the underlying case and that's why I 5 objected to the form or wasn't around when
 2 you a Form 2. There is other stuff he knows, 3 which he has personal knowledge of, which doesn't 4 go to the underlying case and that's why I
 2 you a Form 2. There is other stuff he knows, 3 which he has personal knowledge of, which doesn't
2 you a Form 2. There is other stuff he knows,
1 showed you a proof of claim register, he showed

ORANGE LEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 116 of 159

113

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

ORANG	ELEGAL Orange Legal
25	Q. I don't care about your source, that's your
24	Reich.
23	A. There's ample case law out there, Mr.
22	Q. Is that your understanding?
21	BY MR. REICH:
20	MR. CIMO: Objection to the form.
19	that correct?
18	to the estate and not to the enjoined parties; is
17	okay, is measured by its fairness and equitableness
16	is the fairness and equitableness of these borrowers,
15	question. Your testimony before, as I understand it,
14	Q. My question is a fundamental fairness
13	BY MR. REICH:
12	answer the question.
11	orders him to answer, we'll bring him back to
10	again the substance of the case. If the Court
9	witness not to answer. We're now getting into
8	MR. CIMO: I'll object and instruct the
7	insolvency?
6	Q. What is the measure for the deepening
5	BY MR. REICH:
4	insolvency is, yes, certainly one of them.
3	the damages alleged in there. Deepening
2	allegations. The damages alleged in there are
1	complaints are. The allegations in there are the

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 117 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 understanding. 2 MR. CIMO: Let him answer. I object to the 3 form. 4 THE WITNESS: My understanding is consistent with the ample case law that's out 5 there with regard to borrowers. I didn't sit 6 there and read every case in preparation for this 7 deposition. But Mumford and all the cases that 8 follow it and all the cases from the Southern 9 10 District that are cited in the papers that my 11 counsel filed, that's what I rely on. 12 If you going to --13 BY MR. REICH: 14 0. Let me get this right and it will probably end up more as a question for your counsel but I'll 15 16 ask you it. You're not going to answer any questions 17 today that go to the substantive nature of what McGladrey or Grant Thornton did or did not do with 18 19 respect to conduct of the D&Os; is that correct? 20 MR. CIMO: Objection to the form. 21 THE WITNESS: You want me to requrgitate 22 the stuff that's in writing that's before all of 23 I mean, if you want me to sit here and read us? 24 aloud the papers that were filed. I think that would be a pretty big waste of time but if that's 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 118 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	what you want me to do.
2	BY MR. REICH:
3	Q. Well, every time I tried to inquire between
4	the actions alleged against our clients, the D&Os,
5	and the conduct of the accounting firms as it relates
6	to the D&Os I've been met with an objection by your
7	counsel effectively telling you not to answer, okay,
8	that it's going to the substance of the lawsuits and
9	that we can't acquire into it.
10	My question to you is are you not going to
11	answer today any questions that go into the
12	relationship between the D&Os and the accounting
13	firms with respect to the conduct of the D&Os that
14	perform the basis of the D&O suit?
15	MR. CIMO: I am going to object to the
16	form. And state other than what's in your
17	declaration, other than what's in the actual
18	lawsuits and all the pleadings filed in relation
19	to the lawsuits and I don't know what you
20	discussed with counsel. I really can't instruct
21	you to answer anything else if there isn't
22	anything else.
23	THE WITNESS: Any answer I give would be
24	contained in the complaint, my declaration, any
25	of the responses or the motion that was filed and
ODANC	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 119 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	in not that it would have been through
2	conversations I had with my counsel.
3	BY MR. REICH:
4	Q. So other than conversations with your
5	counsel in support of these motions, you're relying
6	totally upon your declaration, the complaints, the
7	responsive pleadings and motions, the exhibit
8	registers, claims everything that's in the exhibit
9	register, okay, all the claims registers in these
10	cases, no testimony from anybody else; is that
11	correct?
12	MR. CIMO: That is correct. We have no
13	other witness other than Mr. Barmat.
14	MR. REICH: There is no other witness other
15	than Mr. Barmat?
16	MR. CIMO: Correct.
17	MR. REICH: And you're relying on what's on
18	your pleading and responses to our objection and
19	that's it?
20	MR. CIMO: I will stipulate that's it, yes.
21	MS. VILMOS: Can we take a break?
22	(Whereupon, a brief recess was taken.)
23	MR. REICH: We seem to have a dispute here
24	between the parties as to the scope of what this
25	witness can answer with respect to the Mumford



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 120 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	factors. The particular issue is the likelihood
2	of non-settling defendants to prevail on the
3	barred claim. It is our belief that we're
4	entitled to ask questions of the Trustee about
5	him meeting his burden with respect that issue.
6	Their argument is it's not their burden, they say
7	it's our burden and they have not allowed the
8	Trustee to answer questions with respect to the
9	relationship between the D&Os and the accounting
10	firms on the potential barred claims that would
11	be asserted by them.
12	MR. CIMO: I do not agree with your
13	characterization.
14	MR. REICH: What?
15	MR. CIMO: I do not disagree. Let's bring
16	it to the Judge. I am not going to agree to your
17	mischaracterization of what happened here. We
18	already told you multiple times, we're relying
19	upon the complaints, we're relying upon his
20	declaration, we're relying upon the exhibits that
21	we provided to you. We have nothing else to add.
22	If you don't like answer, I can't do
23	MR. REICH: I can't ask questions about
24	what you deem as substance?
25	MR. CIMO: We have the answers in our

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 121 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	complaint. I am not going to argue with you,
2	Ivan. I told you if the Court orders us to
3	answer we'll come back and we will try to be as
4	least inconvenienced as possible.
5	MS. MARK: I want to put you one thing on
6	the record. I know he said that was you said
7	mischaracterizes. The issue was not whether the
8	Trustee would testify as to whether there's any
9	strength in viability with respect to their
10	purported indemnification contribution claims.
11	He did address that at the very beginning of this
12	deposition when he spoke about the Florida law
13	relating to contribution and indemnification.
14	What we said we would not allow Mr. Reich
15	to do is to inquire into the underlying substance
16	and damage model and other liability issues
17	relating to the D&O action and then separately
18	even the other actions because settlements are
19	not about getting to the merits. If we wanted to
20	try this case we would have gone to trial. We
21	decided it was in the estates best interest to
22	settle the case the Trustee decided. That is
23	what is at issue here and not determining if the
24	case went to trial what would have happened.
25	Analyzing the benefits, risk and coming to a

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 122 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	rational business decision which is what the
2	Trustee did.
3	MR. REICH: Have you rested on your closing
4	argument?
5	MS. MARK: You're the one mischaracterizing
6	what the issue is.
7	MR. REICH: The reality is this: You're
8	not allowing us to get testimony
9	MS. MARK: He did testify to that.
10	MR. CIMO: I disagree. Finish up your
11	deposition and ask your questions.
12	MR. REICH: We are not closing the
13	deposition. We'll go back to the Court to see
14	whether the witness will be
15	MR. CIMO: He's here. If you have anything
16	more to ask him, ask him. And on a question by
17	basis we'll decide what we think he can answer.
18	MR. REICH: Every time we tried to
19	inquire
20	MR. CIMO: That's not true. It's not every
21	time, he answered hundreds of questions during
22	this deposition. I only asked him not to answer
23	a few of them a handful compared to the amount
24	of questions you asked. If you asked appropriate
25	questions we would be moving more quickly but
1	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 123 of 159

120

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

you're not asking appropriate questions. 1 2 But you're free to ask him whatever you 3 want. He's here and he's here until the seven 4 hours are up. BY MR. REICH: 5 6 0. You state QuickBooks is an appropriate accounting software program within your complaints --7 8 multiple complaint. 9 MR. CIMO: Which complaint? 10 MR. REICH: The McGladrey complaint. 11 MR. CIMO: Can you show him which 12 particular paragraph so he can confirm that 13 that's true. If you ask him by specific 14 paragraphs then we can have an understanding of what's being asked. 15 16 BY MR. REICH: 17 0. Let me back up. Let's do this. On the 18 McGladrey complaint in docket five in the McGladrey 19 case talks about the Care Management Technology 20 spinoff; you familiar with the Care Management 21 Technology spinoff? 22 Let us know what paragraph. MR. CIMO: 23 MR. REICH: Paragraph 38 through 43. 24 THE WITNESS: To extent it's alleged in the complaint I am. I don't have firsthand personal 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 124 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 knowledge. 2 BY MR. REICH: 3 0. Paragraphs 43 you allege that failure to the former D&Os to cause the reversal and unwinding 4 of the spinoff prior to the petition date constitute 5 a breach of fiduciary duty as well; do you see that? 6 What paragraph? 7 Α. Paragraph 43. 8 0. 9 Α. I was looking at 42, sorry. 10 Paragraph 43 reads, the failure of the former D&Os to cause the reversal and winding of the 11 12 spinoff prior to the petition date constitute a 13 breach of fiduciary duty as well. That's what it 14 says. How is it -- what could have McGladrey have 15 0. done to have the D&Os unwind the Care Management 16 17 Technology spin off? MR. CIMO: Objection to the form. 18 19 Mischaracterizes what that paragraph says and 20 what it means. You can answer if you can. I am not instructing you not to answer. 21 22 MR. REICH: I'll rephrase it. 23 BY MR. REICH: 24 0. Did Care Management -- did McGladrey advise the D&Os to unwind the Care Management Technology 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 125 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	spinoff?
2	A. Did McGladrey advise the former D&Os say
3	the question one more.
4	Q. Did McGladrey advise the former D&Os to
5	unwind the Care Management Technology spinoff?
6	A. If you're asking for my personal knowledge,
7	I don't recall. If it's in the complaint then yes.
8	Are you asking me to read through every
9	paragraph?
10	Q. Are you alleging that they failed to advise
11	the directors and officers of the company to reverse
12	the spinoff?
13	A. I'm alleging everything that's in the
14	complaint and I didn't put the complaint to my
15	memory. So that's my answer. I certainly read it
16	before it was filed. I read it since it's been
17	filed. But I didn't put everything to memory?
18	Q. What could the D&Os have done if McGladrey
19	had advised them to unwind the spinoff; what steps
20	needed to be taken?
21	MR. CIMO: Objection to the form. I am
22	only going to instruct you to answer to the
23	extent it requires you to reveal work product or
24	attorney/client privilege information.
25	THE WITNESS: In order for me answer it, it



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 126 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	would reveal work product or attorney/client
2	privilege information.
3	MR. REICH: Wow, you answered that so
4	quickly.
5	MR. CIMO: My job is to make sure privilege
6	is maintained, Ivan. I'm sure you would do the
7	same thing if you were on my side of the table
8	otherwise you would not be doing your job.
9	BY MR. REICH:
10	Q. So it's your testimony today you don't know
11	whether McGladrey advised the D&Os as to reversal of
12	the spinoff?
13	MR. CIMO: Objection to the form. You are
14	now harassing the witness. I will instruct him
15	not to answer that because we already told you
16	what he said what his answer was based on my
17	objection and he has nothing more to add based
18	upon that objection.
19	BY MR. REICH:
20	Q. Do you know based upon your own
21	investigation as Trustee of the affairs of CCD and
22	CCD NW, what steps first whether McGladrey ever
23	advised the D&Os to reverse the CMT spinoff?
24	MR. CIMO: Objection to the form.
25	I am not going to instruct you not to
ORANO	GELEGAL Orange Legal

Orange Legal 800-275-7991 123

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 127 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1 answer. 2 THE WITNESS: The information for me to 3 answer that question would have been obtained through attorney/client privilege. 4 BY MR. REICH: 5 6 0. With respect to upon your own investigation and knowledge as to the Trustee of CCD and CCD NW 7 what --8 9 Maybe I can short circuit this if you will Α. 10 allow me to? The investigation into the allegations in this complaint are conducted by my counsel. I 11 12 didn't personally. I listened to them, they report 13 to me. When it comes to the specifics of what's in 14 the complaint, my counsel took depositions and my counsel reviewed lots of records and they reported to 15 16 me. 17 So as the client and the ultimate Ο. 18 decision maker in this case your entire source of 19 knowledge about the matters in the three complaints 20 that we're discussing all derive from information provided to you by your counsel; is that correct? 21 22 MR. CIMO: Objection to the form. 23 I'm not going to instruct you but I am 24 objecting to the form. There's probably other 25 THE WITNESS:

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 128 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

MARC B	ARMAT 1
1	information that I would have received. Can I
2	sit here and tell you what it is? No. This case
3	has been going on for a long time. It's a big
4	case and there is a lot of things that took
5	place. So I'm not going to foreclose myself and
6	say 100 percent came through my counsel. But as
7	I sit here, I can't think of anything else other
8	than from my counsel.
9	BY MR. REICH:
10	Q. It's your testimony that whatever knowledge
11	you have regarding the acts and omissions of the D&Os
12	or the accountants came to you through your counsel
13	and you have no independent knowledge beyond that?
14	MR. CIMO: If counsel is not limited to me
15	and also includes his general counsel, I'm not
16	going to object.
17	THE WITNESS: I will rely on my statement
18	and not your restatement of my statement.
19	BY MR. REICH:
20	Q. So what is the source of your knowledge
21	regarding the acts and omissions of the D&Os and the
22	accountants as set forth in these three complaints?

A. I am fairly certain that we discussed that about 10 times. I have nothing else to add other than --



MARC BARMAT So is it only the attorneys? 1 0. 2 MR. CIMO: Objection to the form. 3 BY MR. REICH: 4 0. Both your general counsel and your special 5 counsel? MR. CIMO: Same objection. 6 THE WITNESS: Do you want to have the court 7 reporter read back my testimony. I am not trying 8 9 to be difficult, Mr. Reich. But you know you 10 asked that and you know I answered that. 11 BY MR. REICH: 12 Do you know the date my client was hired by 0. 13 CCD? 14 Α. No. Do you know the relationship between the 15 0. date my client was hired and the date of the Care 16 17 Management Technology spinoff? As I sit here I couldn't tell you any of 18 Α. 19 the dates. 20 0. And part of your job as a Trustee in a 21 bankruptcy, you're charged with taking possession of 22 the information -- on the conversion of the case --23 the debtors' assets -- on the debtors' books and 24 records as well as the deposition transcripts and documents that were produced in the course of 25

ORANGELEGAL

Orange Legal 800-275-7991

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 129 of 159

Comphensive Clinical Development vs. Steven Krupa

126

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 130 of 159

127

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	discovery in that case, were you not?	
2	MR. CIMO: Objection to the form.	
3	THE WITNESS: I don't know that I'm charged	
4	with possession of the deposition transcripts.	
5	But people were actively involved in the Chapter	
6	11 that I wasn't involved in that deal with	
7	issues that may or may not be relevant to what	
8	I'm doing here. So I'm not going to agree with	
9	the entire premise of your question.	
10	BY MR. REICH:	
11	Q. I'll ask you the same question. I'm going	
12	to ask you, am I going to get the same response if I	
13	ask you about subpart F to the McGladrey complaint,	
14	paragraphs 50 through 71 regarding the failure to	
15	adequately maintain and account for clinical trial	
16	records. Any questions that I ask you about that,	
17	you're going to totally rely on the complaint and	
18	that all other sources of information that you have	
19	would be based upon what your counsel provided you?	
20	MR. CIMO: I'll object on "F" because I	
21	know that general counsel was involved in that	
22	process before me.	
23	MR. REICH: I just asked about counsel.	
24	THE WITNESS: The entire debacle of the	
25	clinical trial records I was represented by my	
ORAN	GELEGAL Orange Legal	

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 131 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	law firm. I was a witness to a lot of it. So			
2	that was really not the handling of the records			
3	and the ultimate protocol that was approved by			
4	the Court. I had more involvement that than I			
5	did. Mr. Cimo wasn't really directly involved in			
6	that.			
7	BY MR. REICH:			
8	Q. That's good. Let me ask you a question			
9	about let's talk about the clinical trial records			
10	for a second, okay?			
11	It's your allegations that, what, McGladrey			
12	did not properly pick up in their audits the problems			
13	with the clinical trial records that describe there?			
14	MR. CIMO: Objection to the form. If you			
15	have a specific allegation in the complaint you			
16	want to show him, would you please show him.			
17	MR. REICH: Every time I go specific, you			
18	say go general. Every time I go general, you say			
19	go specific.			
20	MR. CIMO: I'm not buying it, Ivan. Don't			
21	go that road. You're mischaracterizing what the			
22	complaint says. I object to the form.			
23	THE WITNESS: I defer to the allegations in			
24	the complaint.			
25	BY MR. REICH:			



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 132 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Q. Is it your contention that McGladrey failed			
2	to pick up deficiencies in the maintenance of the			
3	clinical trial records?			
4	MR. CIMO: Objection to the form.			
5	THE WITNESS: I defer to the allegations in			
6	the complaint.			
7	BY MR. REICH:			
8	Q. Who was it at CCD who is in change with			
9	maintaining the clinical trial records and the			
10	procedures for doing so?			
11	MR. CIMO: I am going to object. I			
12	instruct the witness not to answer.			
13	Again, we're going into specific questions			
14	that go to the merits of the case which the			
15	settlements were designed to avoid. Moreover,			
16	the burden is clearly on your clients to			
17	establish whether these claims have merit. And			
18	it's not his job to prove up your case. And			
19	moreover, he already testified that he doesn't			
20	think the claims have merit and he has nothing			
21	more to add in that regard. I'll instruct him			
22	not to answer at this time.			
23	However, if the Court concludes Mr. Barmat			
24	has to come back and answer we'll be happy to			
25	bring him back and answer your question.			

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 133 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	THE WITNESS: I will add one thing further
2	to what Mr. Cimo said and that is some of that
3	information that I would have received would have
4	been received through my general counsel as well
5	as he was way more actively involved than I was.
6	BY MR. REICH:
7	Q. I assume you were to answer the same
8	question if I was asking you about the adequacy of
9	the cash control system at CCD, you would answer the
10	same questions?
11	MR. CIMO: Object to the form. You have to
12	ask him so we have a clear record of what you're
13	asking.
14	Every issue is different become some
15	involve general counsel and some don't.
16	MR. REICH: Okay.
17	MR. CIMO: Make the record clear for when
18	we go to the Judge.
19	BY MR. REICH:
20	Q. What materially inadequate information was
21	provided to third-parties or others set forth in
22	subpart G starting on page 18 paragraph 72 through
23	86?
24	A. I'll reiterate my answers. I rely on the
25	allegations in the complaint, my declaration, all the



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 134 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	exhibits that are referenced herein and		
2	communications between my counsel and I, they're		
3	privileged.		
4	Q. Same thing same question with respect to		
5	subpart H; the failure to implement and follow		
6	adequate safeguards and controls in regards to the		
7	business operation related to its functions as set		
8	forth in subpart H starting on page 22, paragraphs 87		
9	through 88?		
10	A. Same answer.		
11	Q. That would be the same answer with respect		
12	to subpart I subpart I, paragraphs 89 through		
13	93 squandered prepetition sale opportunities and		
14	subsequent delay and failure to timely implement and		
15	effectuate a prebankruptcy sale process; would that		
16	be the same answer?		
17	A. It would be.		
18	Q. Would that be the same in subpart J,		
19	paragraphs 94 through 100 regarding the audits and		
20	other services performed by McGladrey?		
21	A. Same answer.		
22	Q. Would the same thing be with respect to		
23	subpart K, Grant Thornton audit set forth in		
24	paragraphs 101 and 102, same answer?		
25	A. Yes, sir.		

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 135 of 159

132

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	Q. Would it be the same with respect to
2	subpart M, the act and omissions in debtors'
3	management as set forth in paragraphs 106 to 108?
4	A. Yes.
5	Q. Would that be the same thing with respect
6	to the issue regarding damages to the claims against
7	the debtors' estate as set forth in subpart P,
8	paragraphs 111 and 112 of this complaint?
9	A. Yes.
10	Q. Would that be the same with respect for
11	every allegation within the McGladrey complaint with
12	respect to the failures of McGladrey to pick up
13	certain acts and omissions on part of the D&Os?
14	MR. CIMO: Which paragraphs?
15	MR. REICH: Paragraph 27, paragraph 28.
16	MR. CIMO: Under C, Charles River? I
17	thought you already asked about Charles River?
18	MR. REICH: I said the entire complaint.
19	I'm going through paragraph 34, paragraph 36,
20	paragraph 37, paragraph 43, paragraph 49,
21	paragraph 50, paragraph 59, paragraph 72,
22	paragraph 73, paragraph 74, paragraph 75,
23	paragraph 76.
24	THE WITNESS: Now you're going over
25	paragraphs that you already asked specifically
ORAN	GELEGAL Orange Legal

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 136 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	MR. REICH: Hold on. Mr. Cimo asked for
2	specific paragraphs and I am not done with the
3	question.
4	MR. CIMO: I thought you were going to
5	point to a section. I didn't know you were going
6	to cherry pick.
7	MR. REICH: You asked for specifics.
8	MR. CIMO: This is ridiculous. He already
9	answered a lot of these questions so
10	MR. REICH: Paragraph 90, paragraph 94,
11	paragraph 96, paragraph 97, paragraph 98,
12	paragraph 103, paragraph 106, paragraph 107,
13	paragraph 108, paragraph 109, paragraph 110,
14	paragraph 120. Actually, just all of count one
15	and all of count two.
16	MR. CIMO: Objection to the form. You can
17	answer.
18	THE WITNESS: What was the question?
19	MR. REICH: Great objection. The first
20	part of the objection was it was to general
21	MR. CIMO: Ask the question.
22	I didn't tell you the basis of the
23	objection. Proceed, counsel.
24	MR. REICH: The question is can you read
25	back the last question?



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 137 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

BY MR. REICH: 1 2 The answer you just gave before, would it 0. 3 be the same answer with respect to the McGladrey's 4 failure to detect and correct or whatever charges you made against them with respect to the audit for 5 picking up or not picking up the acts and omissions 6 of the D&Os as set forth in the specific paragraphs I 7 just mentioned? 8 9 Am I relying upon the same things that I Α. 10 said I was relying upon? 11 The same answer, exactly. 0. 12 All the documents, all the exhibits Α. Yes. 13 and advice of counsel -- or communications of 14 counsel. 15 0. Nothing beyond those? 16 Α. No. 17 And with respect to the GT complaint, I 0. would ask you that same question -- I believe that's 18 19 docket entry one and in particular I'll reference to 20 paragraph nine of that complaint? Do you remember what exhibit it was in 21 Α. 22 this? 23 It's part of the first exhibit that I asked 0. 24 you about today. Α. The Grant Thornton --25



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 138 of 159

135

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

THE WITNESS: Did we have the first 1 2 amended --3 MR. CIMO: I don't think we did. 4 THE WITNESS: I'm looking about Exhibit Number 8. 5 BY MR. REICH: 6 The adversary -- the operative adversary 7 0. complaint in Exhibit Number 8. 8 I wanted to make sure we didn't have the 9 Α. 10 first amended. 11 No, we didn't. Grant Thornton -- in there 0. 12 the only allegations and we have gone through and I 13 ask you the same exact questions with respect to 14 Grant Thornton in paragraph nine? 15 Would your answer be the same as the last 16 answer with respect to McGladrey in those specific 17 paragraphs as it is with respect to paragraph nine in 18 Exhibit Number 8? The answer would be contained in all the 19 Α. 20 documents that we referenced and/or through communications with my counsel. 21 22 MR. REICH: Again, we're not going to 23 conclude this deposition today. We'll continue it and get a ruling from the Court as to whether 24 Mr. Barmat is required to answer what Mr. Cimo 25

ORANGELEGAL

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 139 of 159

136

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	described as substantive questions.
2	MR. CIMO: Let's just take a break before
3	we go down that road. Maybe you can rephrase to
4	try to get answers go off the record.
5	(Whereupon, an off-the-record discussion
6	was held.)
7	MR. REICH: We will reserve further
8	questions until we get a ruling from the Court on
9	this issue.
10	MS. MARK: Also just e-mail if you're
11	going to seek to depose him for more than the one
12	day that we agreed to you then you're going to
13	need to get relief from the Court for that as
14	well.
15	MR. CIMO: I think we have more than enough
16	time to finish.
17	MR. CRINCHLOW: For the record, how much
18	time did we take on record time?
19	THE COURT REPORTER: We started at 10:28
20	a.m. and we had a lunch break from 12:07 p.m. to
21	1:29 p.m.
22	MS. VILMOS: I will order it.
23	MR. CIMO: We will take a copy since it's
24	ordered.
25	MS. VILMOS: We need to look at the



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 140 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

transcript for the redactions. If you guys take the lead on the MR. CIMO: redactions and let us know what you want out, Ivan. (The deposition concluded at 3:22 p.m.)



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 141 of 159

138

1				
2	CERTIFICATE OF OATH			
3				
4	STATE OF FLORIDA			
5	COUNTY OF PALM BEACH			
6				
7	I, TONI MUSACCHIA, Shorthand Reporter and			
8	Notary Public, State of Florida, certify that MARC			
9	BARMAT, personally appeared before me and was duly			
10	sworn.			
11				
12	WITNESS my hand and official seal this 16th			
13	day of December, 2015.			
14				
15				
16	Toni Musacchia			
17	TONI MUSACCHIA Notary Public - State of Florida			
18	Commission No. FF 911505 My Commission Exp. September 18, 2019			
19	Thy commission hap. September 10, 2019			
20				
21				
22				
23				
24				
25				
UKANC	ELEGAL Orange Legal			

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 142 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	CERTIFICATE OF REPORTER	
2	STATE OF FLORIDA	
3	COUNTY OF PALM BEACH	
4	I, Toni Musacchia, Shorthand Reporter and	
5	Notary Public, State of Florida, HEREBY CERTIFY that	
6	I was authorized to and did stenographically report	
7	the deposition of MARC BARMAT, that a review	
8	transcript WAS requested; and the foregoing	
9	transcript, pages 7 through 137, is a true and	
10	accurate record of my stenographic notes.	
11	I FURTHER CERTIFY that I am not a relative,	
12	employee, attorney, or counsel of any of the parties,	
13	nor am I a relative or employee of any of the	
14	parties' attorneys or counsel connected with the	
15	action, nor am I financially interested in the	
16	action.	
17	Dated this 16th day of December, 2015.	
18		
19		
20	Toni Musacchia	
21	Toni Musacchia, Court Reporter State of Florida at Large	
22	State of Florida at Large	
23		
24		
25		
ORANO	GELEGAL Orange Legal 800-275-7991	

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 143 of 159

140

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

1	ERRATA SHEET	
2	IN RE: Comprehensive Clinical Development, Inc et al.	• 1
3	CASE NO: 13-17273-JKO DEPONENT: MARC BARMAT	
4	Page Line Should Read Reason	
5		
6		
7		
8		
9 10		
11		
12		
13	Under penalties of perjury, I declare that I ha read the foregoing document and that the facts	ve stated
14	are true.	
15		
16	Date MARC BARMAT	
17		
18		
19		
20		
21		
22		
23 24		
24		
20		
ORANG	GELEGAL Orange Legal 800-275-7991	

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 144 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

December 16, 2015 1 GENOVESE, JOBLOVE & BATTISTA 2 100 Southeast Second Street, 44th Floor Miami Florida 33131 3 ATTN: DAVID C. CIMO, Esq. MARILEE A. MARK, Esq. 4 DEPOSITION OF MARC BARMAT 5 IN RE: TAKEN ON December 16, 2015 In re: Comprehensive Clinical Development, 6 Inc., et al. 7 Dear Counsel, This letter is to advise you that the transcript 8 taken in the above-referenced deposition has been transcribed. Please contact our office at (800) 9 275-7991 to make arrangements to read and sign or 10 sign below to waive review of this transcript. It is suggested that the review of this transcript be completed within 30 days of your 11 receipt of this letter, as considered reasonable under Federal Rules*; however, there is no Florida 12 Statute to this regard. The original of this transcript has been 13 forwarded to the ordering party and your errata, once received, will be forwarded to all ordering parties 14 for inclusion in the transcript. 15 Sincerely, 16 17 Toni Musacchia Orange Legal 18 cc: NICOLETTE VILMOS, ESQUIRE; DAVID A. CRICHLOW, 19 ESQUIRE; ELAN A. GERSHONI, ESQUIRE; IVAN J. REICH, ESQUIRE 20 Waiver: 21 _____, hereby waive the reading and I, signing of my deposition transcript. 22 23 MARC BARMAT 2.4 DATE *Federal Civil Procedure Rule 30(e)/Florida Civil 25 Procedure Rule 1.310(e)



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 145 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: \$120,000..88

	108 132:3 133:13	17282 12:15 19:1	259,333 75:23	
\$	109 133:13	175 21:4,23 24:9	259,335 75:25	5
\$120,000 46:20	10:28 136:19	28:11 90:5 91:15	26 15:25 16:10,22	5 11:10 16:23 34:8
\$175,000 21:3 24:5,	11 13:14 14:2 22:3	175,000 88:3	26,000 36:2	57:9 68:23
6 87:21	45:9,25 51:4 59:24	18 14:17 130:22	27 16:3 18:1 35:25	50 127:14 132:21
\$23,000 94:14	86:2 87:1 93:18,20, 25 127:6	19 14:22 77:6,9 78:3,	67:24 132:15	59 132:21
\$230,000 49:13 50:5	110 133:13	18,21 79:13,14 80:5 81:16	27.7 48:6 49:2	
\$259,000 21:3 25:13	111 132:8	1994 8:6,7	28 15:6 16:6,10,22	6
74:17 75:23	112 132:8	1:29 56:3 136:21	67:11,16 132:15	6 11:21 35:11,22,23
\$259,333 72:10	117 16:17		29 11:22 17:5 18:6 67:21 68:12,16	47:6 86:19 103:10
\$259,335 81:14	11:26 46:11	2		61,000 46:23,24 88
\$259,355 81:1	11:55 46:11	2 8:18 44:22 49:9	3	7
\$350,000 24:14 45:21	11th 26:12 28:13	60:14 112:2	3 9:5 68:14	/
\$4.25 33:13,14 95:4	12 13:18 14:23 35:12	20 15:1 17:24 18:22	30 15:2 18:7,10	7 7:24 8:10 10:24
\$400,000 31:25	79:1	58:16 77:9 78:10 79:13,15 81:16	31 18:24 19:1,4	12:14 35:24 44:20 45:9 47:6 48:4
32:5,7	12/31/13 86:21	102:2	31,000 94:23	56:13,14 57:25 59:3
\$5 94:1 105:12,14	120 133:14	2000 103:25	32 18:24 19:1,5	16 61:10 63:15,22 86:4,19 105:15
\$60 50:6	12:07 56:3 136:20	2004 58:9,16	33 17:15 19:18,20	7-1 14:24 78:3
\$61,250 46:14	13 13:21 78:4	2010 18:22 103:11,	20:3 35:14 57:13	7-2 15:4
\$666,000 23:23	13-17273 15:15	14 110:16	70:17 104:20	7-3 15:7
\$85,000 60:16	18:10	2011 15:7 67:11,16 68:14 70:3,12 73:9	33,000 35:13,14,20 47:13	7.1 78:7
\$92 35:12	13-17282 15:18 17:7 14 11:14 13:24 14:8	78:18 107:11	34 14:12 17:19 19:25	7.2 78:7
\$93,000 45:5		2012 14:23 15:2 79:1	20:4 132:19	7.3 78:7
\$93,153.20 45:2	14,000 60:10	2013 11:22	35 7:13 14:16 20:5	71 127:14
	15 14:3 20:8 67:7	2015 10:24 11:14	97:6	72 130:22 132:21
1	15-01232 16:2,8	21 15:5 67:9,10 72:7,	350,000 46:23 94:25	73 132:22
1 7:13 8:9 17:7	15-01233 13:3 16:5 69:11	19 76:9,11,22 79:15 80:5 81:16	36 17:23 103:5,6,9 132:19	74 132:22
1.2 35:19 47:12	15-01411 15:21	22 15:9 16:23 107:10	37 110:13 132:20	75 132:22
10 13:11,23 125:24	15-1 103:12	131:8	38 14:21 120:23	76 132:23
100 18:12 22:23	15-1233 13:10,13	23 15:13	3:22 137:5	
23:10 125:6 131:19	15-1411 19:24	23,000 94:21		8
101 18:13 131:24	16 14:9 36:2 105:6,	23.4 48:1	4	8 12:24 57:11 69:7,5
1010 45:3	10	24 15:16 68:12,16	4 10:23 105:5,8	81:1 135:5,8,18
102 131:24	16.2 36:2	105:10 25 15:10 17:12 40:7	42 121:9	8.7 36:2
103 133:12	163 18:17	25 15:19 17:13 49:7 67:21 110:12	43 120:23 121:3,8,10	86 130:23
106 132:3 133:12	17 14:13	259 21:4,23	132:20	87 131:8
107 133:12	17273 11:23 19:1	259,000 72:16	49 132:20	88 131:9



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 146 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: 89..assessment

89 131:12	110:12,15	adversarial 11:17	122:10,13	apply 23:19 89:21
	acronym 17:18	adversaries 54:1	allocate 91:15	appointed 8:1 59:1
9	act 132:2	55:3 61:20 62:7	allocated 91:17	64:6
9 13:5 81:2	acted 99:16	adversary 11:11,12 13:1,8,9,13,16,19,22,	allocation 87:21	appropriateness 54:23
9.2 35:19 47:11	action 24:16 59:18,	25 14:4,10,14,18	allowable 49:24	approval 40:22
90 133:10	21 60:5,17,20,22 61:1 118:17	15:10,20 16:2,5,7 19:21,23 20:1,6	allowed 117:7	50:23 77:15 96:11
9019 12:8 77:12	actions 115:4 118:18	57:10 67:6 68:22 70:5 135:7	allowing 119:8	approve 8:10,18 106:11
83:15 98:17 99:6 108:2	actively 58:25 127:5	advice 71:25 88:25	aloud 114:24	approved 30:10
93 131:13	130:5	134:13	amended 9:25 10:11	44:25 45:15,21,22
94 131:19 133:10	activities 38:20	advise 121:24 122:2,	11:11 17:16,25 18:13,18,19,21,23	46:17,22 49:14 88:3
96 133:11	acts 70:3 73:9	4,10	19:20 20:4,7 104:23	96:17,19 128:3
97 133:11	112:17 125:11,21 132:13 134:6	advised 122:19	135:2,10	approving 91:23
98 133:11	actual 8:17 37:2	123:11,23	amendments 17:8	approximate 33:2 46:20 49:13
0 133.11	115:17	affairs 17:15,18,23 18:16 63:18 123:21	amount 21:22 31:12 32:22 33:2,13 46:25	approximately
Α	add 49:3 117:21	affirm 7:3	47:3,22,24 48:5	21:2 23:23 37:4 50:
	123:17 125:24 129:21 130:1	affirmative 13:8	58:23 91:17 97:4,7 106:13 112:19	94:23
a.m. 46:11 136:20	added 48:16 49:5,7	78:13,16	119:23	area 61:12
abbreviated 56:15	addition 12:2 23:22	afternoon 56:6	amounts 35:3 50:14	areas 65:24 83:13
ability 31:17 33:1 99:18	110:19	agree 36:4,6,11	ample 113:23 114:5	argue 118:1
accept 50:9,10 95:4	additional 23:20	49:12 53:12,21 117:12,16 127:8	analysis 82:25	arguing 82:12 107:24
accompli 59:13	41:16 42:7,18 97:24 111:8	agreed 136:12	89:21,24 90:2	argument 107:22
accompn 39.13 accordance 25:12	address 118:11	agreement 39:2	Analyzing 118:25	117:6 119:4
45:2		8	and/or 70:4 135:20	arguments 23:19
account 45:12 62:14	addressed 30:24	agreements 78:11, 15	announced 71:7	49:24
94:14,22,23,24 95:1	adequacy 130:8	ahead 48:9	answering 28:23	arise 23:3
127:15	adequate 131:6	allegation 106:15	71:5	arrangement 46:1
accountant 66:2 106:9	adequately 70:1 73:7 81:7 127:15	128:15 132:11	answers 28:23 89:20 107:1 117:25 130:24	articulate 41:10
accountants 62:23	admin 48:11	allegations 23:2,7	136:4	ascertain 90:4,6
65:17 125:12,22	administrative	26:1 35:2 68:25 69:4 78:8,13 84:13 100:4	anticipate 36:7	92:1
accounting 26:3	12:11 35:13,20 36:3	101:11 102:21	anymore 110:25	assert 21:16 23:9 29:11 84:11 85:1,12
65:15,21 66:4 99:14, 19 101:16 111:2	46:1 47:13,25 48:16 49:6 70:7 86:25	106:10 113:1,2 124:10 128:11,23	appears 15:8,14	99:18,24 105:16
115:5,12 117:9	92:17	129:5 130:25 135:12	16:16 18:23 103:15	asserted 21:9,11
120:7	administratively	allege 22:5 25:1,25	applicability 40:2	29:17 30:9 60:18 109:4 117:11
accurate 8:14 9:13 11:5 35:4 73:12	24:13 45:19,24 86:23 91:11,13	109:16 112:24 121:3	applicable 27:2 51:11 53:10 63:23	asserting 23:25
acquire 58:12 115:9	admins 45:10,25	alleged 24:20 25:7 29:11 70:5 75:24	92:9 100:1	85:14 89:7 109:8
acquired 57:3,5	49:16,17 50:15	83:21 110:19 113:2,	application 44:25	assessing 63:5
acquisition 57:14,	admit 32:19,23 72:2	3 115:4 120:24	applied 42:6	assessment 104:9
15 66:22 67:14		alleging 23:4 27:1		



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 147 of 159

Index: asset..check

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

	1		1	
asset 24:15 93:14	19:21 20:2 21:2,8	beginning 118:11	131:7	11,15,23 88:5 91:10,
assets 17:22 18:15	23:22 25:16 75:23	behalf 11:19 23:1	buying 128:20	13 93:12,17 101:16
45:18 59:13,17,21	76:24	71:12		109:25 111:14
60:3,7,8 90:25 93:1,	avoidance 26:3,4			114:8,9 116:10
22 94:1 106:17	69:16 71:1,2 76:1	belief 108:24 117:3	C	cash 45:6,7 130:9
108:8 126:23	-	bell 57:21		-
ansist (1.((2.22	aware 38:14 58:9,		calculator 48:22	caveats 50:12 81:8
assist 61:6 62:22 65:6 66:7	15,20,22 67:1,3 69:2	belong 39:13	call 59:18 68:23 78:1	CCD 15:15,17 17:9
03:0 00:7		benefit 26:9,11,14,	95:3	18:11 19:5 35:11,13,
assume 27:18 28:1,9	В	17 27:10 28:4 53:23		24 41:20 47:11 48:5
36:16 41:7 42:20		55:14,17 91:23	called 56:15 71:13	56:15,21,22,25 57:3,
51:1 59:11 130:7	back 22:18 47:1	106:14 108:12 109:2	Capilla 62:24,25	4,5 66:11,22 67:1
assuming 27:16	83:11 100:19 101:7,	benefits 33:6 54:9	63:1,2,3 64:22 65:10	68:6,9,20 86:20,21
49:6	9 113:11 118:3	55:20 118:25	97:25 98:2	87:5,21,23 88:6,8,
	119:13 120:17 126:8			17,20 89:21,22,25
attached 8:17,20	129:24,25 133:25	benefitting 46:2	caption 70:7	90:3,5 91:5,17,24
attest 11:4	bad 111:1	big 114:25 125:3	care 82:3 106:12	123:21,22 124:7
		0	113:25 120:19,20	126:13 129:8 130:9
attorney 8:5 28:20	bank 45:12	biggest 24:15	121:16,24,25 122:5	CCD'S 71:12
37:15,20 45:1	bankruptcy 45:13	blankly 64:11	126:16	CCW 19:5 49:5
attorney's 88:4 89:3	60:23 61:11,13,14,		carve 94:6,7	UUW 19:5 49:5
attorney/client	16 62:21 64:2,3,9	board 64:19	-	cetera 75:6,7 81:8
38:18 70:20 89:14	70:8 91:24 96:12,15	books 32:24 126:23	case 11:12,22 12:15,	cetra 50:15
111:20,22 122:24	107:25 126:21	borrower 83:14	21,22 13:3,17 15:15,	
123:1 124:4	han 20.1(17.21.24	84:23,24 99:18	22 16:1,16,18 17:7	CFO 73:16 81:20
	bar 20:16,17 21:24 26:8,25 27:4 28:11	04.23,24 99.10	18:10 19:4,14 20:11	challenging 72:4
attorneys 111:10	36:21,22 37:6,9,11,	borrowers 113:16	21:7 22:16,20 23:24 25:17 27:23 30:12,	
126:1	14,16,20,22 38:1,5,	114:6	14,19 32:5,16 37:7,	change 9:15 11:7
audit 70:2,11 72:24	10 40:16 41:9,24	boxes 60:10	13,19,21 43:20	36:1 45:4 46:23,24
73:8 74:22 78:18	42:5,6,20,21 43:22		44:19,20 50:13	49:8 88:15,17 129:8
79:9,13,14 81:7	49:20,23 51:13,15,	breach 22:19 73:20	51:11,14 53:10,14,	changed 9:3
102:17 103:14,17,23	19 52:1,17,22,23	121:6,13	18 56:15 57:24 58:4,	
109:15 110:16	53:22 84:17 86:9,13,	breached 69:1	5,11,22 61:19,21	Chapter 7:24 8:10
131:23 134:5	14 98:17 99:7		62:4,12 67:6,10	44:20 45:9,25 56:13, 14 57:24 59:3,16,24
auditing 100:7	D	break 47:18 106:2	69:10 70:6,8 73:10,	61:10 63:15,22 86:2
103:25	Barmat 7:8,21 13:3	116:21 136:2,20	16 83:20 84:12	87:1 93:18,20,25
	15:23 16:1,4,7 28:22	breaks 47:18	85:10 86:3,4,12,20	127:5
auditor 66:3 106:9	56:6 116:13,15 129:23 135:25	huing 54.6 11 55.2 6	87:24 88:3,6,17	
auditors 23:5 100:6,	129.23 133.23	bring 54:6,11 55:2,6, 13 83:11 101:9	89:22,25 90:5 91:10,	characterization
13	barred 29:13 117:3,	113:11 117:15	15 93:23,24 97:8	117:13
-	10	129:25	99:4,17 100:13	charge 98:11
audits 65:21 98:19	based 23:6,12 36:17		101:21,22 102:4,8,9,	
128:12 131:19	39:1 69:18,25 70:3	bringing 64:24	14 103:11,12 104:24	charged 126:21
August 11:22	71:25 73:9 81:6	broad 20:23	107:19,23,24 108:1	127:3
authorize 51:15	84:12 90:2 108:10		109:23,24 110:3	charges 134:4
	123:16,17,20 127:19	broadly 99:8	112:4 113:10,23 114:5,7 118:20,22,	Charles 57:1,14,15
authorizes 52:1	bases 93:9	bucket 17:6 45:11	24 120:19 124:18	66:13,22 67:15 68:5
automatically		burden 117:5,6,7	125:2,4 126:22	69:2 71:14,20 73:22
86:11	basic 26:1	129:16	127:1 129:14,18	76:14 81:17 83:19
	basis 83:5 96:19			84:14 85:6 110:12,
avoid 13:1 19:21	115:14 119:17	burdened 112:20	cases 8:3 22:4 24:6	14 132:16,17
20:1 129:15	133:22	business 50:16	28:14,15 48:13 51:5,	
avoidable 13:2		59:23 106:18 119:1	6 53:17 54:7 56:8,11	check 17:1 47:4
			62:4,14 63:6 86:9,	
	1	1	1	1



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 148 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

checks 72:17

cherry 133:6

chose 72:1 99:24

Cimo 9:23 10:7,18

26:15,21 27:12,17

28:7,25 29:22 30:1

39:4,14 40:8 41:25

50:8,21 51:17 52:2,

21 34:3 38:8,17

42:13,23 43:11

44:10 47:7 49:3

9,20 53:3,15,24

54:14,18 55:8,16

62:5,13,16 63:20

64:7 69:21 70:18

71:4,7,15,21 72:8

75:14,20 76:10 77:3,

7,11,18,23,25 78:22

80:2,12,18,20 81:22

82:3,7,12,15 83:2,7,

10 84:1,15 85:3,8,11

89:5,11,16 90:9,13,

93:2 95:12,15,18,25

98:15,20,24 99:10,

21 100:21,24 101:5,

17 102:10,18 103:1

105:24 106:2 107:5

108:4,21 109:18,25

110:17 111:4,16,25

119:10,15,20 120:9,

11,22 121:18 122:21

123:5,13,24 124:22

127:2,20 128:5,14,

20 129:4,11 130:2,

135:3,25 136:2,15,

11,17 132:14,16

133:1,4,8,16,21

23 137:2

Cimo's 62:15

125:14 126:2,6

112:22 113:8,20

114:2,20 115:15

116:12,16,20

117:12,15,25

19 91:1,6,18 92:4

96:10 97:15,23

104:2,10,20,25

87:7,14 88:11,21

73:1,24 74:9,25

79:3.5.17.21.23

31:7 32:17 33:10,18,

chief 68:14

code 45:13 64:9 **circuit** 22:3 26:13 134:17,20 135:8 28:12 45:12,14 28:13 48:7 51:4 46:17 50:13 53:9 **Cohen** 7:23 44:25 complaints 13:9 124:9 100:3 114:5 24:20 57:7,8 110:23 45:1 61:21 62:9 circumstance 23:8 111:3,15 112:15,18, consolidated 86:24, collected 60:14 25 87:3 91:25 51:15,25 52:3,6,8, 25 113:1 116:6 14,17,23 collectively 96:22 117:19 120:7 124:19 **constitute** 121:5,12 125:22 cited 114:10 commas 35:17 consult 41:7 complete 24:1 100:8 claim 18:25 19:13 comment 29:2 consultation 25:21 22:8,11,13,16,20 completely 64:12 **committee** 58:5.13 104:12 27:10,14 28:5,10 **contact** 28:24 59:6 85:20 47:2 83:25 84:11 complex 21:14 contained 44:11 85:13,16 112:1 committees 58:8 62:12 78:14 115:24 135:19 117:3 communications compliance 107:12 contention 129:1 claiming 82:20 131:2 134:13 135:21 110:6 complicated 76:15 context 59:4 community 61:11 106:8 claims 11:21 12:14 contingency 92:16 **companies** 65:14,16 17:25 18:23 19:6 **comply** 9:22 106:8 94:25 97:2,5 66:10 21:13 22:5 27:9,25 comprehend 64:12 continue 29:3 28:2,3 29:12,14,17 company 35:1 36:10 135:23 30:8 31:18 32:6 Comprehensive 63:17 65:25 66:2 35:3,6,10,11,18,25 56:18 68:3,8,15,19 68:20 73:17,22 continued 55:1 36:1,13 38:5,11,15 71:13 107:11 122:11 continues 39:7 39:3,12,24 40:5,11, comprised 36:1 compared 47:22 16 42:22 43:18,22 continuing 18:17 119:23 60:4 47:4,10,11,18,23,24 97:19 48:1,4,6,11,17 49:1 concern 40:15 comparing 30:19 contribution 22:13, 50:7,14 55:7 62:17 conclude 135:23 competent 24:7 17 27:9,14,25 28:2, 76:6 85:2 86:9,13, 25:20 3,6,10 29:12,15,17 14,16,21 87:18 90:3 concluded 137:5 30:8 31:18 32:6 92:24 93:7,8,10 94:8 complained 80:7 concludes 129:23 36:12 39:23 40:11 99:19,24 112:21 112:18 42:22 43:17,21 116:8,9 117:10 conclusion 71:25 complaining 80:10, 54:20 83:24 84:11 118:10 129:17.20 25 **conduct** 67:2 71:11 85:2 118:10,13 132:6 99:14 111:1 112:17 control 70:4 130:9 complaint 11:11 clause 23:11 114:19 115:5,13 13:1,22 15:10 19:21 controls 103:25 **clear** 130:12,17 conducted 71:12 20:1,8 25:5,17,20,21 104:5,7,8 131:6 26:5,6 33:25 34:6, 124:11 **client** 73:16 77:22 10,12,23 57:9,11,12 conversations 81:20 83:1,17,20,22 conducting 75:12 68:22 69:6,15 70:17 38:25 40:19 41:12 84:10,20 85:1 91:12 83:18 71:10 72:3,11,22 108:22 109:11 92:23 99:23 124:17 75:1,22,24 76:6,15, confidential 93:4 111:7,10 116:2,4 126:12,16 16 77:1,21 78:8 **confirm** 32:13 conversion 58:4,12 clients 38:11 73:19 80:7,8,24 98:11 59:4,16,25 85:21 48:22,24 57:6 83:1 91:4 101:12 102:20 104:6,16,18, 126:22 120:12 115:4 129:16 23 105:20,25 106:4, 16 109:16 110:9,13, **converted** 58:2 86:4 confused 84:4 clinical 56:18 60:11 23,24 112:9 115:24 93:23 67:15 68:5 127:15, connection 86:2 118:1 120:8,9,10,18, 25 128:9,13 129:3,9 copy 44:22 136:23 25 122:7,14 124:11, consideration 32:4 **closing** 119:3,12 14 127:13,17 40:5 corporate 63:18 128:15,22,24 129:6 86:11 CMT 98:6,25 123:23 consistent 26:12 130:25 132:8,11,18



Orange Legal 800-275-7991

Index: checks..corporate

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: corporations..directly

corporations 63:25	couple 26:5	D&os 22:5,8,10,19,	decide 55:19 119:17	demand 19:22 20:3
64:3,5,10	court 7:3 28:1 32:4	24 23:1,2,4,9 24:21, 22 29:11 35:2 36:8,	decided 118:21,22	deplete 106:17
correct 10:14,16 16:24 17:3 19:7	40:21,24 45:15 46:17 82:7 83:8,10	12 42:14,21 43:21	decides 33:22	depletes 108:8
29:6,7,13 32:12,22	89:18 95:19,21	46:5 49:21,24 54:7	decision 64:4,15,20,	depose 136:11
35:23 36:6,25 37:10	96:12,15,20 111:13,	68:23,25 73:10 98:12 99:15,16,18	21,23 65:1,3,5 119:1	deposition 10:11
41:2,3 42:15 43:18	24 113:10 118:2	100:5,18,19 102:16	124:18	57:10,12,13 81:24
46:16 48:15,21 49:4, 7,22 56:9,17,19	119:13 126:7 128:4 129:23 135:24	107:4 109:8 111:1	decisions 24:3,4	82:9 85:19,23 92:7
57:4,25 58:1,3,6	136:8,13,19	114:19 115:4,6,12,	63:17 64:5	95:9,14 114:8
59:8 60:5 61:1,7,15,	Court's 9:22 12:4	13 117:9 121:4,11, 16,25 122:2,4,18	declaration 9:6,13	118:12 119:11,13,22 126:24 127:4 135:23
18,22,23 62:6 63:5,		123:11,23 125:11,21	10:23 11:9 20:18	120:24 127:4 135:23
8,11,19 64:1,6,16,25 65:7,15,22,25 66:5,	covenants 107:12, 13	132:13 134:7	22:1 23:14 27:4	
6,8,23,25 67:4 69:5,	_	damage 118:16	29:10 32:10,19 35:8 44:24 45:4 52:6,12	depositions 58:16, 21 124:14
16 72:7,20,25 73:23	cover 36:13 76:6,20		53:8 112:7 115:17,	
74:3,4,8,11,24 78:19	103:25	damages 19:22 20:2 34:20 35:1 113:2,3	24 116:6 117:20	derive 124:20
79:16 87:6 88:6,10 90:25 91:11 92:18	covered 75:10,12	132:6	130:25	describe 128:13
90.23 91.11 92.18 94:4,5,6,12 95:20	78:8	date 11:13,22 44:19	declarations 9:23	designed 101:10
96:12,15,17 97:2,9,	covers 72:20	86:20 90:16 121:5,	12:2 51:21	129:15
22 100:20,23 101:23	credit 105:12,19	12 126:12,16	deem 117:24	detail 26:24 111:23
113:19 114:19 116:11,12,16 124:21	106:5 107:2 108:17	dated 10:24 11:13	deems 9:20	detailed 50:1
134:4	109:9,17 110:7	14:23 15:2 67:16	deepening 110:3,7	details 68:24
correctly 42:25	creditor 94:3	68:14	113:3,6	
-	creditors 17:24	dates 86:9,14 126:19	defend 55:6	detect 134:4
Correspondence 14:23 15:2	18:22 58:8,13 87:6,	day 112:19 136:12		determine 21:18
	12 88:8 90:1,6 91:24 92:2,24 93:12,16	DE5 104:23	Defendant 13:7,15 14:5	85:15 92:7 100:1
cost 97:18,20	94:17	DE71 78:4	defendants 11:13,	determined 22:25
counsel 24:7 25:20	creditors' 58:5		18 20:14 36:22	determining 118:23
29:1 35:5 37:1 38:4, 23 39:1,25 40:19	Crinchlow 73:19	DE73 67:6 72:6	117:2	Development 56:19
41:13 43:20 44:15	136:17	deadline 86:13	Defendants' 20:7	dictated 64:8
46:15,20 61:19,21	cross 56:4 87:9	deal 127:6	defense 21:11 23:25	difference 68:2
62:3 63:7 66:21 71:25 85:18,24 86:7	108:6	dealt 29:14 78:17	24:1 107:16 108:16,	
88:25 93:5 96:17	cross-claim 54:12	debacle 127:24	20	differently 16:20
97:12 102:12 107:23			defenses 13:8 21:9	difficult 60:9 126:9
108:22 109:1,11,21	cross-claims 54:4	debitor's 73:8	78:14,16	diligence 66:5,8,12,
114:11,15 115:7,20 116:2,5 124:11,14,	cross-motion 14:6,	debt 110:8 112:20	defer 25:17,19 26:7	16,21 67:2 71:11,19
15,21 125:6,8,12,14,	16,20	debtor 59:6 69:19	31:15 35:4,18 38:9	72:5,19,25 74:6,14,
15 126:4,5 127:19,	crossover 87:11	85:20 105:18 109:14	39:25 51:21 52:5	23 75:10,12 76:8,13 79:11,12,15 81:12,
21,23 130:4,15		debtors 70:2,4 81:6,	68:10 97:6 105:20 110:2 128:23 129:5	19 82:24 83:19,23
131:2 133:23 134:13,14 135:21	D	8 104:1		84:10 98:23 100:14,
	DQ 245.550	debtors' 17:21	deficiencies 129:2	16 101:4
count 69:15 71:1,2 133:14,15	D&o 34:5 57:9 62:14,17 70:6 73:10	18:15 126:23 132:2,	deficient 65:25	diligent 82:20
-	91:10 97:8 99:17	7	definition 22:24	DIRECT 7:15
counterclaims 54:3,5	101:16,22 102:4,9,	debts 87:13	delay 131:14	directed 15:3
-	20 104:5 110:23	December 8:2 10:24	delicto 23:25 107:15	directly 23:14 30:20
counts 23:22 26:2,5 69:16	115:14 118:17	103:11	108:16,19	38:3 128:5
			,	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 150 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: director..extraordinary

				directorextraordina
director 11:12,18 15:10 20:14	DLA 66:16,19,21 71:19	49:20	21,24 15:4,7 18:11, 12,13 69:10 103:12	exhibit 8:9,18 9:5 10:22 11:10,21 12:4
directors 20:21	docket 13:3,10,13,	early 59:22 93:25 earmarked 94:13	134:19	5,8,14,16,18,20,24 13:5,11,14,18,21,24
24:17 25:10 26:9,11,	17,19,23 14:1,8,12,		equal 48:17	14:3,9,13,17,22
17 27:1 28:5 33:3 39:22 40:15 43:17	16,20,24 15:4,7,14, 17,20 16:4,7 18:11,	easier 77:5	equally 109:13	15:1,5,9,13,16,19,2
50:20,25 53:23	12,13 69:10 103:12	easy 77:7	equitable 20:13,21,	16:3,6,10,22,23 17:
54:11 55:15,19	109:12 120:18	ECF 16:17 17:7,13,	22 24:22 26:19	19:11,18,20,25 20:: 34:7 35:10,11,22,22
63:16 64:19 70:4	134:19	15,19,23 18:17,21	41:23 50:6,11,16	24 47:6 48:4 57:9,
73:18 81:21 122:11	document 8:12 9:7,	19:24 20:3,8 45:2	equitableness	11,13 67:7,9,10,20
directors' 27:8 40:5	10 10:25 11:15,24	47:11	113:16,17	68:23 69:7,8 70:17
disagree 49:17	13:6 16:11 68:13	effectively 115:7	equivalent 21:17,19	72:5,6,7,19 76:9,11
117:15 119:10	78:23 79:5,19 104:12,13	effectuate 131:15	25:14 69:20 72:23	22 77:5,9 78:3,4,10 18,20,21 86:19
disagrees 82:10		effort 21:21	73:7 76:25 81:3	103:5,6,9,10,24
0	documents 19:12		escrow 94:22	104:19,20 116:7,8
disclaimers 17:21 18:15	34:4 86:1 126:25 134:12 135:20	elbow 31:24	essentially 23:3	134:21,23 135:5,8,
		element 51:20	essentially 23:3 27:5 50:3	18
disclose 40:18	dollar 30:25 31:5,13 33:2	elements 52:11	establish 129:17	exhibits 7:12,13
disclosed 96:15		employed 7:22		10:10 12:1 34:1
disclosure 13:23	dot 108:7	46:18	estate 11:19 12:11	77:10 86:18 117:20
14:1	drafted 28:12		24:13,15 39:13 41:15 45:19 46:2,4,	
disclosures 13:12,	drilling 99:9	encompasses 81:1	21,25 49:13 55:18	exist 22:6 38:16
20	0	end 94:15 112:19	60:4,23 61:1 64:3	40:12 51:19 54:17 60:20 89:25 90:1,2
discovery 58:9,13	due 45:3 66:5,8,12, 16,21 67:2 71:11,19	114:15	65:10 90:15,18,24	-
59:5 106:16 127:1	72:5,19,25 74:6,14,	endeavor 59:5	91:17 94:24 106:14,	exists 22:14 94:21
	23 75:10,12 76:8,13	ending 70:3,12 73:9	17,18 107:1,20 108:8,13 112:11	expect 24:22
discussed 24:8 40:14 57:8 98:10	79:11,12,15 81:12,	engage 42:7 58:8	113:18 132:7	expense 21:21
115:20 125:23	19 82:19,23 83:19,	0.0		-
discussing 95:23	23 84:10 89:10,12 98:23 100:14,16	enjoin 38:10	estates 87:17 91:25 92:3 118:21	expenses 45:17 46: 92:18 97:18
124:20	101:4	enjoined 38:5		
	duly 7:9	113:18	evaluation 63:10	expensive 24:18 46:7
discussion 10:19 18:4 47:8 96:7		enter 41:1,5 108:12	event 84:12	
102:24 105:11 136:5	dunk 21:4	entered 37:5 40:20	evidentiary 9:21	expert 13:23 14:1
	duplicate 19:8	44:8 49:21 51:16		97:19,21
discussions 93:5	duplicates 18:24		exact 10:5 27:3 31:12 34:10,12,15,	experts 63:8 92:23
dismiss 20:7	1	entering 39:2 45:8	18 48:24 67:2 107:3	95:2 106:12
dispute 58:10,19	duties 24:24 25:12 59:3 62:22 69:1	entire 80:8 91:16	135:13	explain 20:20 37:2
116:23	73:21 76:8 83:21	124:18 127:9,24 132:18	EXAMINATION	77:17,23 78:1
distinguishable	105:18		7:15 56:4	extent 9:19 20:16
32:15	duty 22:19 26:16	entirety 105:21	examinations 58:17	36:12 38:18 45:5
distinguishes 23:24	121:6,13	entities 56:14 63:19		70:20,24 88:22 93:
e		112:20	examined 7:9	108:22 109:19 111: 120:24 122:23
distribution 87:23 92:11,12	E	entitled 50:5 93:14	exchange 25:15	
		117:4	75:25 76:25 81:14	extraordinary
district 28:15 51:7 114:10	e-mail 10:1,13	entity 100:16	execution 9:3	52:8,14,17
	136:10		executive 63:17	
divulge 93:3 109:19	earlier 11:8 47:2	entry 13:4,10,13,17, 19,23 14:2,8,12,16,	68:14	
8	earner (1x4/)			



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 151 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: faced..happen

	feel 44:2	Florida 22:15,17	Furr 7:23 44:24 45:1	36:15,20 37:25 38:2,
F	6 45 6 5 4 4 6 6 4	27:23 99:25 118:12	61:21 62:9	16 39:3,12,24 40:6,
	fees 45:2,3 74:19,21	a		25 42:3,11 43:1,25
faced 42:12 50:6	88:4	flow 92:2 100:17	future 43:14 88:25	46:13 54:2 55:1
	feet 34:4	follow 37:18 89:3		57:10 67:1,6,13
facility 105:11,13,19		114:9 131:5	G	69:6,10,18,25 70:10,
106:5 107:2 108:17	felt 30:20			15,25 71:10 72:3,13
109:17 110:7	fiduciary 22:19	foreclose 125:5	GAAP 21:20 25:12	73:5 74:5,15 76:21
fact 32:4 57:18 65:9	24:24 26:16 64:9	form 26:15,21 27:11,	GAAF 21.20 25.12 106:8,11	83:18,23 84:9,25
67:5 82:1 84:24 92:9	69:1 73:21 121:6,13	12 28:7 30:3 31:7	100.8,11	85:2 100:18,19
101:21	-	32:17 33:10,21 38:8	GAAS 21:20 25:12	101:21 102:8 114:18
101.21	figure 91:22	39:5,14 40:8 41:25	106:8,11	131:23 134:25
factor 52:25	figuring 60:10	42:13,23 43:11	gained 111:6	135:11,14
factors 52:5,11		44:10,22 50:8 51:17	gameu 111.0	
62:18 77:12 117:1	file 86:13,20	52:2,20 53:15,24	gamble 24:4	Gray 29:1
02.10 //.12 11/.1	filed 11:18 14:24	54:14 55:8 60:14	gather 71:24	great 20:25 56:7
facts 23:3,12 24:20	20:19 25:7 35:3	63:20 64:7 69:21	gather /1.24	68:25 77:13 133:19
30:19 100:2 108:18	40:21 43:20 44:12,	70:18 72:8 73:1,24	gave 134:2	
factual 28:22,23	15 87:18,24 95:18	74:9,25 75:14,21	general 17:9 23:12	greater 27:9 28:3,5
	101:15 102:5 109:3	76:10 77:3 78:22	39:1 42:5 61:18,20	36:18
factually 30:11,13	110:10 114:11,24	80:12 84:1,15 85:3,	65:19,20 80:9 92:20	grounds 28:20
31:4	115:18,25 122:16,17	11 87:7,14 88:11,21	93:5 94:20 96:21	
failed 21:11 105:17,		90:9,19 91:1,6,18	106:21 125:15 126:4	GT 19:11,15 75:12
23 106:6 122:10	filing 11:13 110:2	92:4 93:2 97:15,23	127:21 128:18	76:4 80:7 81:2,18
129:1	final 64:20,21,23	99:21 100:21 104:2,	130:4,15 133:20	82:19 87:20 89:19
	65:1,3	10 108:21 109:18	150.4,15 155.20	96:6 97:8 100:15,16
failure 70:1 76:7,22		111:4,16,25 112:2,5,	generally 22:1	110:24 134:17
81:6 82:23 109:15	financial 17:15,18,	22 113:20 114:3,20	58:22 100:5 106:7	GT'S 76:7
121:3,10 127:14	23 18:16 32:20 33:1	115:16 121:18	Genovese 62:4,10,	CTL 01.4.(
131:5,14 134:4	70:2,11 73:8 81:8	122:21 123:13,24	16 64:15 92:16 97:1	GTL 81:4,6
failures 132:12	105:12 107:12,13	124:22,24 126:2		guarantee 107:21
	find 59:2 64:14	127:2 128:14,22	Genovese's 94:25	
fair 20:13,21,22	107:1	129:4 130:11 133:16	Ginger 57:19	guess 34:18 44:15
23:16 24:21 26:19,	C 1 00 1	formatted 16:13,19		55:12 61:24 71:12
22 41:22 50:6,11,16,	finds 28:1	101 matteu 10.15,19	give 7:4 18:1 27:9	100:25
24 61:17 62:1 65:19,	fine 69:23 77:24	formulating 108:23	29:20 47:17 48:22,	guys 54:15 95:3
20 104:9 106:13	80:19	forward 59:7	23 77:25 81:25	137:2
fairly 25:22 125:23		101 waru 39:7	88:23 106:21 115:23	
	fingertips 23:15	found 83:20 84:12	gladly 30:15	Н
fairness 113:14,16,	finish 108:4 119:10	85:5		<u>п</u>
17	136:16	fraudulent 21:15	glance 60:15	
fait 59:13	firm 20.1 (1.15.16	26:4	global 17:20 18:13	hand 8:8 12:24 13:5
	firm 29:1 61:15,16,			103:4
fall 51:8	22 62:5,10,16 63:1 64:16 65:10 66:11	free 120:2	good 7:17,18 31:25	handed 10:22
falls 21:5 23:17	92:16 96:10 97:1,25	front 26:7 32:8,11	32:2 56:6 62:17	
	98:3 128:1	108:10	74:21,23 84:9 128:8	handful 119:23
familiar 57:2,15,20	70.3 120.1		graduated 8:6	handing 11:10
66:19 98:5 107:15	firms 65:15,21 66:4,	FTP 16:14		
120:20	7 99:14,20 111:2	full 32:21 94:8 100:8	Grant 8:11,15 9:1,	handled 62:9 73:21
fault 22:25	115:5,13 117:10	107:16	25 10:9,24 13:3,7,9,	handling 61:24
	firsthand 120:25		13,15,16,20,25 14:5,	62:17 128:2
February 15:6		functions 131:7	10,14,24 15:3,6 16:4	
67:11,16	Fish 34:3	fund 24:14	20:10 21:1,9,14,16	hands 59:5
fee 44:25 94:25 97:2,	flipping 79:18		22:6,8,11,12,14,18,	happen 88:1,15
5	mpping 79.10	fundamental	21,22 23:2,5,9,16	
		113:14	25:2,9,11 32:20	
				I



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 152 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: happened..learned

happened 112:6	important 21:13	individual 86:12	interrelated 22:4	jury 19:23 20:3
117:17 118:24 happening 50:13	26:23 impossible 23:7	96:19 individually 61:3	intricacies 21:20 59:15 106:15	Justice 22:2 23:17 24:9,20 40:2,23
	improper 79:22	-		51:10 52:10
happy 95:15 98:18 129:24		inequitable 26:23	invading 89:10 90:7	
harass 80:21	improperly 73:21	information 23:5, 15 25:10 38:19,20,	investigate 60:25	K
harassing 29:3	inaccurate 23:5 36:17	22 44:14 70:21	investigation 59:7 123:21 124:6,10	hearing 17.5
107:8 123:14	inadequate 25:10	81:25 93:4 100:6,13, 17 108:11,23 109:20	involve 130:15	keeping 17:5
hard 59:17,19	130:20	111:8 122:24 123:2		kick 23:11
harm 110:14 112:11,	inappropriate 29:2	124:2,20 125:1	involved 36:25 37:13,14,15,21	knowledge 110:25 111:6 112:3 121:1
19	80:13	126:22 127:18 130:3,20	58:25 98:25 99:1	122:6 124:7,19
harmed 109:14	incidentally 44:23	initial 13:12,20	127:5,6,21 128:5 130:5	125:10,13,20
head 39:18 66:14	include 18:19 35:2	inquire 115:3	involvement 128:4	L
hearing 9:21 12:10	72:4,12,13,18	118:15 119:19	issue 28:21 30:23	
held 10:20 18:5 47:9	included 12:5 26:2 37:22 78:12 80:6	inquiring 70:20	31:1 32:3 37:21	lack 69:22 72:23
96:8 102:25 136:6		insolvency 12:11	117:1,5 118:7,23	73:6 81:3 104:6
hire 61:4,6 64:15	includes 125:15	46:1 110:3,7 113:4,7	119:6 130:14 132:6 136:9	language 10:5 27:3 38:9 49:23 50:1
66:2,4,7	including 47:25 50:15 59:19 62:5,22	insolvent 24:13	issues 93:6 110:4	73:13 78:14 80:15
hired 24:6 62:10 66:12 126:12,16	63:10 78:9 95:22	45:20,24 91:11,14	118:16 127:7	largest 17:24 18:22
hiring 64:22	inclusive 81:11,13,	instances 61:6	Ivan 49:5 56:10	late 59:22 93:25
Hold 133:1	15	instruct 38:17 39:6 70:19 81:22 82:5	118:2 123:6 128:20 137:4	law 8:6 14:8,19
	inconsistent 25:19 44:23	88:22 101:5 104:11	157.7	22:15 26:12,13 27:
holding 17:24 18:22 94:13		107:6 109:21 111:5	J	19,22,23 28:13 36:18 49:25 51:11
hours 120:4	inconvenienced 118:4	113:8 115:20 122:22 123:14,25 124:23		53:10 55:10 66:7,1
hundreds 119:21	incorporated 14:7	129:12,21	January 14:23 15:2 79:1	99:25 100:1 108:1
hypothetical 54:25	incorrect 35:5 48:15	instructing 80:17		111:13,24 113:23 114:5 118:12 128:1
• •	57:6 66:24	83:7 89:5 110:1 121:21	job 60:24,25 61:2 74:22,23 84:9 123:5,	lawsuit 11:17 20:2
hypothetically 53:17	incredibly 23:16	instruction 9:22	8 126:20 129:18	21:1,12 23:21 25:7
	60:9	71:4,15,21 111:17,	Joblove 62:4 64:15	55:14 60:15 75:10, 13 76:4,18,19,20
I	indemnification	19	John 68:13	83:5 101:7,15
identification 7.14	28:6 29:11,16 30:8 31:18 32:6 39:23	instructions 89:4	judge 22:24 24:3	107:22
identification 7:14 8:9 103:7	42:22 43:18,22	insurance 31:20,23	33:22 77:17 81:25 82:10 85:15 100:1	lawsuits 55:1 60:9
identified 19:2	118:10,13	33:6 36:10	101:8 117:16 130:18	19 64:25 65:2 99:1 112:23 115:8,18,19
identify 12:25 13:6	indemnity 22:14,20 23:11 27:9,14,25	intellectual 59:19	judgment 13:16	lawyer 28:24 61:11
17:6 18:9 19:3,18	28:2,3,10 29:15	intended 76:6,20	14:6,7,12,16,20	13
ignore 27:19,22	36:13 40:10 54:20	interest 118:21	21:10 36:9 50:16 78:17 95:22 96:1	lawyers 111:7
imagine 53:16 54:1	83:25 84:11 85:2	interested 85:14	106:18	lead 137:2
implead 54:5	independent 87:13 125:13	internal 103:25	judgments/	leads 99:16
implement 131:5,14	indicating 41:22	104:5,7	proposal 33:12	learned 109:20
		internally 62:9	jump 42:3	
	1	1	1	1



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 153 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: leave..Neuroscience

IARC BARMAT			inde/	c leaveNeuroscienc
leave 30:20 48:12 49:8 55:18	lowest 21:6 51:9 lunch 136:20	marked 8:8 10:22 15:8,10 35:9 103:6	memorize 25:5 memory 25:22 32:1,	95:2,5 97:12,20 107:1,20
led 110:7	luncheon 56:2	materially 23:4 25:9 130:20	2 57:23 122:15,17	monies 88:2,9 92:15 94:10,16
legal 28:21 29:20,21 56:14 69:18	M	materials 58:13	mentioned 66:19 80:5 134:8	Morales-perez 15:4
letter 15:7 67:11,12, 13 79:2 103:11	made 9:12 29:1	59:6 math 36:18	merit 129:17,20	morning 7:17,18
letterhead 14:25 15:3,6	64:5,15 71:25 76:7 95:9 108:19 134:5	matter 82:1	merits 99:4 111:14 118:19 129:14	motion 8:10,18,21 12:3 13:15 14:6,11 20:7 21:10 33:18
liabilities 17:22	main 19:14 61:21	matters 124:19 maximum 21:22	met 115:6 method 54:6	64:6 76:5 78:16 83:15 98:17 99:6
18:16 liability 45:6,7 83:4	maintain 49:21 127:15	Mcgladrey 8:19,24 9:2,6 15:23 19:11,	methodology 17:21 18:14	115:25 motions 12:9,16
118:16 liable 83:20 84:12	maintained 123:6 maintaining 129:9	15,23 20:1,6,11 23:6,20,21,24,25	mill 21:8	109:3 116:5,7 move 15:11 28:18
85:5 98:12 99:17 likelihood 117:1	maintenance 129:2	25:24 32:20 36:15, 21 37:25 38:2,16	million 33:13,14 35:12,15,16,19,25	29:1 33:15 95:7 107:5,6
limitations 17:20 18:14 31:22,23	make 10:8 24:3 49:24 54:3 63:17 64:20,21,23 65:1,3	39:3,12,24 40:6 41:1 42:4,12 43:25 46:14 54:2 55:2 57:12	36:2 47:12 48:1,6 49:2,7,9,10 50:6 94:1 95:4 105:12,14,	moving 119:25
limited 80:15 125:14	67:7 77:5 83:24 102:8,14 123:5	70:16 71:1 76:3 89:19 96:5 97:8	15 millions 33:4,5	Mukamal 63:2,3 multiple 117:18
limits 36:5 list 17:24 18:22	130:17 135:9 maker 64:4 124:18	102:14,16,19 103:11,12,13 104:7, 9,16,18,23,24	mind 18:1 24:5 44:7	120:8 multitude 66:1
listed 12:15 19:14,15 48:11	makes 24:3 101:21 102:20	105:16,23 106:6 109:14 110:13,15,24	minds 42:3 mine 60:23	Mumford 22:3 23:18 24:10,19
listened 124:12	making 65:5 77:7	114:18 120:10,18 121:15,24 122:2,4,	minus 46:23,24 94:25	28:13,14 29:5,6,13, 14,16 30:7,12,14,15,
litigate 46:6 97:12 litigated 37:20	malfeasance 75:11 76:21 85:6 103:2	18 123:11,22 127:13 128:11 129:1 131:20 132:11,12 135:16	minutes 102:2	17,18,22,23 31:10, 14,19,21,23 32:8,13 40:2,23 51:10 52:11
litigation 12:13 42:7,11 97:19	malfeasances 102:15	Mcgladrey's 43:2 134:3	mischaracterizatio n 117:17	114:8 116:25
litigations 62:2 96:21,22,24	malpractice 26:3 62:14 70:16	Mcgovern 14:25 15:7 16:1,7 67:14	mischaracterize 75:3	N
LLP'S 13:7	management 63:16 120:19,20 121:16,	68:14 73:18 81:21	mischaracterizes 75:1 104:12 112:23	names 56:16 narrow 99:11
logical 66:9 long 7:24 8:4 58:23	24,25 122:5 126:17 132:3	means 90:24 121:20 measure 113:6	118:7 121:19 mischaracterizing	nature 114:17
60:16 125:3	Marc 7:8,21 13:2	measured 113:17	119:5 128:21	necessarily 91:2
looked 32:24 47:2 86:5,6,7,8 98:9 103:21	March 68:14 107:11 mark 9:17,25 10:8,	mediation 21:11,12 meet 22:2 40:22 51:3	misconduct 25:7 missed 23:13	needed 59:15 97:12 122:20
lot 21:21 58:24 59:11 86:5 98:9 125:4	13,17 11:8 18:3 19:10 27:11 62:5,16	meeting 24:23 117:5	missing 25:18	negligence 23:22 26:2 70:15 71:3
128:1 133:9	82:18 83:9 101:8 103:4 118:5 119:5,9 136:10	meets 24:9 memo 14:7	model 118:16 moment 33:25 34:3	negotiating 37:2 39:21 40:7 41:12
lots 107:19 124:15 love 24:5	Mark's 96:10	memorandum 14:19	money 24:18 41:16, 17,19 43:12,14 46:4, 7 91:9 92:1 94:13	net 88:4,20 90:5 Neuroscience 68:3,



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 154 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: nice..performed

8,15,19 71:13		obvious 42:1	option 55:4	8,10,19 122:9
nice 28:21	0	occurred 93:15	order 20:16,17	130:22 132:15,19,
Nicolette 17:2		95:13 98:14	21:15,17,24 22:8,10,	20,21,22,23 133:10, 11,12,13,14 134:20
	Oaks 22:2 23:17	off-the-record	16,19 24:17 26:8,25	135:14,17
non-bankruptcy	24:9,20 40:2,23 51:10 52:11	10:19 18:4 47:8 96:7	27:4,18 28:11 36:21,	-
27:2		102:24 136:5	22 37:6,9,11,14,16,	paragraphs 110:12 120:14 121:3 127:14
non-settling 117:2	object 28:18,25 30:2	offer 33:11 96:1	20,22 38:1 40:16 41:9,24 42:5,6,21	131:8,12,19,24
nonbankruptcy	31:7 33:18,20,21 39:4 70:18 75:20		43:22 45:4 49:21,23	131:8,12,19,24
49:25	90:9,19 92:4 93:9	offered 36:23	51:15,19 52:1,17,22,	134:7 135:17
	98:15 99:3 101:5	offers 95:22	23 84:18 98:17 99:7	paralegal 10:2
63:15,22	108:21 109:18	office 62:15	106:11 107:20 108:7	
	111:4,25 113:8		122:25 136:22	paraphrase 73:11
onresponsive	114:2 115:15 125:16	officer 11:12,18 15:9	ordered 136:24	pari 23:25 107:15
28:19	127:20 128:22	20:14 68:14 70:4	orders 38:5,10 51:14	108:15,19
ormal 59:3 61:2	129:11 130:11	105:11	53:22 82:7 83:8,10	part 20:15 36:24
orthwest 12:22	objected 112:5	officers 20:22 24:16	101:8 113:11 118:2	40:9,22,25 43:5
15:17 17:9 19:5	objecting 24:25	25:10 26:9,11,17		45:25 58:11 59:3,7
35:13,24 48:3,5 49:5	30:7 39:5 82:9 90:12	27:1 28:5 33:3 39:23	original 20:4	60:24 62:21 74:17
56:19,22,23 67:15	124:24	40:5,16 43:16 50:20,	originally 57:24	76:21 100:4,9
68:6 86:21 88:17		25 53:23 54:12 55:15,18 63:16	63:3	110:11 126:20
otes 17:20 18:13	objection 26:15,21 27:11,12,17 28:7	73:17,18 81:20	outs 94:6,7	132:13 133:20
	32:17 33:10,15 38:8	122:11	-	134:23
otice 86:13 92:10	39:14 40:8 41:25		outstanding 45:17	partial 14:7,20
November 8:1,2	42:13,23 43:11	officers' 27:8	overseeing 37:1	parties 30:7 31:17
umber 8:9,18 9:5	44:10,13 50:8,21	Olson 22:25 77:17	Oxford 94:2,3,8,10,	42:18 101:12 113:1
10:23 11:10,21,23	51:17 52:2,9,20	omission 25:8	15,22 105:19 106:5	116:24
12:14,15,24 13:5,11,	53:3,15,24 54:14,18		107:2 108:17 109:9,	
14,18,21,24 14:3,9,	55:8,16 63:20 64:7	omissions 70:3 73:9 112:17 125:11,21	17 110:7	party 53:13
13,17,22 15:1,5,9,13,	69:21 72:8 73:1,24 74:9,25 75:14 76:10	132:2,13 134:6		past 30:16 103:22
16,19,25 16:2,3,5,6,	77:3 78:22 79:20,22	-	Р	pay 31:17 32:21 36:
17 17:5,7 18:10,21	80:12,16 84:1,15	ongoing 59:7		41:15,16,17,19
19:18,20,24,25 20:3,	85:3,8,11 87:7,14	opened 100:12	p.m. 56:3 136:20,21	43:12,13 45:9 46:5
5 34:8,10,12,18	88:11,21 89:11 91:1,	-	137:5	49:15 93:16 95:5
35:11,22,23,24 45:3 47:11,17 48:2,4,24	6,18 93:2 95:12	operates 108:1	70,19,24	97:12
57:9,11,13 58:18,21	97:15,23 99:21	operating 65:14,16	pages 79:18,24	payment 92:17
67:7,9,10 68:23,25	100:21,24 104:2,10	operation 131:7	paid 25:13 44:18	
69:7,8 70:17 72:7,19	107:5 110:17 111:16 112:22 113:20	-	45:1,17 46:20 91:12	payments 42:8,11 45:9 76:1 92:15,16
76:9,22 78:3,4,10,	112:22 113:20 114:20 115:6 116:18	operative 57:7 104:22 105:1 135:7	93:13 94:8 97:2	
18,21 86:19 103:5,6,	121:18 122:21		paper 18:2 51:8	pending 54:1 70:7
9,10 104:20 135:5,8,	123:13,17,18,24	opinion 20:13 22:4	papers 20:18 26:25	76:5 93:10 105:1
18	124:22 126:2,6	24:2 28:21 29:20,21	28:17 43:19 44:12,	people 95:5 127:5
umbers 7:13	127:2 128:14 129:4	30:15,16 31:15 32:13 39:1 50:4,17	15 53:8 110:10	percent 22:23 23:1
16:10,22,23 36:18	133:16,19,20,23	51:4 55:22 110:6	114:10,24	125:6
47:5,6 48:13 77:5,9	objections 93:8 99:6		paragraph 69:13	
W 35:25 56:15,22,	0	opportunities	72:17,22 73:2,3,5,	percentage 97:4
25 57:3,5 66:11,22	obligations 87:13	131:13	12,14 74:20 75:2	perform 76:7,22
68:6 87:5,22,23	obtain 59:5	opportunity 85:18	80:7,8,13 81:1,2	115:14
88:8,20 89:22,25	obtained 85:20	opposition 14:5,15	101:22 102:1 104:15	performed 72:4,12
90:5 91:5,24 123:22	111:9 124:3	28:16,17 109:3	105:6,10 107:10	18 74:14 131:20
124:7			120:12,22,23 121:7,	



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 155 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

				•
period 58:23	22:11 38:19 40:10	priority 35:13,20	prove 82:13 129:18	119:16 122:3 124:3
permissible 55:9	60:4,20 83:24 88:19 117:10	36:2 47:12,25 48:11, 16 49:6,15 94:16	provide 28:4 30:14	127:9,11 128:8 129:25 130:8 131:4
personal 110:25	potentially 12:19	privilege 38:19	31:13 44:23 55:15 69:19 82:19 84:18	133:3,18,21,24,25
112:3 120:25 122:6	21:22 36:14 41:16	70:21 71:6 89:7,10,	100:6	134:18
personally 37:20	61:1	12 90:8 93:4 111:22	provided 12:2,7	questioning 98:16
41:11 85:22 109:1	practice 61:12	122:24 123:2,5 124:4	23:4 25:9,14 35:9	questions 28:22
110:25 124:12	practiced 56:8		72:24 75:5,25 77:1	29:24 39:7 56:1
persons 70:5	practicing 8:4	privileged 131:3	78:7,10 80:11,25 81:2,4,5,14 100:13	76:18 99:4 101:10 106:23 114:16
perspective 44:3		problems 128:12	117:21 124:21	115:11 117:4,8,23
petition 17:12,13	pre-mark 7:12	procedures 129:10	127:19 130:21	119:11,21,24,25
18:11,13 121:5,12	pre-marked 7:13	Proceed 133:23	providing 46:4	120:1 127:16 129:13 130:10 133:9 135:13
phase 59:22 94:1	prebankruptcy	proceeding 13:10,	55:17 74:6 81:19	136:1,8
phone 77:19	131:15	19,25 14:4,10,14,18	provision 10:6	quick 48:8 60:14
pick 105:17 109:15	Preceding 59:25	15:20 16:2,5,8 19:24	provisions 84:18	•
128:12 129:2 132:12	preconversion	20:6 70:6	pull 21:25 31:24	Quickbooks 120:6
133:6	93:15,19,20	proceeds 88:20	69:7 101:24	quickly 119:25 123:4
picked 102:16	premature 22:7	process 62:21 65:5	purchase 59:12	123.4
picking 104:8	49:18 91:19	88:24 127:22 131:15	purported 118:10	R
110:16 134:6	premise 50:10 127:9	produced 86:2 126:25	purpose 12:7,17	
Piper 66:16,20,21	preparation 114:7		95:21	raise 89:11
71:19 100:19	prepared 25:20	product 70:21 72:1 88:23 89:14 108:23	purposes 8:9 9:17	range 21:6 34:20
place 51:6 125:5	99:5,6	109:20 122:23 123:1	57:8 95:21	51:9 58:15
Plaintiff's 13:8,12,	prepetition 131:13	professional 23:21	pursue 24:18 72:1	rational 119:1
22 14:4,15,18	presented 108:9,16,	26:2 50:17 70:16	107:1	rationale 31:13 43:2
plan 12:17 67:23	18	71:2 105:18	put 10:6 26:6 35:8,	re-answer 90:20
pleading 22:15	presume 43:5	professionals 44:19	17 50:12 51:4 118:5	re-reading 52:10
116:18	presuming 43:9	61:4,6 62:22 65:6 70:22	122:14,17	
pleadings 68:11	pretty 20:23 114:25			read 27:4 30:15 34:23 50:1 67:18
109:2 115:18 116:7	prevail 21:15 22:10,	program 120:7	Q	75:2 79:4,19,24
plural 44:5	24 23:8 24:2 32:21	prohibit 26:25	question 17:1 20:9,	80:14 103:20 105:24
pocket 36:8	36:7 117:2	Project 57:19	23 25:24 27:20	106:4 110:20 114:7, 23 122:8,15,16
point 9:18 22:1	previous 11:9	proof 112:1	29:19,23 30:2,4 31:9	126:8 133:24
30:20 77:25 82:17 87:25 107:8 133:5	previously 44:25	proper 10:12 93:9	33:16 36:19 37:18 39:4 40:3,4 42:25	reading 30:18
	primarily 61:15	properly 70:1,11	45:20,22 47:14,21	reads 121:10
policy 31:20 32:5 33:6,8 36:5	primary 61:12	73:7 81:7 82:23	50:10 51:23 52:13 61:5 63:21 65:16	real 48:7
position 76:3 110:8	1 0	109:8 128:12	71:5 73:15 75:18,20	
1	printed 16:14	properties 59:20	76:17 80:22 83:2,3,	reality 119:7
possession 126:21 127:4	printout 15:14,17	proposed 21:3	4,17 84:4,22,23 89:15 90:7,20 92:14,	reallocate 88:19
	prior 9:20 10:2,11	67:14,23	21 99:8 100:3,25	reason 53:1,4,7
possibly 108:19	58:4 85:21 98:20 121:5,12	protection 84:19	101:2,8 102:7	59:10 70:25 71:9,18 73:6 74:20 87:25
post 59:4			104:14 107:3,7,10	15.017.2001.25
•	priorition 45.12	protocol 128:3		88:16
potential 12:10	priorities 45:13	protocol 128:3	110:14 113:12,14,15 114:15 115:10	88:16



Index: period..reason

Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 156 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: reasonable..reversal

MARC BARMAT			Index	c: reasonablereversal
reasonable 21:17,18	131:1 135:20	100:11,22 101:3,14,	remains 24:15 88:12	resolves 54:9
23:17 25:14 73:6		18 102:12,13,23		
76:25 106:13	references 57:13	103:3,8 104:4,18,21	remember 30:16	respect 37:1 44:24
/0.25 100.15	95:8,20 102:20		31:21 52:4 57:1	62:12 63:18 64:24
reasonableness		105:3,4 106:3 107:9	85:23 86:5 98:10	65:2 66:10,12,16
21:6 51:9 82:14	referred 57:18 98:6	108:14 109:6,24	134:21	69:2 71:11,13,19,20
21.0 51.7 62.14	D of our in a 17,10	110:5,21 111:11,18,	134.21	
reasons 12:12,19	Referring 47:10	21 112:10 113:5,13,	reopen 88:17 90:15,	72:19,25 75:11
18:25 20:17 22:6	reflect 8:24 79:17	21,24 114:13 115:2	18 91:5	76:21 81:17 84:13
43:19 66:2	Teneet 0.2179.17	116:3,14,17,23	10,7110	85:6 87:20 98:12,22
45.17 00.2	reflected 72:5	117:14,23 118:14	reopened 88:1	105:18 106:5 107:4
recall 30:22 31:3,4,	112:21			108:17 109:9,16
16,22 32:3 37:19		119:3,7,12,18 120:5,	Reopening 90:24	110:11,22 114:19
47:3 58:14 68:4	reflects 102:6	10,16,23 121:2,22,23	repeat 30:4 51:23	115:13 116:25
		123:3,9,19 124:5	repeat 30.4 31.23	117:5,8 118:9 124:6
122:7	refresh 66:17 68:18	125:9,19 126:3,9,11	repeating 73:11	-
receivables 60:13	regard 9:6 10:23	127:10,23 128:7,17,		131:4,11,22 132:1,5,
		25 129:7 130:6,16,	rephrase 52:16	10,12 134:3,5,17
received 38:23	12:2,8,15,16 23:19	19 132:15,18 133:1,	84:5,6,7 89:16	135:13,16,17
72:11 91:9 94:10,11	25:2 31:5 50:19 61:7		121:22 136:3	
125:1 130:3,4	65:6 78:14 81:4	7,10,19,24 134:1		respective 69:1 88:5
	114:6 129:21	135:6,22 136:7	reply 14:11,19 28:16	92:2 111:3
receiving 45:9,21	register 11:21 12:8,	reiterate 130:24	report 124:12	response 14:5,15
			report 124.12	28:17 71:16,22
recess 46:9,10 56:2	14,16 19:6,11,12	relate 19:12,13	reported 24:7 87:23	127:12
116:22	35:10,11,18,25		124:15	127:12
recognize 25:11	47:10,18 48:1,5 49:2	related 74:6,14	121.10	responses 44:12
65:14 103:13	78:5 86:16 90:3	131:7	reporter 7:3 126:8	115:25 116:18
05.14 105.15	103:10 112:1 116:9	relates 20:10,13	136:19	110.20 110.10
recollection 37:24	• • • • • • • •	41:19 51:13 72:24		responsible 22:23
66:18 68:18 90:16	registers 18:25		reporter's 95:21	23:10
	19:13 35:3 47:2	81:19 82:25 98:17	reports 83:23	• • • • •
record 7:20 9:17	112:21 116:8,9	115:5	1 cports 05.25	responsive 116:7
10:7,18 12:25 18:3	registry 12:6,20	relating 76:7	represent 20:14	restatement 125:18
47:7 79:17 95:7 96:6		118:13,17		restatement 125.16
101:17 102:5,23	regurgitate 114:21	110.15,17	representation	rested 119:3
118:6 130:12,17		relation 115:18	8:14	
136:4,17,18	regurgitating 112:8		represented 127:25	result 25:13 35:1
	Reich 10:10,16	relationship 115:12	represented 127.25	88:9 91:10 92:25
records 32:24 60:11		117:9 126:15	reputation 62:15,17	93:14 94:11 110:15
124:15 126:24	12:21 15:22 16:10,		-	
127:16,25 128:2,9,	22 17:2,10 19:4,6,8	relevance 77:12	request 53:13	retain 65:6,15,17,21
13 129:3,9	28:18 29:19,22,24	relevant 39:15	magnested 26:21.22	retained 62:3,20
10 129.0,9	33:15,20 35:14 47:6,	127:7	requested 36:21,22	65:12 67:1 96:11
recourse 27:6 49:22	14,21 48:2,7,10,18,	127.7	37:3,6,8,11 42:21	
	23 56:5 63:24 64:13	reliance 99:15	53:5	97:20,21
recover 13:1 19:21	69:22,24 70:23 71:8,		requesting 38:1	retainer 77:9 78:11,
20:2 21:22 73:23	17,23 72:15 73:4	relied 83:18 99:15		15
recovery 21:2 75:22		relief 13:2 19:22	41:21	1.5
	74:1,12 75:8,15		require 21:20 71:6	retaining 62:19
76:24 82:21 91:4	76:2,12 77:4,8,17,	20:3 99:7 136:13	87:8 89:3	
redacted 95:10,24	21,24 78:2,24 79:3,	rely 83:22 114:11		retention 62:23
	7,10,20,22 80:4,16,	125:17 127:17	required 51:20	76:13 78:19 96:14
redaction 95:19	19,23 82:1,5,11,13,	130:24	135:25	103:14
nodestions 127.1.2	16,19 83:6,9,16	130.27		notrious 100.12
redactions 137:1,3	84:6,8,21 85:4,9,17	relying 116:5,17	requires 38:18	retrieve 109:13
reference 87:9	87:10,19 88:13 89:8,	117:18,19,20 134:9,	88:23 93:3 109:19	return 74:18,21
95:22 101:22 102:8,	13,19,23 90:12,17,23	10	122:23	
15 134:19	91:3,8,21 92:13			reveal 122:23 123:1
15 154.17	93:11 95:7,13,17,20	remain 45:19 88:14	requiring 52:23	roversel 121.4.11
referenced 28:16		nomaining 15-2	reserve 9:18 136:7	reversal 121:4,11
51:7 78:7 81:15	96:1,4,9 97:16 98:1,	remaining 45:3		123:11
	4,19,22 99:8,12,13	92:25		



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 157 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: reverse..stop

reverse 122:11	school 8:6	settled 60:15 84:25	slam 21:4	spend 34:13 106:25
123:23	scope 64:12 67:17,20	101:13	small 60:6	spending 107:19
review 30:15 85:19,	79:4 83:14 100:14,	settlement 8:11,15,	SOFA 17:16,17	spin 121:17
22	15 103:16 116:24	17,19,21,23 9:2,3 12:3 20:16 21:3,5	software 120:7	spinoff 98:6 120:20,
reviewed 98:9	scopes 81:15	23:16,20 24:5 26:8		21 121:5,12 122:1,5,
124:15	section 103:18 133:5	29:6,8 30:9 31:4	sold 59:21,24 93:22	12,19 123:12,23
ridiculous 133:8	secured 35:12,19	33:12 36:24 37:16,	94:1	126:17
rights 55:13	36:2 47:11,25 48:10,	22 39:2,16,21 40:1, 7,10,20,25 41:2,8,9,	Soneet 62:25 63:1,2	spoke 118:12
ringing 57:21	16 49:6,15 92:24	22 43:5 44:8,13	sort 99:19	spoken 38:3
ripe 22:7,9	93:12,16 94:3 105:11	52:21 53:6,22 65:2	sound 66:25	squandered 131:13
ripen 22:12	seek 21:11 136:11	76:5,19 77:15 82:14 87:20 88:3,20 89:17,	sounds 35:4 57:2	stack 34:4
•		18 91:16,23 95:4,8,	66:19 67:4	
risk 24:11,12 107:18, 19 118:25	seeking 32:22 33:7,8 36:9 51:14 54:2 76:1	25 96:1,4,5 100:15	source 113:25	stand 54:22
		105:2 108:2,12	124:18 125:20	standard 21:8,15
River 57:1,14,15 66:13,23 67:15 68:5	separate 19:10 78:11 87:17	settlements 20:10,	sources 127:18	26:10 50:23 106:12
69:2 71:14,20 76:14		12 24:14,24 36:15,	Southern 51:7	standards 22:2,3
81:17 83:19 84:14	separately 118:17	20 37:5 38:6 44:5	114:9	23:18 24:9,10,19
85:6 110:12,15	September 11:14	45:8,22 46:3,13,15, 21 49:14 50:11,23	speak 27:6 38:2	40:23 51:3 92:9
132:16,17	serve 63:14,16	51:8,16,18 52:1,18	speak 27:6 38:2 41:11 108:25	stands 56:18 76:16
road 128:21 136:3	served 33:9,11	55:15 63:10 88:9	speaking 79:22	start 34:11
Robinson 29:1		92:8 118:18 129:15	80:16	started 136:19
role 56:13 63:13,14,	service 63:7 72:23 78:6 81:5	settling 31:17 53:13	speaks 78:23 79:5	starting 80:21 105:5
16		76:5 82:22 106:12	80:14 101:17 104:13	110:11 130:22 131:8
-	services 60:16 67:15	short 48:7 124:9		
roles 64:8	68:5 69:20 72:18 75:5,24 76:22 77:1,2	show 12:10 22:21	special 62:3 63:7 126:4	state 7:19 115:16 120:6
roughly 49:9 94:1	78:9 79:4 80:6,11,25	104:17 120:11		
Rule 58:9	81:2,9,12,13,15,19	128:16	specific 37:23 101:22 102:8,14	stated 11:8 64:17 73:19
ruling 135:24 136:8	82:20,22,24 83:18,	showed 112:1	101.22 102.8,14	
0	24 98:25 103:16,17, 24 131:20	shows 35:25 48:5	120:13 128:15,17,19	statement 17:14,18,
run 21:8 24:11 64:18 107:18,19			129:13 133:2 134:7	22 18:16 28:25 65:19,20 70:2,11
107.10,19	set 20:18 22:3 43:19	side 123:7	135:16	73:8 125:17,18
S	45:13 48:1 51:10 52:11 53:7 72:16	signature 9:9 11:2	specifically 26:20	
	73:10 76:8 77:1	68:13	28:13 39:22 40:4,14	statements 9:12 11:4 17:20 18:14
safe 42:20	86:10,11 100:2	single 30:17 98:10	42:21 50:19 51:13	
	103:24 109:11	106:15 107:24	52:4 55:22 58:14	states 108:1
safeguards 131:6	111:2,15 112:14	sir 70:8 131:25	85:24 86:8 98:8 132:25	stating 74:20
sale 93:1,19,20	125:22 130:21 131:7,23 132:3,7	sit 30:17 35:7 39:8,	specificity 111:1	Statutes 22:17 27:23
131:13,15	134:7	19 55:24 68:4 90:21	specifics 60:12	statutory 69:16
sales 93:14 94:12	setoff 10:6 27:3,10	114:6,23 125:2,7 126:18	92:11 106:19 124:13	steps 122:19 123:22
scenario 55:5	28:4 30:23 31:6,13		133:7	stick 73:13
scheduled 92:7	36:14 50:5	site 16:14	speculate 43:1,10	
schedules 17:8,9,10,	setoffs 49:25	sitting 42:10,17	44:1	stipulate 79:25 80:2 95:11 102:10,12,18,
11,14,16,22 18:15,	sets 87:18	skilled 24:7 35:5	speculating 43:9	19 104:25 116:20
18,19,20,21	settle 31:10 43:7,8	skills 62:11	speculative 39:6	stop 54:8



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 158 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: strength..Unitedhealthcare

strength 118:9	116:5	testified 7:10 40:11	90:10 132:17 133:4	127:15,25 128:9,13
strengths 63:5	supported 108:15	42:2 49:20 52:13 53:9 55:23 129:19	threatened 38:15	129:3,9
strike 28:19 29:2 33:15,19,23 76:4 95:8 107:6	suppose 20:24 41:20 54:3,7 55:4 66:1 supposed 82:19	testify 86:6 92:10 99:5 111:13 118:8 119:9	tie 77:13 98:19 time 7:25 21:21 30:9 34:14 39:5 57:3	trick 34:24 true 11:5 32:25 61:8 68:7,10,11,21 72:21
strong 107:22,23 stuff 58:24 86:5 98:9 112:2 114:22	sustainable 108:20 swear 7:3	testimony 7:4 9:5 13:23 48:18,20 54:22 75:9 91:16	58:23,24,25 59:13, 16 71:12 79:6 83:8 104:3 105:1 108:9	90:13 96:25 97:10 119:20 120:13 truncate 99:2
subject 11:8 72:11 76:5 96:11	sworn 7:9 9:5 system 108:1 130:9	113:15 116:10 119:8 123:10 125:10 126:8	114:25 115:3 119:18,21 125:3 128:17,18 129:22 136:16,18	Trustee 7:24 8:10, 15,24 9:20 28:24 37:4,14 41:21 56:13,
subpart 105:5 127:13 130:22 131:5,8,12,18,23 132:2,7		theory 55:4,5 69:18 thing 18:7 23:23 30:17 64:21,24 65:3 86:1 98:10 118:5	timely 131:14 times 30:16 57:19	14 59:4 60:23,24 61:2,10,14,19,21 63:13 64:2,6 71:9 117:4,8 118:8,22
subsequent 10:13 131:14	table 123:7 takes 41:8	123:7 130:1 131:4, 22 132:5	117:18 125:24 today 35:7 42:10 47:1 75:9,10 99:5	119:2 123:21 124:7 126:20
subsequently 87:2 91:25	taking 55:12 81:23 82:8 126:21 talents 62:11	things 26:24 59:20 61:17 70:1 74:2 75:6 81:7,10,11 106:9	114:17 115:11 123:10 134:24 135:23	truth 7:5,6 turn 24:4 69:13
substance 101:7,11 109:23,24 113:10 115:8 117:24 118:15	talk 29:5 56:21 104:6 111:20,23,24	109:15 110:16 125:4 134:9 thinking 54:8	told 47:3 66:15 117:18 118:2 123:15	turned 58:11 type 29:12 59:21
substantial 58:20 60:8	128:9 talked 40:1 102:2	third-parties	tomorrow 95:3 top 46:15 66:14	types 62:12 typos 10:4
substantially 59:23	talking 30:25 34:5 45:25 54:19 56:23	third-party 38:15	67:22	U
substantive 81:23 82:9 83:13 99:3 114:17 136:1	61:20 72:14 97:25 100:5,9	Thornton 8:11,16 9:2 10:1,9,24 13:3,7, 9,13,16 15:3,6 16:4	total 36:1 46:19 47:22,24 48:5,17 50:14	ultimate 64:4 111:13 112:19
substantively 10:4 83:3 109:22	talks 120:19 tangibles 59:19	20:11 21:1,10,14,16 22:6,9,11,12,14,18, 21,22 23:3,6,10,16	totally 116:6 127:17 transaction 66:13,	111.13 112.19 124:17 128:3 ultimately 92:11
subtract 48:10 sue 70:14,15 71:10, 19 74:5,13 104:7	task 60:10 tax 65:10,12,15,17 78:9 79:9,13,15	25:2,9,11 32:20 36:15,20 37:25 38:2, 16 39:3,12,24 40:6	17 67:3 69:2 71:14, 20 73:23 74:7 81:18 83:19 85:7 98:5,13	underlying 83:5 112:4 118:15
sued 70:25 71:1 82:21 84:25 100:15	80:11,25 81:12 Technology 120:19, 21 121:17,25 122:5	41:1 42:3,12 43:1,25 46:13 54:3 55:1 57:10 67:2,6,13	transactions 66:5,8 112:6,12,13,14 transcript 95:10,17,	understand 31:8 42:24 48:25 56:24 59:2 77:11,14 92:6 100:7 101:4 106:10
<pre>suing 33:3,16 74:18 suit 104:7,9 115:14</pre>	126:17	69:6,10,19 70:10,15, 25 71:10 72:3,13	24 137:1	113:15
sum 46:19	telling 40:24 80:21 102:4 111:19 115:7	73:6 74:5,15 84:9,25 85:1,2 100:18,19 101:21 102:8 114:18	transcripts 85:19, 23 126:24 127:4	understanding 41:23 43:6 56:25
summary 13:16 14:6,7,11,16,20 18:18 21:10 78:16	tenacity 109:5 term 57:20	131:23 134:25 135:11,14	transfer 21:8,15 23:23 transfers 13:2 19:22	58:7 61:18 78:25 103:23 105:22 109:7,10 113:22
100:8 supplement 9:19 65:24	terms 8:15,24 9:2 31:5 40:1 42:6 84:17,22 96:14 97:1	Thornton's 13:15, 20 14:1,5,11,15,24 69:25 76:21 83:18,	20:2 21:2 26:4 72:18 75:23 76:24 81:6	114:1,4 120:14 understood 22:15 unique 62:11
support 14:11,19	test 25:22	23 thought 59:9 88:24	trial 19:23 20:3 24:11 60:11 107:21,	Unitedhealthcare



Case 13-17273-JKO Doc 1076 Filed 02/05/16 Page 159 of 159

Comphensive Clinical Development vs. Steven Krupa MARC BARMAT

Index: unsecured..yesterday

60:16,18 62:8	violated 105:17 106:7	Y	
unsecured 17:24			
18:22 47:4,14,16 48:12,19 49:10,15	virtue 73:22	year 70:2,11 73:8	
92:21,25 94:20	W	103:25	
unusual 51:15,25		years 7:25 8:2 37:4	
52:3,6,16	wanted 9:18 24:12	yesterday 33:13	
inwind 121:16,25	43:7,12 44:14	j	
122:5,19	118:19 135:9		
nwinding 121:4	warrant 107:13		
ploaded 10:2	warranted 53:14		
tilized 63:6	warrants 52:17		
tilizing 12:18	waste 79:6 114:25		
	weaknesses 63:6		
V	website 12:4		
valid 43:17 85:15	well-known 61:11		
validity 60:25	Wernick 61:24		
VALMOS 46:9	wherewithal 32:21		
values 21:19	wholly 22:22		
verbatim 27:5 50:2	win 107:21		
version 10:3 56:19	winding 121:11		
versus 13:3	wire 72:17		
viability 118:9	withdrawn 87:24		
video 79:23	witnesses 97:19,21		
view 98:3	word 95:25 103:1		
Vilmos 7:11,16	words 59:17 75:17		
10:21 15:8,12,24	96:20		
16:12,19 17:3,4 18:8	work 61:25 65:10,		
19:9,17 26:18 27:7,	12,15,17 67:17,20,23		
15,21 29:4 30:5,6	70:21 72:1,4,12		
31:11 32:18 33:24	74:6,13 82:21 88:23		
34:7,17 35:21 38:13,	89:14 108:22 109:19		
24 39:10,17,20 40:13 42:9,15,19	122:23 123:1		
43:4,15 44:17 46:12	works 101:4		
47:15 48:9 49:11	worth 28:11 50:7		
50:18 51:12,22,24	Wow 123:3		
52:7,15,24 53:11,20 54:10,16,21,24			
55:11,21,25 96:3	writing 114:22		
97:11 116:21	wrong 25:1,3,25		
136:22,25	34:23 52:5 57:22		
	81:18 100:20,23		
Vilmos' 73:19 92:14	107:2		

